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the  interface  of  the  body with  the  environment.  The  skin  forms  a  structural  barrier  that 
protects the  inner tissues against physical stress and  invasion of micro‐organisms and toxic 
agents, but  it  also prevents  the  loss of essential body  fluids. The  social  and psychological 
function of skin is shown by its influence in a person’s attraction, self‐esteem, social contacts 
and  standing  in  society.  Human  skin  consists  of  an  outer  layer  of  stratified,  keratinizing 
epithelium,  the  epidermis, which  is  anchored  to  a  basement membrane,  separating  the 
epidermis  from  the  underlying  connective  tissue  layer,  the  dermis,  which  contains  the 
vascular  network,  the  hair  follicles,  the  sweat  glands,  and  the  sebaceous  glands.  Correct 
development  of  the  epidermis  is  vital  for  skin  barrier  function  as  abnormalities  in 
cornification and desquamation can  lead to severe skin disorders. Therefore, elucidation of 
the molecular processes  that underlie epidermal differentiation  is of great  importance  for 






agents,  and  loss  of  essential  body  fluids,  the  skin  has  evolved  an  intricate  terminal 
differentiation  process  that  results  in  a  tough, water‐impermeable  outer  covering  that  is 
constantly renewing. The outcome of this epidermal differentiation process  is an organized 
tissue in which morphologically distinguishable cells are arranged in discrete layers of basal, 
spinous,  granular,  and  cornified  cells  (Figure 1)1,2.  The  stratum basale  is  the  layer of  cells 
directly contacting the basement membrane and supposedly harbours epidermal stem cells 
as  this  layer  provides  the  germinal  cells  that  are  necessary  for  epidermal  regeneration3.  
 
 
Figure  1:  Structure  of  human  epidermis. 
Human  skin  consists  of  dermis  (connective 
tissue)  and  epidermis  (epithelium), which  are 
separated  by  a  basement  membrane.  The 
epidermis  is  a  stratified  structure  in  which 
keratinocytes migrate  from  the  basal  layer  to 
the stratum corneum as they differentiate into 
dead corneocytes and eventually are shed from 
the  skin  surface.  Reprinted  from:  Alonso,  L., 
Fuchs,  E.  (2003)  Proc.Natl.Acad.Sci.U.S.A  100 





Newly  formed cells move upwards  into  the stratum spinosum and  the process of  terminal 
differentiation starts as the cells are migrating towards the skin surface. In the spinous layers 
the  intermediate  filament  network  of  the  cytoskeleton  is  composed  of  large  amounts  of 
keratins4. The  intermediate filaments are anchored to desmosomes,  intercellular  junctions, 
which  number  increases  during  terminal  differentiation  to  improve  tissue  integrity  and 
resistance to mechanical forces. The stratum granulosum is the last layer of viable cells and 
is characterized by the accumulation of keratohyalin granules. The granular cells also present 
“lamellar  granules”  containing  lipids  that  after  incorporation  into  the  cornified  envelope 
form  a waterproof  barrier  to  prevent  the  loss  of  body  fluids. As  keratinocytes  terminally 
differentiate, rupture of the stratum granulosum cell integrity results in release of lysosomal 
proteases into the cytoplasm that eventually cause cell death. These cells that have lost their 
nuclei  and  cytoplasmic  organelles,  are  now  called  corneocytes  and  form  the  stratum 
corneum.  The  corneocyte  contains  a  stable  and  insoluble  cornified  envelope  that  was 
synthesized  just  beneath  the  disintegrating  plasma  membrane.  This  cornified  envelope 
consists of several specific proteins that are cross‐linked together in an orchestrated way by 
Ca2+‐dependent  transglutaminases  (TGMs;  Figure  2).  The  terminal  stage  of  the 
differentiation  process  is  desquamation,  which  involves  degradation  of  lipids  in  the 
intercellular spaces and loss of residual intercellular desmosomal connections. Cells reaching 
the  skin  surface, which  consist  largely of dead proteinaceous  sacs of keratin  intermediate 






of  cornified  envelope  assembly;  ii)  formation  of  the  corneocyte  lipid  envelope;  and  iii) 
reinforcement  of  the  cornified  envelope9‐11.  As  intracellular  Ca2+‐concentrations  rise  in 
suprabasal cells, envoplakin, periplakin and  involucrin are expressed, which  then associate 
with keratin intermediate filaments and desmosomal junctions (Figure 3). Nearly at the same 
time,  TGM1  is  expressed, which docks  into  the plasma membrane where  it  catalyzes  the 
intrachain  head‐to‐head  and  head‐to‐tail  cross‐linking  of  involucrin,  as well  as  interchain 
cross‐linking  between  both  plakins  and  involucrin.  These  events  first  occur  at 
interdesmosomal sites on the cell membrane, and eventually, involucrin, the plakin proteins 
Figure  2:  Protein  crosslinking  by 
transglutaminases.  Ca2+‐dependent 
transglutaminases  (TGM)  catalyse  the 
acyl‐transfer  reaction  of  the  glutamine 
residue of protein 1 to the lysine residue 
of protein 2. The two proteins are linked 




of  the  plasma  membrane,  including  the  desmosomes,  thereby  forming  a  scaffold.  The 
second step  in this model  is the formation of the corneocyte  lipid envelope. At a particular 
time  point,  perhaps  coincident with  initiation  of  scaffold  assembly,  lamellar  granules  are 
thought  to  fuse with  the  plasma membrane of  the  granular  cell  and  discharge  their  lipid 
membranes  into  the  intercellular  space  to  form  a  water‐repelling  envelope  around  the 
cornified envelope. Finally, other structural proteins including loricrin and small proline rich 
proteins  (SPRs),  which  together  comprise  about  80%  of  the  total mass  of  the  cornified 
envelope, are crosslinked onto  the scaffold  to  reinforce  the  initial structure. The cytosolic, 
activated  TGM3  enzyme  catalyzes  the  homodimerization  of  loricrin  and  the 
heterotrimerization of loricrin and SPRs, which are subsequently translocated to the border 
of  the cell, where TGM1 crosslinks  them onto  the pre‐existing scaffold. Minor amounts of 
other proteins (cystatin A, SKALP/elafin, LCE proteins, repetin, and trichohyalin) also become 
crosslinked  to  the cornified envelope. The  last stage of  the cornified envelope assembly  is 
characterized  by  rupture  of  the  cell  integrity,  which  results  in  degradation  of most  cell 
organelles and internal structures. Together, the complete cornified envelope, consisting of 




layers with  the  attachment  of  envoplakin,  periplakin,  and  involucrin  to  the  plasma membrane  by 
transglutaminases. This  is  followed by  incorporation of  lipids  to  form  the  lipid envelope  for water 
barrier  function.  In the granular  layers additional structural proteins  including  loricrin and SPRs are 
crosslinked to the scaffold for reinforcement of the cornified envelope. Eventually, other proteins are 







provide  strong  cell‐cell  adhesion  and  that  are  anchoring  points  for  the  intermediate 
filaments of the cytoskeleton. These functions are  important  in maintaining the  integrity of 
the  tissue  and  in  providing  the  cells  resistance  to  physical  stress  and  pressure12,13. 
Desmosomes  constitute  proteins  from  three  separate  families:  desmosomal  cadherins, 
armadillo proteins, and plakins  (Figure 4). The adhesive  intercellular  junction  is  formed by 
the  extracellular  domains  of  two  types  of  transmembrane  cadherins:  desmogleins  and 
desmocollins14.  Four  desmogleins  (DSG1‐4)  and  three  desmocollins  (DSC1‐3)  have  been 
identified, all clustered on chromosome 18, each with its own epidermal expression pattern, 
e.g. DSG1 and DSC1 are more expressed  in  the upper granular  layers, whereas DSG3 and 
DSC3 are expressed  in the basal and spinous  layers (Figure 5). These differential expression 
patterns could have a role in epidermal morphogenesis as DSG1 and DSC1 seem to promote 
strong  cell‐cell  adhesion  and  keratinocyte  terminal  differentiation, whereas  expression  of 
DSG3  and  DSC3  may  be  related  to  inhibition  of  differentiation  and  stimulation  of 






intercellular  junctions. Deletion of  the desmoplakin gene  in mice  results  in  lethality during 
embryonic development, whereas a double knockout of both envoplakin and periplakin  in 
mice  does  not  affect  skin  barrier  formation  and  function17,18.  In  corneodesmosomes  the 
intercellular  junction  is enhanced with  the  secreted  glycoprotein  corneodesmosin  (CDSN), 
 
 
Figure  4:  Structure  of  desmosome  super‐
imposed  on  electron  micrograph.  The 
extracellular  domains    of  desmosomal 
cadherins  (DSG  and  DSC)  form  the  adhesive 
intercellular junction shown as a dense midline 
(DM).  The  outer  dense  plaques  (ODP) 
represent the armadillo proteins  (PG and PKP) 
that  form  the  link  between  desmosomal 
cadherins  and  plakins  (DP).  Plakins  are 
anchoring  points  for  intermediate  filaments 
(IF)  of  the  cytoskeleton.  Reprinted  with 
permission  from:  Green,  K.J.,  Simpson,  C.L. 




intercellular  junctions  between  corneocytes,  proteolysis  of  corneodesmosomal  proteins, 
especially the desmosomal cadherins and CDSN,  is essential  in this process. Degradation of 
corneodesmosomal proteins  is mediated by  secreted  skin proteases, primarily  serine, but 
also aspartic and cysteine proteases. It has been suggested that desquamation results from 
pH‐dependent  activation  of  several  protease  families  as  the  pH  of  the  stratum  corneum 
changes  from neutral  in  the  lower  layers  to  acidic  in  the upper  layers21. Previous  studies 
have  demonstrated  that  the  serine  proteases  kallikrein‐5  and  7  (KLK5,  KLK7)  are  able  to 






Proteolytic enzymes  are proteins  that hydrolyse peptide bonds  and  are  commonly 
termed proteases, proteinases, peptide hydrolases or peptidases, of which the latter term is 
actually  recommended  by  the  Nomenclature  Committee  of  the  International  Union  of 
Biochemistry  and  Molecular  Biology  (NC‐IUBMB),  but  here  the  term  protease  is  used. 
Proteases  act  as  either  endopeptidases,  that  cleave  internal  bonds  within  a  protein,  or 
exopeptidases,  that cleave at or near  the N‐ or C‐terminus of  the polypeptide chain. Since 
















as apoptosis, antigen presentation,  inflammation,  tissue  remodelling, angiogenesis, wound 
healing,  fertilization,  neurodegeneration,  tumorigenesis,  and  metastasis.  Regulation  of 
protease activity  is essential as alterations  in protease expression,  structure, or  regulatory 
mechanisms could lead to physiologic disturbance and pathology26‐28.  
15  years  ago  Rawlings  and  Barrett  introduced  a  system  for  classification  of  all 
proteases, that has developed since and is implemented in the MEROPS peptidase database, 
that  contains  “Summary pages” with  information and  links  for ~3000 proteases  (Figure 6; 
merops.sanger.ac.uk)29.  In  this  system  the  proteolytic  enzymes  are  categorized  into  six 
classes  of  proteases  depending  on  the  nature  of  their  catalytic  mechanism:  aspartic 
proteases, glutamic proteases, metalloproteases, serine proteases, threonine proteases, and 
cysteine  proteases;  and  each  class  is  denoted with  its  initial  letter  (A, G, M,  S,  T,  and  C, 
respectively).  Some  proteases  are  grouped  as  “Unclassified”  (U)  due  to  uncertainty  of 
catalytic mechanism. Metalloproteases  incorporate a metal  ion  in their catalytic site that  is 
essential for hydrolysis, while in the other protease classes certain amino acid residues in the 
catalytic  site  are  essential.  Remarkably,  aspartic  proteases,  glutamic  proteases  and 
metalloproteases  use  an  activated water molecule  as  nucleophile  in  catalysis, while  the 
attacking nucleophile of  serine,  threonine and  cysteine proteases  is an  internal oxygen or 
sulphur  atom  in  the  side  chain  of  the  amino  acid  (Figure  7).  Each  class  of  proteases  is 






proteases.  Proteases  cleave  peptide  bonds  via 
hydrolysis.  In  serine  proteases,  threonine 
proteases, and cysteine proteases the attacking 




Subsequently,  the  peptide  bond  is  cleaved  by 
the  attack  of  the  sulfur  atom  (step  2)  and  the 
proton  is  used  to  create  the  new  amino 
terminus  of  the  cleaved  substrate  (step  3).  A 
water molecule  (H2O)  catalyzes  release  of  the 
protease‐substrate complex (step 4). H2O is used 
to  restore  the  sulfhydryl group of  the protease 
and  to  create  a  new  carboxy  terminus  of  the 
remaining  substrate  (step  5).  Contrary,  in 














no  aspartic  exopeptidases  have  been  described  so  far.  In  aspartic  proteases  the  catalytic 
residues are two aspartate (Asp) residues (for names, abbreviations, and structures of amino 
acids  see  figure  8),  that  are  centrally  located  in  the  substrate‐binding  cleft,  although  the 





residues31. Most  aspartic proteases  are  stable at neutral pH, but  show optimal  activity  at 
acidic pH. Six clans of aspartic proteases have been assigned of which clan AA contains the 
large  family  A1  of  pepsin‐like  proteases.  Family  A1  includes  gastric  enzymes  pepsin  A, 
gastricsin, and chymosin, which are involved in digestion32; lysosomal proteases cathepsins D 
and E, which have been implicated in several physiologic and pathophysiologic mechanisms 
including  skin barrier  formation  and  tumorigenesis33‐35;  β‐secretase BACE‐1  (memapsin‐2), 
which  is  responsible  for  generation of  amyloid plaques  in Alzheimer disease36;  and  renin, 
which  is  part  of  the  renin‐angiotensin  system  that  is  involved  in  control  of  body  fluid 




Class      Clan    Family      Protease 
Aspartic    AA    A1      Pepsin 
      and others  and others 
Cysteine    CA    C1      Papain 
          C2      Calpain 
          and others 
      PA(C)    C3      Picornain 
          and others 
      CD    C13      Legumain 
          C14      Caspase 
      and others  and others 










Recently,  the  group  of  glutamic  proteases  was  added  to  the  classification  of 
proteolytic  enzymes  due  to  the  identification  of  a  new  catalytic  mechanism  in  fungal 
proteases39,40.  Glutamic  proteases  share  common  features  with  aspartic  proteases  since 









also  cobalt, manganese, nickel or  copper. Most metalloproteases  require one  zinc  ion  for 
catalysis,  but  some  families,  including  metalloproteases  that  incorporate  cobalt  or 
manganese, use two metal ions that act co‐catalytically. Co‐catalytical metalloproteases act 
as exopeptidases, whereas metalloproteases with one metal  ion may be exopeptidases or 
endopeptidases.  In  the  catalytic  site  specific  amino  acid  residues  (histidine,  glutamate, 
aspartate or  lysine) act as  ligands for positioning of the metal ion, while another one  is the 
catalytic  residue  that  activates  the  water  molecule,  usually  Glu.  The  largest  clan  of 
metalloproteases  is  clan  MA  comprising  zinc‐dependent  metalloproteases  and  is 
characterized by  the  zinc‐binding motif containing  two histidine  (His)  residues,  that act as 
zinc‐binding ligands, and one Glu as catalytic residue: His‐Glu‐Xaa‐Xaa‐His (“HEXXH motif”)41. 
Clan MA can be divided  into two subclans based on the third zinc  ligand that  is  located C‐
terminally  of  the HEXXH motif.  The  gluzincins  of  subclan MA(E)  have Glu  as  third  ligand, 
whereas His or Asp  is  the  third  ligand  in metzincins of subclan MA(M). The metzincins are 
also distinguished by the presence of a conserved β‐turn that contains a methionine residue 
(“Met‐turn”)  and  all metzincins  are  endopeptidases42.  Family M10  of  the metzincins  are 
known  as  matrix  metalloproteases  (MMPs),  including  collagenases,  gelatinases, 
stromelysins, matrilysins,  and membrane‐type MMPs,  that  are  involved  in degradation of 










generally  little  activity  in  acidic  environments.  Family  S1,  categorized  in  clan PA(S),  is  the 
20
largest  family of all proteases and  compromises only endopeptidases  that are  involved  in 
several  pathways  of  differentiation  and  development,  blood  coagulation,  immunity,  and 
digestion.  Within  family  S1  three  main  activity  types  can  be  distinguished:  trypsin‐like, 
chemotrypsin‐like,  and  elastase‐like  activity  with  cleavage  following  arginine  or  lysine 
residues, hydrophobic amino acids (e.g. leucine), and alanine at the P1 position, respectively. 
Family  members  include  granzymes,  which  induce  cell  death  in  virus‐infected  cells47; 




Threonine proteases  form a small class with  five  families of which  four  families are 
categorized in clan PB(T) containing N‐terminal nucleophile hydrolases (Ntn‐hydrolases) and 
one  family not assigned  to a clan yet. Ntn‐hydrolases are endopeptidases  in which  the N‐
terminal  residue  of  the mature  protein  is  catalytic  (serine,  threonine  or  cysteine).  In  all 
families of clan PB, except family T1, protease activity is restricted to autocatalytic activation 
of  the  proenzyme  and  once  the mature  protein  is  generated  it  ceases  to  have  protease 
activity.  In  family  T1  of  proteasome  proteases  the  hydroxyl  group  of  the  N‐terminal 
threonine (Thr) is the attacking nucleophile with Asp/Glu and Lys as other catalytic residues 
that  act  in  a  similar  way  as  His  and  Asp  in  serine  proteases50,51.  The  identification  of 
threonine proteases is linked to the resolution of the structure of proteasomes, large protein 
complexes that degrade proteins tagged by ubiquitination, thereby preventing accumulation 
and  aggregation  of  misfolded,  damaged,  and  potentially  toxic  proteins,  and  controlling 
cellular processes through signal‐mediated proteolysis of regulatory proteins. A proteasome 









PA(C),  CD,  and  others),  but  other  amino  acid  residues  have  also  been  found  in  certain 
families such as the caspases that use proline (Pro) or Thr55,56. Contrary to serine proteases, 
most  cysteine  proteases  are  active  at  acidic  pH  with  generally  little  activity  in  neutral 
environments. The class of cysteine proteases is divided into twelve clans of which clans CA, 
PA(C), and CD are best‐known. Clan CA  includes  the papain  family  (C1),  that  is  formed by 
lysosomal  cysteine  proteases  known  as  cathepsins  (more  about  cathepsins  in  further 
sections),  and  the  calpain  family  (C2)  of  cytosolic  calcium‐dependent  proteases,  that  are 
involved  in muscular dystrophy  and neurodegenerative diseases  through  their  function  in 
cellular  processes  such  as  cytoskeletal  remodelling,  signal  transduction  pathways,  and 
21
apoptosis57,58.  Clan  PA(C)  comprises  viral  proteases  including  family  C3  of  picornains, 
endopeptidases from RNA viruses of the Picorna group such as polio and hepatitis A viruses. 






  Lysosomal  proteases  were  long  considered  to  be  primarily  responsible  for 
intralysosomal  protein  degradation,  mediating  “housekeeping”  functions  in  the  cell. 
However,  numerous  investigations  have  shown  that  these  proteases,  the  classical 
cathepsins, are involved  in a variety of physiologic processes such as proenzyme activation, 
enzyme activation, antigen presentation, hormone maturation, tissue remodeling, and bone 
matrix  resorption60.  Recent  studies  also  suggest  that  cathepsins  act  as  mediators  of 
programmed  cell death, and have demonstrated apoptosis pathways  to be dependent on 
lysosomal cathepsin activity61,62. Cathepsins are cysteine proteases of the papain family (C1 ) 
with  the  exception  of  aspartic  proteases  cathepsins  D  and  E  and  the  serine  protease 
cathepsin G; so far eleven human cysteine cathepsins have been decribed (cathepsins B, C, F, 
H,  K,  L,  O,  S,  V/L2,  W,  and  X).  The  subfamily  of  cathepsin  L‐like  cathepsins  (including 
cathepsins K,  L, S, and V)  can be  recognized as  they have  larger proregions  (compared  to 
cathepsin B) and contain  two conserved motifs  in  their amino acid sequence  (“GNFD” and 
“ERFNIN” motifs)63,64. Most  cathepsins  are monomeric  proteins  with  sizes  of  20‐40  kDa 
except cathepsin C (also known as dipeptidyl‐peptidase I) that can form functional oligomers 
of 200 kDa65. Some cathepsins are widely expressed, such as cathepins B, C, and L, which are 
considered  to  be  responsible  for  general  “housekeeping”  functions  next  to  their  specific 
functions, whereas others have a more restricted tissue distribution, such as cathepsins K, S, 
and V, suggesting that these only fulfil organ specific functions.  
The  production,  activation,  and  compartmentalization  of  cysteine  cathepsins  is  an 
intricate process, that  involves multiple  factors and pathways, and varies among cell types 
and  tissues. Most  studies have  focused on  cathepsins B,  L,  and  aspartic  cathepsin D, but 
generally  the main mechanisms  that  are  described  in  this  section,  can  be  applied  to  all 
cathepsins  due  to  their  overall  similarity.  Cathepsins  are  synthesized  as  inactive 
preproenzymes at the rough endoplasmic reticulum (ER) and targeted into the lumen of the 
ER by  the  signal peptide. After  cleavage of  the  signal peptide by ER  signal peptidase  and 
proper folding of the proteins, the procathepsins are transported to the Golgi apparatus for 
post‐translational glycosylation and mannose‐6‐phosphorylation. The proregion  is essential 
for  these  processes  since  loss  of  the  proregion  results  in  improper  folding with  protein 
instability, ER retention, and lack of mannose‐6‐phosphorylation as secondary effects66,67. At 
the  trans‐Golgi  network  procathepsins  are  transported  into  clathrin‐coated  vesicles  via 
mannose‐6‐phosphate  receptor‐mediated  sorting  and  subsequently  directed  to  late 




have  shown  to  be  inhibitors  of  the  mature  enzymes70‐74.  The  mechanisms  behind  the 
processing and functions of the various cathepsin forms are not completely elucidated yet, 
but  several  studies  have  shown  that  autoactivation  mechanisms,  both  intermolecularly 
(mature  cathepsin  processes  procathepsin)  and  intramolecularly  (procathepsin  processes 
itself),  as  well  as  proteolytic  processing  by  other  lysosomal  proteases  including  other 
cysteine  cathepsins,  legumain,  and  cathepsin  D,  are  involved  in  cysteine  cathepsin 
maturation. X‐ray crystallography of procathepsin B, L, and S has shown that the proregion 
interacts  with  the  mature  part  of  the  protease  at  the  substrate  binding  cleft,  but 
interestingly  it  binds  to  the  active  site  cleft  in  the  reverse  substrate  orientation75‐81. 
Procathepsin is first processed into the cleaved propeptide and an active single‐chain form, 
that  subsequently  can  be  further  cleaved  into  an  active  two‐chain  form.  The  latter 
processing step presumably occurs  in  lysosomes after mature single‐chain cathepsins have 
been transported there from  late endosomes. No  functions specifically  for the single‐chain 
or two‐chain forms have been found, and it is not known whether this conversion regulates 
cathepsin  activity  or  substrate  specificity,  but  the  distribution  and  ratio  of  both mature 
forms may differ among tissues as has been shown for cathepsin L82. 
Besides the default endosomal‐lysosomal pathway, additional trafficking mechanisms 
for  cathepsins  exist  depending  on  cell  type  or  tissue.  In  thyrocytes,  keratinocytes,  and 
osteoclasts  mature  cathepsins  can  be  selectively  loaded  from  lysosomes  into  transport 
vesicles, directed to the plasma membrane, and subsequently secreted into the extracellular 
space, where  they may process and activate other proteases or contribute  to extracellular 
matrix  remodelling83‐86.  Another  secretory  pathway  involves  direct  secretion  of  inactive 
cathepsins  via  the  tubulovesicular  structures  of  the  trans‐Golgi  network  by  alternative 
sorting  signals  located  in  the  proregion,  or  by  absence  of  mannose‐6‐phosphorylation 
receptor‐mediated  sorting  in  cells  such  as  macrophages  and  fibroblasts  due  to  missing 
receptors  or  lack  of  mannose‐6‐phosphorylation.  Acidic  microenvironments  in  the 
extracellular  space  could  then  trigger  processing  and  activation  of  procathepsins,  or  re‐
internalization at the plasma membrane via endocytosis could traffic the previously secreted 
procathepsins back  to endosomes and  lysosomes  (Figure 9:  routes B‐D)69,87,88. The  finding 





occurs,  procathepsins  secreted  by  the  trans‐Golgi  network  avoid  the  acidic  lysosomal 
compartments  and  could  form  these  complexes  autocatalytically  in  slightly  acidic 
environments during transport through the trans‐Golgi network.  In body  fluids that have a 





Figure  9:  Trafficking  pathways  of  cathepsins.  Multiple  trafficking  pathways  of  cathepsins  exist 
depending on cell type and tissue. RNA is translated for protein synthesis by ribosomes. The classical 
route  via  the  endoplasmic  reticulum,  trans‐Golgi  network,  and  endosomes  to  the  lysosomes  is 
depicted as route A. Secretory pathways of  the  (pro)cathepsins  from  the  lysosomes and  the  trans‐
Golgi network are routes B and C, respectively. Endocytosis could traffic previously secreted inactive 
procathepsins back to endosomes and lysosomes (route D). Route E represents release of cathepsins 
from  lysosomes  into  the  cytosol  through  lysosomal destabilization or membrane permeabilization 
leading  to  cell  death.  Alternative  splicing  and  exon  skipping  results  in  transport  of  cathepsins  to 
mitochondria and the nucleus (routes F and G, respectively). 
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Lysosomal  destabilization  or  membrane  permeabilization  by  oxidative  stress, 
lysosomotropic agents, and other molecules  results  in  leakage of mature  cathepsins  from 
lysosomes  into  the  cytosol  where  they  perform  proteolytic  functions  in  apoptotic 
pathways61,62,90.  Alternative  splicing  and  exon  skipping  of  cathepsin  mRNA  may  occur 
resulting in protease variants that lack the signal peptide and are not directed to the ER. In 
chondrocytes,  a  cathepsin  B  splice  variant  lacking  exon  2  and  3  is  directed  to  the 
mitochondria, because N‐terminal truncation exposes a latent mitochondrial import signal91. 
Experiments with N‐terminally  truncated cathepsins have shown  that  these can also enter 
the  cell  nucleus  and  participate  in  processing  of  transcription  factors  (Figure  9:  routes  E‐










has  SP1,  SP3,  and  NF‐Y  sites  for  transcriptional  regulation.  Alternative  splicing  results  in 
multiple cathepsin L variants that differ at the 5’ untranslated mRNA region60,94,95. Generally, 
mRNA translation produces preprocathepsin L   of 333 amino acids with a mass of ~37 kDa, 
and  during  intracellular  transport  to  the  lysosomes  the  preproenzyme  is  subsequently 
modified  to  procathepsin  L  of  ~35  kDa  (residues  18‐333)  and  processed  into  the mature 
forms of cathepsin L  (residues 114‐333). Processing of procathepsin L  results  in a ~30 kDa 
single‐chain form of cathepsin L, which  in turn can be further processed  into the two‐chain 
form   by cleavage of  the single peptide chain after Asp291  into heavy and  light chains  (25 
and 5 kDa; Figure 10)96. Human cathepsin L contains three internal disulfide bonds and one 
N‐glycosylation  site  (Asn221);  its  catalytic  triad  is  formed by Cys138, His276,  and Asn300. 
Cathepsin L mainly acts as an endopeptidase and preferentially cleaves peptide bonds with 
aromatic  residues  in  the P2 position and hydrophobic  residues  in  the P3 position97,98. The 
protease is catalytically active within the pH range of 3.5‐6.5, but optimal pH is 5.5, while at 
neutral  pH  cathepsin  L  is  highly  unstable  and  irreversibly  inactivated99‐101.  Inhibitors  of 




cardiac  function,  antigen  presentation,  and metabolism.  In  lysosomes,  cathepsin  L  could 
process and activate other proteases such as cathepsin D, but also perform degradation of 
proteins  such  as  membrane  receptors  and  molecular  chaperones104‐107.  Insufficient 
lysosomal  protein  degradation may  lead  to  enlargement  and  accumulation  of  lysosomes 
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disturbing  cellular  homeostasis  and  inducing  apoptosis.  In  addition,  cytosolic  cathepsin  L 
could  cleave  the  anti‐apoptotic  Bcl‐2  family member  Bid  into  a  truncated  form, which  is 
involved in apoptotic signaling pathways. Truncated Bid translocates into the mitochondria, 
where  it  stimulates  release of  cytochrome  c  that  leads  to apoptosome  formation and  cell 
death61,62. In many cancers overexpression of cathepsin L is reported, which could contribute 





most  evident  characteristic  of  cathepsin  L  deficient mice  is  the  skin  and  hair  phenotype 
showing  epidermal  hyperplasia  and  hyperkeratosis  with  abnormal  hair  follicle 
morphogenesis and cycling113. Enhanced  recycling of epidermal growth  factor  receptors  in 
ctsl‐/‐  mice,  probably  due  to  longer  half‐life  of  the  receptors  because  of  insufficient 
degradation  in  lysosomes, results  in  increased keratinocyte proliferation114. Ctsl‐/‐ mice also 
suffer from dilated cardiomyopathy as cathepsin L is essential for maintaining the structure 
of  the  endosome‐lysosome  compartment  in  cardiomyocytes.  In  addition,  sarcomeric 





Figure  10:  Processing  of  human  cathepsin  L,  cathepsin  V,  and  legumain.  Cathepsin  L  (CTSL), 
cathepsin V (CTSV), and legumain (LGMN) are produced as inactive preproenzymes. Cleavage of the 
signal peptide by signal peptidase  (A) at  the ER  results  in  the  inactive proenzyme. Proenzymes are 
processed  in multiple  steps  into  the  active mature  forms  via  autocatalytic mechanisms  (B)  and 






the  thymus  and  periphery118,119.  A  role  in  obesity  and  diabetes  has  been  suggested  as 
cathepsin L might participate  in adipogenesis and glucose  intolerance. Cathepsin L  in vitro 
degrades  the matrix protein  fibronectin  that  restrains pre‐adipocytes  from differentiation, 
thus  inhibition of cathepsin L resulted  in reduced  lipid accumulation. Cathepsin L deficient 
mice that were put on a rich diet gained little body weight and stayed lean, whereas control 
littermates  showed  increased body mass and accumulation of adipose  tissue. The glucose 
metabolism  is affected since  insulin receptors are degraded by cathepsin L resulting  in  low 







Cathepsin  V,  also  known  as  cathepsin  L2,  is  closely  related  to  cathepsin  L  sharing 
~80% protein sequence  identity  for the mature proteins resulting  in a similar structure  for 
cathepsin V  as described previously  for  cathepsin  L.  Their encoding  genes  are  located on 
adjacent sites on chromosome 9q21‐22 with similar genomic organization, suggesting  that 
cathepsin  V  and  cathepsin  L  have  evolved  from  an  ancestral  gene.  Interestingly,  no 
orthologue  of  cathepsin  V  in  mouse  has  been  discovered  yet  and  cathepsin  V  is 
phylogenetically  more  related  to  mouse  cathepsin  L  than  to  human  cathepsin  L.  The 
cathepsin V gene spans ~6.4 kb, consists of eight exons and seven introns, and its promoter 
misses  a  TATA  box  and  has  a  SP1  site  for  transcription  initiation125‐128.  Cathepsin  V  is 
produced as a preproenzyme of 334 amino acids with a mass of ~37 kDa and subsequently 
processed into procathepsin V (residues 18‐334, ~35 kDa) and mature cathepsin V (residues 
114‐334).  Only  a  single‐chain  form  of  ~30  kDa  has  been  described  (Figure  10)125,126,129. 
Cathepsin  V  contains  three  internal  disulfide  bonds,  but  has  two  N‐glycosylation  sites 
(Asn221  and  Asn292)  compared  to  only  one  in  human  cathepsin  L;  its  catalytic  triad  is 
formed by Cys138, His277, and Asn301. Cathepsin V differs  from  cathepsin  L  in  substrate 
specificity as both aromatic and non‐aromatic hydrophobic residues are preferred in the P2 
position, however, cathepsin V  is  inhibited by  the same natural and synthetic  inhibitors of 
cathepsin L126,130,131. Another difference with cathepsin L  is  that cathepsin V  is significantly 
more stable at mildly acidic and neutral pH, which  is reflected  in  its activity range from pH 
4.1 to 7.4, although the pH optimum of 5.7 is close to that of cathepsin L126. 
Little  is  known  about  the  biological  functions  of  cathepsin  V,  but  the  protease 
probably  fulfills  tissue  specific  functions  as  its  expression  is  limited  to  specific  tissues: 




thymic  epithelial  cells  cathepsin  V,  and  not  cathepsin  L,  is  the  dominant  cysteine 
protease126,127,129. Its role in testis has not been studied yet, but cathepsin V may be involved 
in  fertilization  processes  as  has  been  suggested  for  other  lysosmal  proteases127,132. 
Previously named as stratum corneum thiol protease (SCTP)25,133, cathepsin V was identified 
as a secreted cysteine protease of late epidermal differentiation that is probably associated 
with  desquamation  as  its  pH  optimum  reflects  the  acidic  environment  of  the  stratum 
corneum. Specific epidermal  transgenic expression of human cathepsin V  rescued  the skin 
and hair phenotype in cathepsin L deficient mice indicating that cathepsin V can compensate 
for  cathepsin  L  in  epidermal  differentiation134.  Furthermore,  cathepsin  V  expression 
correlates  inversely with  skin  color, both on  the mRNA and protein  level, as expression  is 
higher in lightly pigmented skin compared to darkly pigmented skin. However, no differential 
expression  of  cathepsin  V  in melanocytes  could  be  found  suggesting  that  differences  in 
ethnic  skin  are  not  directly  associated  with  melanogenesis,  but  expand  beyond  the 
pigmentation process135. Cathepsin V has a role in eye physiology as it is highly expressed in 
corneal epithelium. Recent studies have suggested that cathepsin V is involved in the control 
of angiogenesis  in the eye, which  is  important for maintenance of corneal avascularity and 
transparency  that  are  essential  for  optimal  visual  performance.  Cathepsin  V  from 





be  a  cathepsin V  specific  function  as  cathepsins  B,  K,  and  L were  not  able  to  proteolyse 
plasminogen136,137. Cathepsin V has also been  implicated  in cardiovascular pathologies such 
as  atherosclerosis  since  cathepsins  K,  S,  and  V  contribute  to  the  elastolytic  activity  of 
macrophages in atherosclerotic plaques and diseased blood vessels. Increased expression of 
cathepsins  K,  S,  and  V  has  already  been  shown  in  aortic  stenosis  and  may  accelerate 
destruction of elastin matrix138,139. A role in tumorigenesis has been suggested as cathepsin 




  Legumain,  also  known  as  aparaginyl  endopeptidase  (AEP),  is  a  lysosomal  protease 
that  belongs  to  family  C13  of  cysteine  proteases  and  is  strictly  specific  for  hydrolysis  of 
asparaginyl  bonds.  However,  glycosylation  of  the  Asn  residue  in  the  substrate  prevents 








pH  4.5  resulting  in  an  active  legumain  form  of  46  kDa  that  cannot  be  further  processed 
autocatalytically (Figure 10). Autoactivation of  legumain  is an  intermolecular mechanism as 
activated legumain is able to process and activate prolegumain. However, since legumain in 
vivo has a mass of ~36 kDa,  the active 46 kDa  legumain  is not  the  final mature  form and 
further  processing  by  a  yet  unknown  lysosomal  protease  is  required142,143.  Legumain  is 
inhibited  by  α1‐macroglobuline,  some  of  the  cystatins  (C,  F,  and  M/E),  iodoacetate, 
iodoacetamide,  and  maleimides,  but  not  by  E‐64,  that  inhibits  most  cysteine  proteases 
including the cathepsins140,141,144.  
  Legumain  is  expressed  in  various  tissues,  but  found  abundantly  in  kidney,  more 
specifically in the proximal tubule, where in mice legumain might have a role in extracellular 
matrix  remodeling  via  intracellular  degradation  of  fibronectin145.  Studies  in  legumain 
deficient mice  showed  enlarged  lysosomes  in  kidney  cells  and  complete  absence  of  two‐
chain forms of cathepsins B, H, and L, indicating a function for legumain in lysosomal protein 
degradation and proteolytic processing of other  lysosomal proteases. Although  legumain  is 
essential  in  processing  of  single‐chain  cathepsin  L  to  two‐chain  cathepsin  L  in mice,  the 
single‐chain form alone  is sufficient enough for cathepsin L function  in vivo146,147. Legumain 
has been  shown  to be  involved  in  class  II MHC antigen presentation, but  legumain  is not 
essential  in this process as no differences  in processing of  invariant chain or maturation of 
class II MHC products were found between legumain deficient mice and wild type mice147‐149. 
Furthermore,  legumain  deficient mice  develop  a  phenotype  resembling  hemophagocytic 
syndrome  (hemophagocytic  lymphohistiocytosis,  HLH),  which  is  characterized  by  fever, 
anemia,  cytopenia,  hepatosplenomegaly,  and  hemophagocytosis  (ingestion  of  red  blood 
cells) by macrophages  in bone marrow, suggesting that  legumain might have a role  in HLH 
pathophysiology150. Overexpression of  legumain  in cancer has been correlated with  tumor 





invasive  and metastatic mechanism of malignant neoplasias,  and  the  course of  infectious 
diseases,  has  revealed  that  fundamental  knowledge  of  the  regulatory  mechanisms  of 






lysosomal  proteases  play  important  roles  in  physiologic  processes  not  restricted  to 
lysosomes only. For example, protease activity and regulation outside lysosomes potentially 
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contributes  to  propagation  of  apoptosis,  a  process  that  is  distinct  from  terminal 
differentiation  of  the  epidermis  but  nevertheless  shares  some  molecular  and  cellular 
features158. The  importance of regulated proteolysis  in epithelia159  is well demonstrated by 
the identification of the SPINK5 serine protease inhibitor as the defective gene in Netherton 
syndrome  (MIM  256500)160,  cathepsin  C  mutations  in  Papillon‐Lefevre  syndrome  (MIM 
245000)161, matriptase  deficiency  due  to mutations  in  the  ST14  gene  in  ichthyosis  with 






The  regulation  of  activity  of  cysteine  proteases  for  correct  functioning  is  a  fragile 
balance of many  factors, one of  the most  crucial being  their  cognate protease  inhibitors, 
which  include members of  the  cystatin  gene  family. Cystatins  are  small proteins  that  are 
widely distributed in several human tissues and body fluids. They are generally tight binding 
inhibitors of cysteine proteases such as cathepsins B, H, K, L, and S102, and should therefore 
serve  a  protective  function  to  regulate  the  activities  of  such  endogenous  proteases.  It  is 
thought  that  cysteine  proteases  and  their  inhibitors  play  an  important  role  in 
pathophysiologic  processes  such  as  invasion  of  normal  tissues  by  tumors  or  micro‐
organisms, viral  infections, and  inflammation164‐167. Cystatins are members of a superfamily 
of  evolutionary  related  proteins  and  can  be  divided  into  three  major  families:  family‐1 
cystatins (A and B), family‐2 cystatins (C, D, F, G, M/E, S, SN, and SA), and the kininogens (L‐ 
and H‐kininogens), which belong to family‐3 cystatins.  In general, cystatins are competitive 
reversible,  tight‐binding  proteins  that  inhibit  cysteine  proteases  in  a  µM  to  pM  range168. 
Family‐2 cystatins are viewed as “emergency” inhibitors, which means that they rapidly trap 
a  protease  without  delay  and  keep  it  in  a  stable  complex,  preventing  any  additional 
proteolysis155,169.  In  normal  situations  such  an  inhibitor  would  have  a  physiologic 
concentration  in  large excess over  the putative protease  target(s). These  inhibitors  are  in 




In  order  to  obtain  a  systematic  and  quantitative  overview  of  genes  expressed  by 
human  epidermal  cells  transcriptomes  of  cultured  human  keratinocytes  and  purified 
epidermal  cells were established via Serial Analysis of Gene Expression  (SAGE) and micro‐






primary breast  tumor  cells173.  Independently,  the  same molecule was  found by others via 
expressed sequence tag sequencing  in cDNA  libraries derived from epithelial cells, and was 
designated  cystatin  E174.  It  was  shown  that  it  was  really  a  protease  inhibitor,  as  the 
recombinant protein was able to  inhibit the plant protease papain. However,  in vivo target 
proteases and the function of this protease inhibitor were unknown.  
Cystatin M/E  is  a 14  kDa  secreted protein  that  shares only 35% homology with  the 
human  family‐2  cystatins.  Cystatin M/E  has  an  overall  structure  similar  to  other  family‐2 
cystatins,  such  as  a  signal  peptide  and  two  intrachain  disulfide  bonds,  but  possesses  the 
unusual  characteristic of being a glycoprotein. This protein  is only distantly  related  to  the 
other known family members as reflected by the genomic position of the cystatin M/E gene 
on  chromosome  11q13175,  whereas  all  other  family‐2  cystatin  genes  are  clustered  in  a 
narrow region on chromosome 20p11.2176. The full‐length cystatin M/E gene was cloned and 
sequenced, and deposited  as CST6  in  the GenBank database  (accession no. AY145051)177. 
The cystatin M/E gene is organized in three exons and two introns, and from the translation 
start  site  to  the  translation  termination  site  it  spans  1354  bp  of  genomic  DNA. 
Characterization of the genomic sequence of cystatin M/E shows some differences with the 
other type 2 cystatins. The size of both  introns was remarkably smaller compared to other 
cystatin  family‐2 members  (e.g. cystatin S, SA, SN, C, D). These cystatins harbor  introns of 
respectively 1.1 kb to 2.2 kb, whereas the introns of the cystatin M/E gene are only 542 bp 
and 365 bp  long. Besides, these family‐2 cystatins contain an  identifiable TATA‐box  in their 
5’‐flanking sequence, whereas cystatin M/E lacks this conserved sequence. Database analysis 
predicted three transcription start sites at respectively –75 bp, –42 bp, and –34 bp upstream 
to  the  translation  initiation  codon.  This  is  in  accordance with  the  average  length  of  the 
expressed  sequence  tags  found  in  the  public  database,  in which  the  start  positions  vary 
between approximately –60 bp and –20 bp. 
The  expression  pattern  of  human  cystatin M/E  is  unique  among  cystatins,  as  high 
expression  levels  are  largely  confined  to  cutaneous  epithelia,  while  other  cystatins  are 
mainly  ubiquitously  expressed.  In  human  skin,  cystatin  M/E  is  expressed  in  the 
differentiating  and  cornifying  layers  of  the  epidermis178.  This  is  in  accordance  with  the 
observation  that  in  vitro  cystatin  M/E  is  only  expressed  in  differentiating  but  not  in 
proliferating keratinocytes178. Cystatin M/E, which has a putative signal peptide, is indeed a 
secreted protein and is found in vitro in culture supernatant and in vivo in human sweat and 
semen178,179. Furthermore,  cystatin M/E  is also highly expressed  in  the appendages of  the 
skin like the secretory coils of the eccrine sweat glands, the sebaceous glands, and the hair 
follicles178.  Immunohistochemical data have also shown a moderate but specific expression 
of  cystatin M/E  in  the  bronchi  of  the  lung,  the  proximal  tubuli  of  the  kidney,  and  in  the 
cornea of the eye180. Cystatin M/E protein expression was recently also reported  in normal 






Analysis  of  adult  mouse  tissues  has  revealed  an  expression  pattern  that  is  less 
restricted  than  observed  previously  in  humans184.  Relatively  high  levels  of  cystatin M/E 
mRNA expression were found in skin, ileum, stomach, eye, and cerebellum; moderate to low 
levels  of  expression were  found  in  tongue,  palatum,  nasal  cavity,  colon,  bladder,  skeletal 
muscle, placenta, and thymus. During embryogenesis, mRNA expression of cystatin M/E was 
observed  from  day  16  onwards,  which  is  a  developmental  stage  where  epidermal 
stratification is completed. Cystatin M/E protein was found to be highly expressed in ciliated 
tracheal  epithelium  and  in  bronchial  epithelium.  Similar  to  the  expression  pattern  in 
humans, cystatin M/E was  found  in  the  infundibular epithelium of hair  follicles and  in  the 
stratum granulosum of  interfollicular epidermis. The mouse cystatin M/E gene, which was 
subsequently  cloned  and  characterized  (deposited  as  Cst6  in  the  GenBank  database, 
accession no. AY093591), has an exon‐intron structure  identical  to  that of all other  type 2 
cystatins  and  encodes  a  149  amino  acid  protein184.  Alignment with  its  presumed  human 
orthologue  revealed  69%  amino  acid  identity  and  82%  amino  acid  conservation.  The 









M/E  gene was  identified  in  these mutant mice.  This  42delG  deletion  alters  the  reading 
frame,  resulting  in  a  premature  stop  codon  at  amino  acid  position  20. 
Immunohistochemistry confirmed  the absence of  cystatin M/E at  the protein  level  in  ichq 
mice.  Mice  that  were  homozygous  for  two  null  alleles  displayed  a  hyperplastic, 
hyperkeratotic epidermis and abnormal hair follicles and died between 6 and 12 days of age. 
Heterozygous mice  and wild  type  littermates  displayed  a  normal  cystatin M/E  expression 





the  skin of  the cystatin M/E deficient mice  is  increased when compared  to phenotypically 







the  result of abnormal expression or processing of  structural components of  the cornified 
envelope. In two previous studies no abnormalities were found in structural proteins such as 
cytokeratins,  involucrin,  and  filaggrin185,187.  This  was  investigated  again  by  studying  the 
expression and distribution of loricrin, involucrin, and filaggrin, which are important stratum 
corneum proteins  that are  involved  in skin barrier  function.  Immunohistochemical analysis 
showed that all three proteins are normally expressed  in the skin of cystatin M/E deficient 
mice. However, Western blot analysis  revealed  that  loricrin monomers and  loricrin dimers 
are  strongly  diminished  in  skin  extracts  of  cystatin M/E  deficient mice186.  Although  two 
abundant protein bands of approximately 13 and 15 kDa were observed  in  the extracts of 
cystatin  M/E  deficient  mice,  in‐gel  tryptic  digestion  followed  by  matrix‐assisted  laser 
desorption/ionization  time‐of‐flight  (MALDI‐TOF)  mass  spectrometry  revealed  that  these 
were  not  low molecular  weight  degradation  products  of  loricrin.  The  13  kDa  band  was 
identified  as  S100  calcium binding protein A9  (or  calgranulin B),  and  the  15  kDa band  as 
epidermal  fatty  acid  binding  protein  (E‐FABP),  which  have  been  described  as  epidermal 
proteins  that  are  strongly  upregulated  during  epidermal  inflammation  and  following  skin 
barrier  disruption,  respectively188,189.  The  strongly  diminished  expression  of  loricrin 










protease  resulting  in  the  release  of  30  kDa  and  47  kDa  fragments, which  then  associate 
together  and  form  the  active  enzyme191.  Western  blot  analysis  revealed  an  abundant 
presence  of  proteolyzed  (and  hence  activated)  TGM3  in  skin  extracts  of  cystatin  M/E 
deficient  mice  at  day  6,  whereas  no  appreciable  levels  of  proteolyzed  TGM3  could  be 
detected in skin extract of wild type littermates186. This indicated that premature, high levels 
of  activated  TGM3  are  present  at  the  time  when  skin  lesions  develop  in  cystatin  M/E 
deficient mice.  It was hypothesized  that  cystatin M/E  controls  the activity of an unknown 
protease  that  is  responsible  for  TGM3  activation,  which  leads  to  crosslinking  of  loricrin 







Several  studies have  shown  that cysteine proteases  such as cathepsins B and L are 
involved  in  cancer  through  their  role  in  proteolytic  pathways  that  enable  tumor  growth, 
migration,  invasion,  and  metastasis.  This  is  supported  by  increased  cysteine  protease 
expression  in  a wide  variety  of  cancers154.  The  importance  of  the  fine  balance  between 





a  primary  tumor  to  a  metastatic  phenotype173.  This  hypothesis  was  tested  in  vitro  by 
transfection of  the highly  tumorigenic and metastatic human breast cancer cell  line MDA‐





showed  no  effect  on  cell  proliferation  and  endothelial  adhesion.  This  finding made  the 
authors  suggest  that cystatin M/E may act as a  tumor and metastasis  suppressor  through 
other mechanisms (than cathepsin inhibition), perhaps via its inhibitory effects on legumain 
or even through modulation of gene transcription. Cystatin M/E expression in MDA‐MB‐435S 
cells  significantly  changed  the  expression  of  several  genes  involved  in  tumor  growth, 
invasion, and angiogenesis including downregulation of autotaxin, a signaling molecule that 
has been  linked  to breast  cancer  invasiveness194. Subsequently,  the  transfected MDA‐MB‐
435S cells were  injected  into scid mice to test  if cystatin M/E expression might have  in vivo 
tumor suppressing functions195. The mice were analyzed for tumorigenesis and spontaneous 
metastasis  in the  lungs and compared with mice  implanted with mock controls. During the 
first  45  days,  scid mice  bearing  orthotopically  injected  cystatin M/E‐expressing MDA‐MB‐
435S cells developed significantly smaller tumors than mock‐injected controls, however, no 
difference was  found  in  the  incidence  of metastasis  and  number  of  lesions  in  the  lungs. 
Cystatin  M/E  expression  showed  no  effect  on  seeding  and  survival  of  tumor  cells,  but 
reduced the growth of established  lung tumors, which suggests that cystatin M/E has anti‐
proliferative  activity. One  should  keep  in mind  that  there  is  some  controversy  about  the 
origin  of  the MDA‐MB‐435S  cancer  cell  line,  as  it was  reported  that  these  cells may  be 
derived  from melanocytes and as  such  cannot be  considered with absolute  certainty as a 
model  for  breast  cancer196.  Preliminary  studies  using  laser‐capture  dissection  of  human 
breast cancer cells varied  in outcome. Zhang and co‐workers reported a downregulation of 
cystatin  M/E  mRNA  and  protein  expression  in  invasive  ductal  carcinomas  compared  to 




(BCC) of  the skin, squamous cell carcinomas  (SCC)  from  the  lung, and  in  lung cancer198,199, 
but  in  oropharyngaeal  SCC  cystatin  M/E  expression  was  found  to  be  increased  with 
metastasis along with elevated  cathepsin expression200. Silencing of  cystatin M/E by  small 
interference  RNA  (siRNA)  in  a  metastatic  oral  cancer  cell  line  increased  in  vitro  cell 
proliferation,  migration,  and  Matrigel  invasion,  emphasizing  the  tumor  and  metastasis 
suppressing  abilities  of  cystatin M/E201.  Gene  expression  profiling  of  cutaneous  SCC  and 
psoriasis,  a  study  designed  to  compare  malignant  versus  benign  keratinocyte 
hyperproliferation, revealed that cystatin M/E and several proteases were among the genes 




Collectively  these  data  suggest  that  cystatin M/E  could  act  as  a  tumor  suppressor 
through various mechanisms of action  including  inhibition of cysteine protease activity and 
modulation of gene transcription. However, it is not yet clear what the exact role of cystatin 
M/E  is  in  tumorigenesis  and metastasis  as  both  down‐  and  upregulation  has  been  found 
depending  on  the  type  of  cancer,  suggesting  that  altered  cystatin M/E  expression  could 
either have a causative effect or is, alternatively, a protective response. In a previous study 
we concluded that cystatin M/E expression was not a useful marker to discriminate between 









altering  DNA  sequence,  and  it  explains  how  gene  activity  is  regulated  in  response  to 




development, mental health, and ageing, and  therefore, are  thought  to be  involved  in  the 
pathophsyiology  of  multifactorial  diseases  and  cancer.  Genomic  DNA  is  wrapped  in 
chromatin, which  can be  structured as decondensed euchromatin,  that  is  transcriptionally 





transcription  (e.g.  histone  acetylation  is  associated  with  transcriptional  activity).  DNA 
methylation  involves  methylation  of  the  cytosine  in  CpG  dinucleotides,  especially  those 
located in CpG islands within gene promoters, and represses transcription by either blocking 
the  binding  of  specific  transcription  factors  to  DNA  or  by  recruiting methyl‐CpG‐binding 
proteins that are associated with chromatin remodeling205‐209.  
Recently,  epigenetic  studies  reported DNA methylation‐dependent  silencing  of  the 
cystatin  M/E  gene  in  breast  cancer  cell  lines,  primary  breast  tumors,  and  metastases. 
Hypermethylation,  especially  of  the  CpG  island  present  in  the  CST6  proximal  promoter 
region, was  significantly  associated with  gene  silencing  and  loss  of  cystatin M/E  protein 
expression, while  treatment with  the  demethylating  agent  5‐aza‐2’deoxycytidine  induced 
cystatin M/E mRNA expression  in breast  cancer  cell  lines182,210,211. Cystatin M/E promoter 
methylation (and loss of cystatin M/E protein expression) occurred more frequently in lymph 
node metastases,  whereas  primary  tumors  were  found  to  be  negative  for  cystatin M/E 







cystatin M/E  was  the main  inhibitor  of  legumain  in  skin  since  absence  of  cystatin M/E 
resulted in free cellular activity of legumain in epidermis and hair follicles. This matched the 
localization of tissue pathology  in these mice such as excessive cornification  in hair follicles 
and epidermis  leading  to plugging of  the hair  follicle  and  ichthyosis. No  legumain  activity 
could  be  demonstrated  in  the  skin  of  wild  type  littermates,  which  suggested  that  the 
presence  of  cystatin M/E  normally  regulates  legumain  activity  in  skin  in  vivo.  However, 
cystatins are generally considered to be inhibitors of the papain‐like cathepsins, but despite 
biochemical  enzyme  assays  on  cathepsin  inhibitory  activity  of  cystatin M/E,  the  cognate 
target cathepsin of cystatin M/E was still not identified. Although expression of cystatin M/E 
has been found in other organs such as kidney, lung, and eye, studies in ichq mice could not 
indicate  if cystatin M/E deficiency has  (patho)physiologic consequences  in  these organs as 
offspring dies 6‐12 days postnatally from the lethal skin phenotype before other organs are 
fully  developed.  The  studies  performed  in  this  thesis  were  aimed  on  investigating  the 
following issues: 
 
I. Identification  of  target  proteases  of  cystatin M/E, more  specifically: which 
cysteine cathepsin(s) are inhibited by cystatin M/E? 
 











IV. Role of cystatin M/E and  its  target proteases  in  skin diseases with  impaired 
barrier formation and function.  
 
V. Function  of  cystatin M/E  in  other  organs:  transgenic  expression  of  cystatin 
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Cystatin M/E Is a High Affinity Inhibitor of Cathepsin V
and Cathepsin L by a Reactive Site That Is Distinct
from the Legumain-binding Site
A NOVEL CLUE FOR THE ROLE OF CYSTATIN M/E IN EPIDERMAL CORNIFICATION*
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CystatinM/E is a high affinity inhibitor of the asparaginyl endopep-
tidase legumain, and we have previously reported that both proteins
are likely to be involved in the regulation of stratum corneum forma-
tion in skin. Although cystatin M/E contains a predicted binding
site for papain-like cysteine proteases, no high affinity binding for
anymember of this family has been demonstrated so far.We report
that human cathepsin V (CTSV) and human cathepsin L (CTSL) are
strongly inhibited byhuman cystatinM/E.Kinetic studies show that
Ki values of cystatin M/E for the interaction with CTSV and CTSL
are 0.47 and 1.78 nM, respectively. On the basis of the analogous
sites in cystatin C, we used site-directed mutagenesis to identify
the binding sites of these proteases in cystatinM/E.We found that
the W135A mutant was rendered inactive against CTSV and CTSL
but retained legumain-inhibiting activity. Conversely, the N64A
mutant lost legumain-inhibiting activity but remained active against
the papain-like cysteine proteases. We conclude that legumain and
papain-like cysteine proteases are inhibited by two distinct non-over-
lapping sites. Using immunohistochemistry on normal human skin,
we found that cystatin M/E co-localizes with CTSV and CTSL. In
addition, we show that CTSL is the elusive enzyme that processes
and activates epidermal transglutaminase 3. The identification of
CTSV and CTSL as novel targets for cystatin M/E, their (co)-
expression in the stratum granulosum of human skin, and the
activity of CTSL toward transglutaminase 3 strongly imply an
important role for these enzymes in the differentiation process of
human epidermis.
The cellular activity of a protease is the result of many regulatory
mechanisms such as the concentration and compartmentalization of
substrates, the enzyme itself, and its cognate inhibitors. Cystatins are
the natural and specific inhibitors of endogenousmammalian lysosomal
cysteine proteases and have shown important regulatory and protective
functions in cells and tissues against proteolysis by cysteine proteases of
host, bacterial, and viral origin (1–3). The inhibitory activity of cystatins
is regulated by a reversible, tight-binding interaction between the
protease inhibitor and its target protease (4). Disturbance of the
normal balance between cysteine proteases and their inhibitors at a
wrong time and location can lead to several pathological conditions
such as chronic inflammatory reactions (5), tumor malignancy (6),
and faulty differentiation processes in the epidermis and hair follicle
(7). Little is known on the specific biological functions of cystatin
family members. However, mutations in the genes encoding the cys-
tatin family members cystatin B and C cause neurological pheno-
types in humans (8, 9).
Cystatin M/E is a 14-kDa secreted protein that shares only 35%
homology with other human type 2 cystatins. Nevertheless, it has a
similar overall structure including the two characteristic intrachain
disulfide bridges (10, 11). Expression of cystatin M/E is found to be
restricted to the epidermis, more specifically in the stratum granulo-
sum, sweat glands, sebaceous glands, and the hair follicles (12, 13). In
addition to its function as a cysteine protease inhibitor, cystatin M/E
also serves as a target for cross-linking by transglutaminases (12). These
findings have suggested an important role for cystatinM/E in skin phys-
iology. We have previously reported that a null mutation in the mouse
cystatin M/E gene causes the murine ichq phenotype, which is charac-
terized by neonatal lethality and abnormalities in cornification and des-
quamation, demonstrating an essential role for cystatinM/E in the final
stages of epidermal differentiation (14). However, cystatin M/E was
excluded as the causative gene in a lethal form of ichthyosis in humans
(15). Recently, we proposed the involvement of the asparaginyl endopepti-
dase legumain in disturbed epidermal cornification in cystatin M/E-defi-
cient mice (16). Legumain belongs to family C13 of cysteine proteases,
which is unrelated to the family of papain-like cysteine proteases, and is
strictly specific for hydrolysis of asparaginyl bonds (17). This lysosomal
protease was shown to be involved in the processing of other lysosomal
proteases such as cathepsins B, H, and L (18, 19). Furthermore, a bio-
chemical study on legumain has indicated that cystatin M/E in vitro
binds to this protease with high affinity (20). We have shown that
cystatin M/E deficiency in mice leads to free cutaneous legumain
activity, increased transepidermal water loss, and dehydration. We
have reported that disturbed cornification is caused by abnormalities
in loricrin processing, whichmay be the result of abnormal activation of
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transglutaminase 3 (TGase 3)3 by cathepsins, whose activities in their
turn could be regulated by legumain (16). During keratinocyte differen-
tiation, TGase 3 is activated by limited proteolysis of a 77-kDa zymogen
(21, 22), a process that is apparently under control of cystatin M/E, at
least during skin morphogenesis in the neonatal phase. These data sug-
gest that cystatin M/E plays a key role in the regulation of proteolytic
events that are involved in barrier formation and maintenance. To
understand this process in more detail at the molecular and cellular
level, we set out to identify the relevant enzymes and inhibitors and to
study their localization in human skin. The identification of CTSV and
CTSL as novel targets for cystatinM/E, their expression in human skin,
and the processing activity of CTSL toward TGase 3 strongly imply an
important role for these enzymes in the differentiation process of
human epidermis.
EXPERIMENTAL PROCEDURES
Three-dimensional Modeling of Cystatin M/E—A three-dimensional
model of human cystatin M/E was generated using MODELLER (23).
The crystal structure of human cystatin D (Protein Data Bank identifi-
cation number 1Roa) was used as a starting point. Human cystatin D
and cystatin M/E have a 26% sequence identity. The sequences were
aligned using the internal aligner ofMODELLER; this routine uses a gap
function that depends on the secondary structure.
Production of Cystatin M/E Variants—Cystatin M/E variants N64A
and W135A were obtained using the recombinant plasmid pGEX-2T/
cystatinM/E (a kind gift of DrGeorgia Sotiropoulou) andQuikChange
site-directedmutagenesis kit (Stratagene, La Jolla, CA). Primers used
for the generation of the N64A variant were 5-GCTACAACAT-
GGGCAGCGCCAGCATCTACTACTTCC-3 (sense) and 5-GGAAG-
TAGTAGATGCTGGCGCTGCCCATGTTGTAGC-3 (antisense).
Primers for theW135A variant were 5-GGTCCTTGTGGTTCCCGCG-
CAGAACTCCTCTCAGC (sense) and 5-GCTGAGAGGAGTTCT-
GCGCGGGAACCACAAGGACC-3 (antisense). All primers were from
Biolegio (Malden, The Netherlands). Sequence analysis was performed to
check for the desired mutations in the cDNA.
Production of Recombinant Proteins—Production and purification of
recombinant wild type and mutant forms of human cystatin M/E were
performed as described previously (10) with minor changes. pGEX-2T
plasmids containing thewild type ormutated cystatinM/E cDNAswere
transformed into Escherichia coli BL21 Star (DE3) bacteria (Invitrogen).
Cultures were grown from one single colony overnight at 37 °C in LB
medium with ampicillin followed by induction with isopropyl-1-thio-
-D-galactopyranoside (RocheApplied Science) at a final concentration
of 0.5 mM for 2 h at 37 °C. Cells were lysed by four cycles of freezing in
liquid nitrogen and thawing. Glutathione-Sepharose 4B beads (Amer-
sham Biosciences) were used for purification of glutathione S-transfer-
ase fusion protein from the lysate. Cleavage of the fusion protein into
glutathione S-transferase and cystatin M/E occurred overnight at 4 °C
with thrombin (Sigma) at a thrombin to fusion protein ratio of 1:500 in
a buffer containing 50mMTris-HCl (pH 7.5), 150mMNaCl, and 2.5mM
CaCl2. Recombinant cystatin M/E was purified from glutathione S-trans-
ferase using glutathione-Sepharose 4B beads and dialyzed against phos-
phate-buffered saline with an YM3 filter (Millipore, Billerica,MA). Protein
concentration was determined using a BCA protein assay (Pierce).
Fluorimetric Enzyme Assays—Protease inhibitory activity of recom-
binant human wild type cystatin M/E, the N64A and W135A variants,
and the recombinant human cystatins A, B, C, D, F, and S (all fromR&D
Systems,Minneapolis,MN) against recombinant human legumain (24),
human CTSV (R&D Systems), and human CTSL (one-chain form,
recombinant protein, R&D Systems; two-chain form, purified from
human liver, Sigma) was determined by measuring inhibition of the
proteases using the fluorogenic synthetic substrates Z-Ala-Ala-Asn-
MCA (4-methyl-coumaryl-7-amide) (Peptides International, Louisville,
KY) for legumain and Z-Leu-Arg-AMC (7-amino-4-methyl-coumarin)
(R&D Systems) for CTSV and CTSL. Protease inhibition was measured
after an incubation period of 5min (CTSL) or 10min (legumain, CTSV)
at room temperature. The buffer that was used in the legumain assay
contained 0.1 M phosphate (pH 5.7), 2 mM EDTA, 1 mM dithiothreitol,
2.67 mM L-cysteine, and 100 g/l bovine serum albumin. CTSV and
CTSL assayswere performed in buffer (pH 5.5) containing 0.1M acetate,
1mMEDTA, 2mMdithiothreitol, and 100g/l bovine serum albumin.
Reactions were stopped by adding 0.1 M Na2CO3 (pH 8.5). Ki values
were determined using the Easson-Stedman plot as described by Bieth
(25) and as indicated in the legend of Fig. 2.
Immunohistochemistry—Human skin biopsies were processed for
immunohistochemistry as described previously (13, 26). Immunohisto-
chemical staining was performed according to the avidin biotinylated-
enzyme-complex method (Vector, Burlingame, CA) using polyclonal
rabbit-anti-human cystatinM/E antibodies (12), polyclonal sheep-anti-
human legumain antibodies (24), monoclonal mouse-anti-human
CTSV antibodies (R&D Systems), and monoclonal rat-anti-human/
mouse CTSL antibodies (R&D Systems).
Digestion of TGase 3 Zymogen with Cathepsins—Baculovirus expressed
recombinant humanTGase 3 zymogen (22) was processed by treatment
with recombinant human CTSL, CTSV, cathepsin B (CTSB), cathepsin
S (CTSS), and cathepsin D (CTSD) (all from R&D Systems). To prepare
the proteolyzed form of TGase 3, 4 g of zymogen was treated with
cathepsins using a molar ratio of 0.001: CTSL (2.8 ng), CTSV (2 ng),
CTSS (2 ng), and CTSB (1.9 ng). In the case of CTSD, the ratio is about
0.05 (80 ng). Each incubation was performed in the appropriate buffers
as follows: for CTSL, CTSV, CTSB, andCTSS, 100mMMES (pH6.0), 16
mM dithiothreitol, 1.6 mM EDTA; and for CTSD, 100 mM sodium ace-
tate (pH 4.0), 100 mM KCl. For controls, the same reaction mixtures
were prepared but with the addition of pepstatin (Nacarai, Kyoto,
Japan), which is an inhibitor of the aspartic protease CSTD, or E-64
(trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane, Peptide Insti-
tute Inc., Osaka, Japan), a synthetic inhibitor of the cysteine proteases
CTSL, CTSV, CTSB, andCTSS. Both controls were used at a final concen-
tration of 10M.Reactionswere performed at 37 °C for the indicated times
(see Fig. 4).
Immunoblotting—Reaction mixtures with proteolyzed TGase 3 were
subjected to SDS-PAGE and electroblotted onto polyvinylidene difluo-
ride membrane as described previously (27). The membrane was incu-
bated with anti-human TGase 3 monoclonal antibodies C2D and C9D,
which specifically recognize the zymogen form and the proteolyzed 30-
and 47-kDa fragments, respectively (27). Detection of the proteins was
established with peroxidase-conjugated anti-mouse IgG and IgM (Jack-
son ImmunoResearch Laboratories, West Grove, PA) and SuperSignal
West Pico chemiluminescent substrate (Pierce) according to the man-
ufacturer’s protocol.
TGase 3 Activity—Prior to the assay, E-64 was added to the reaction
mixture to block cathepsin activity. TGase 3 activity was measured by a
96-well plate assay as described previously (28, 29). Briefly, 1% dimethylca-
sein was fixed at the plate, and the uncoated sites were blocked with
skimmed milk. The sample was incubated with 5-(biotinamido-)pen-
tylamine (Pierce) in a buffer containing 100mMTris-HCl (pH 8.0), 10 mM
3 The abbreviations used are: TGase, transglutaminase; CTSV, cathepsin V; CTSL, cathep-
sin L; CTSB, cathepsin B; CTSS, cathepsin S; CTSD, cathepsin D; MES, 2-(N-morpho-
lino)ethanesulfonic acid; E-64, trans-epoxysuccinyl-L-leucylamido-(4-guanidino)bu-
tane; Z, benzyloxycarbonyl.
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dithiothreitol, and 5 mM CaCl2. After various periods of incubation, the
reaction was blocked by adding EDTA at a final concentration of 10 mM.
TGase-catalyzedconjugationof 5-(biotinamido-)pentylamine todimethyl-
caseinwasmeasured by avidin-conjugated peroxidase, hydrogen peroxide,
o-phenylenediamine, andhydroxyperoxide.Anequal volumeof2MH2SO4
was added, and the absorbance was measured at 450 nm.
Determination of the TGase 3 Cleavage Site—Ten micrograms of
human TGase 3 was digested with 10 ng of CTSL, and the resulting
fragments were subjected to SDS-PAGE, blotted onto polyvinylidene
difluoride membrane, and subsequently stained with Coomassie Blue.
TheN-terminal amino acid sequence of the 30-kDa fragmentwas deter-
mined by automated Edman degradation.
RESULTS
Inhibition of ProteaseActivity byCystatinM/E—Based on the homology
with cystatin C, we predicted that cystatinM/Ewould contain two distinct
binding sites for papain-like cysteine proteases and for the asparaginyl
endopeptidase legumain. A three-dimensional model of human cystatin
M/Ewas generatedon thebasis of the published crystal structure of human
cystatin D (30), which revealed that the overall predicted structure of cys-
tatinM/Ecloselymatched thatof cystatinD(Fig. 1).To study thepresumed
reactive sites and the inhibitory activities of cystatin M/E, variants of the
protein with an inactive site for either legumain or papain-like cysteine
proteases were generated by substitution of one of the conserved amino
acids. As shown in Fig. 1, the N64A variant has a substitution of the Asn64
residue of the proposed legumain inhibitory site by anAla residue, whereas
theW135A variant has its Trp135 residue of the papain-like cysteine prote-
ase inhibitory site substituted by an Ala residue. Wild type and mutant
cystatinM/Ewas tested for inhibitory activity against legumain and several
papain-like cysteine proteases. In previous studies, it was found that cysta-
tin M/E was a poor inhibitor of most lysosomal cathepsins. Here we
extended our studies to include CTSV and we also included the one-chain
form of CTSL, as this form is the one expressed in skin. Ki values were
determined using an Easson-Stedman plot as illustrated in Fig. 2 for CTSV
and wild type cystatin M/E. When the Ki could not be determined in the
case of very low affinity, the ratio of protease activity in the presence (Vi )
and absence (V0) of inhibitor was determined, and the remaining protease
activity at a fixed high inhibitor concentration was calculated. Ki values of
wild type human cystatin M/E and the N64A and W135A variants for
interactionwithhuman legumain and thehumancysteine proteasesCTSV
and CTSL are shown in Table 1. Wild type cystatin M/E is a high affinity
inhibitor for legumain,CTSV, andCTSLaswitnessedby their respectiveKi
valuesof0.25, 0.47, and1.78nM.SimilarKivalueswere found for interaction
of the N64A variant with CTSV and CSTL but not with legumain (Vi /
V0 0.60 at [I] 100 nM). TheKi value of theW135A variant for interac-
tionwith legumainwas in the same range as that of wild type cystatinM/E,
whereas the Ki value for interaction with CTSV could not be determined
(Vi /V0 0.50 at [I] 100 nM). TheW135Amutation did not decrease the
affinity for CTSL at a similar order of magnitude as for CTSV but still
caused a 6-fold increase of the Ki value as compared with that of wild type
cystatin M/E (11.7 nM versus 1.78 nM). Similar experiments with several
other human cystatins were performed and Ki values for the interaction
with human legumain, CTSV, and CTSL are shown in Table 2. CTSVwas
efficiently inhibited by cystatins A, B, and C (Ki values below 0.15 nM),
FIGURE 1. Predicted three-dimensional representation of cystatin M/E. The crystal
structure of cystatin D was used as a basis for this model. The regions of the inhibitory
sites for papain-like cysteineproteases and for legumain aremarked. The locationsof the
amino acids substituted in the cystatin M/E variants are shown in white.
FIGURE 2. Determination of the dissociation constant Ki of the protease/protease-
inhibitor complex. The dissociation constant Ki was determined by measuring the
residual enzymatic activity of a fixed concentration of enzyme (as shown here for CTSV)
incubatedwith increasing concentrations of inhibitor (cystatinM/E). AnEasson-Stedman
plot (inset) was used to calculate the Ki. The inset is a replot of the data according to the
following equation: [I]/1  a  (Ki/a)  E
0, where I is the inhibitor concentration, E0 the
enzyme concentration at time 0, and a is the fractional activity, i.e. the ratio between
the enzyme activity in the presence (Vi) and absence (V0) of the inhibitor. The plot yields a
straight linewhose slope is Ki. A representative curve of three experiments is shown.
TABLE 1
Ki values of wild type cystatin M/E and mutated variants for
legumain, cathepsin V, and cathepsin L
Cystatin
M/E Ki legumain Ki cathepsin V Ki cathepsin L
nM nM nM
Wild type 0.25 0.47 1.78
N64A 100a 0.34 1.77
W135A 0.72 100b 11.7
a v i/v0 0.60 at I	  100 nM.
b v i/v0 0.50 at I	  100 nM.
TABLE 2
Ki values of human cystatins for legumain, cathepsin V, and
cathepsin L
Cystatin Ki legumain Ki cathepsin V Ki cathepsin L
nM nM nM
cystatin A 100a 0.11 0.05
cystatin B 100a 0.13 0.05
cystatin C 7.28 0.02 0.08
cystatin D 100a 29.6 2.81
cystatin F 100a 100b 0.49
cystatin S 100a 100c 100d
a v i/v0 0.99 at I	  100 nM.
b v i/v0 0.70 at I	  100 nM.
c v i/v0 0.90 at I	  100 nM.
d v i/v0 0.85 at I	  100 nM.
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whereas the affinity of CTSV for cystatin Dwas weaker (Ki of 29.6 nM) and
not detectable with cystatins F and S. CTSL was efficiently inhibited by
cystatins A, B, C, and F (Ki values below 0.5 nM), whereas the affinity for
cystatin D was somewhat weaker (Ki of 2.81 nM). Cystatin S showed no
inhibition with any of the tested cysteine proteases, whereas the ubiqui-
tously expressedcystatinCdemonstrated strong inhibitoryactivity for all of
them, although its affinity for legumain ismuchweaker than thatof cystatin
M/E (7.28 nM versus 0.25 nM).
Co-expression of Cystatin M/E and Its Biological Targets in the Stra-
tum Granulosum—To establish a functional link between cystatin M/E
and its putative target proteases, we investigated their expression at the
tissue level in human skin. Immunohistochemistry was performed on
skin biopsies from healthy volunteers. In normal human skin, cystatin
M/E and CTSV are strongly and specifically expressed in the stratum
granulosum of the epidermis (Fig. 3). In addition, both proteins are also
expressed in the hair follicle. CTSV is only present in a small layer of the
hair follicle root sheet, whereas cystatin M/E is expressed throughout
the inner half of the root sheet. The sweat glands showed no expression
of CTSV, whereas the secretory coil epithelium but not the ductal part
of the sweat glands was positive for cystatin M/E. CTSV and cystatin
M/E both show a positive staining in the inner, mature cells of the
sebaceous glands. In contrast to cystatinM/E andCTSV, the expression
of legumain and CTSL was not limited to a specific cell layer but was
found throughout all layers of the epidermis and its appendages (Fig. 3).
Activation of TGase 3 by CTSL—In a previous study, we have found
that lysosomal cysteine proteases are probably involved in the process-
ing of human epidermal TGase 3 in vitro, suggesting that this could be a
mechanism for activation. So far, the responsible proteases for this acti-
vation remained unknown. To address this issue more in depth at the
functional level, recombinant human TGase 3 was incubated with a
panel of recombinant human lysosomal cysteine proteases to investi-
gate their proteolytic activity toward the zymogen form of TGase 3.We
found that CTSL is able to proteolyze TGase 3 into 30- and 47-kDa
fragments (Fig. 4A) in a concentration- and time-dependent manner.
When the cathepsin inhibitor E-64 was added to the reaction mixture,
no TGase 3 proteolysis could be detected. Other cathepsins were not
FIGURE 3. Immunostaining for cystatin M/E,
cathepsin V, cathepsin L, and legumain in nor-
mal human skin and its appendages. Note the
stratum-specific expression of cystatin M/E and
CTSV in the stratum granulosum of the epidermis.
CTSV is only present in the inner layer of the outer
root sheet of the hair follicle, whereas cystatinM/E
is also expressed in many more layers of the outer
root sheet of the hair follicle. The secretory coil epi-
thelium of the sweat glands is positively stained for
cystatin M/E (arrowheads), but the ductal part is
almost negative (the asterisk is surrounded by
ducts). No expression of CTSV was found in the
sweatglands.CTSLand legumainarealsoexpressed
in the stratum granulosum. Furthermore, positive
stainingwasalso found in theother layersof theepi-
dermis and its appendages. The sweat gland ducts
as well as the secretory coils are both positively
stained for CTSL and legumain. Scale bar 100m.
FIGURE 4. Proteolysis of human TGase 3 by ca-
thepsins. Four micrograms of recombinant human
TGase 3was treatedwith several cathepsins at 37 °C
for the indicated times. The reaction mixtures were
subjected to SDS-PAGE followed by immunoblot-
ting analysis using monoclonal antibodies C2D and
C9D. Reactions were also performed in the pres-
ence of specific inhibitors (E-64 or pepstatin) at a
final concentration of 10 M. The 77-kDa TGase 3
zymogen is rapidly proteolyzed into its 30- and
47-kDa fragments by CTSL (A) but not by CTSV (B),
CTSS (C), CTSB (D), and CTSD (E). The open and
closed arrowheads indicate zymogen and proteo-
lyzed TGase 3, respectively.
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able to cleave the TGase 3 zymogen in this experimental setup (Fig. 4,
B–E), except in the case of longer incubation timeswith cathepsin S (Fig.
4C). In the presence of relatively high amounts of cathepsins B, S, and V
in the reaction mixture (molar ratio of 1:10), TGase 3 was limitedly
proteolyzed (data not shown).Next, wemeasured the enzymatic activity
of the proteolyzed products of TGase 3 zymogen that was digested by
CTSL. Although the TGase 3 zymogen showed no enzymatic activity,
TGase proteolyzed by the action of CTSL demonstrated an apparent
enzymatic activity (Fig. 5). N-terminal sequencing of the 30-kDa TGase
3 fragment revealed that the CTSL cleavage site in TGase 3 is before
Ala467, two amino acids downstream as compared with the cleavage site
generated by dispase digestion (Fig. 6).
DISCUSSION
In this study, we show that the protease inhibitor cystatinM/E inhib-
its legumain and papain-like cysteine proteases due to two distinct non-
overlapping sites. The papain-like cysteine proteases CTSV and CTSL
are strongly inhibited by cystatin M/E, suggesting that these proteases
are new targets for cystatin M/E. Immunostaining of cystatin M/E,
CTSV, CTSL, and legumain in normal human skin shows co-expres-
sion, especially in the stratumgranulosumand the hair follicles, suggest-
ing that these enzymes have an important role in human epidermal
differentiation and hair follicle morphogenesis. Our data indicate that
CTSL is the elusive protease that can process and activate TGase 3, an
enzyme that is involved in cornified envelope formation.
Based on the homology with cystatin D, we generated a three-dimen-
sional model of cystatin M/E. This model shows that a loop located on
the opposite side to the cysteine protease-binding surface, between the
-helix and the first strand of the main -sheet of the cystatin M/E
structure, contains the asparaginyl residue that is probably involved in
legumain binding. Site-directed mutagenesis was used to identify the
presumed binding sites of papain-like cysteine proteases and that of the
asparaginyl endopeptidase legumain in cystatin M/E. Substitution of a
conserved amino acid by alanine in the two reactive sites resulted in loss
of inhibitory activity. We could confirm that the conserved Asn64 resi-
due (cystatin M/E numbering) in the legumain inhibitory site is impor-
tant for cystatin-legumain interaction. OurKi values for this interaction
are somewhat higher than the Ki values found by Alvarez-Fernandez
et al. (20), but this could be explained by our use of recombinant human
legumain, whereas pig legumain extracted from kidney was used by the
group of Alvarez-Fernandez. Cystatins are known as inhibitors of lyso-
somal cysteine proteases of the papain family (C1). Although cystatin
M/E contains a predicted binding site for papain-like cysteine proteases,
no high affinity binding for any member of this family had been dem-
onstrated so far (11, 12, 16). The present study shows that cystatin M/E
is a high affinity inhibitor of CTSV and CTSL. For this study, we used
recombinant CTSL that was obtained as a one-chain form, which is the
relevant form for skin (31). In general, CTSL is translated as prepro-
CTSL, and during intracellular transport to the lysosomes, the preproen-
zyme is subsequently modified to pro-CTSL and processed into the
mature one-chain and two-chain forms of CTSL. Processing of pro-
CTSL results in a 30-kDa one-chain form of CTSL, which in turn
can be further processed into the two-chain form (5 and 24 kDa)
(32). It is not known whether this conversion regulates CTSL activity
or substrate specificity, but recently, it has been reported that both
forms are proteolytically active and can execute the essential functions
of CTSL (19, 32). As we had previously found that CTSL purified from
human liver (the two-chain form) was only weakly inhibited by cystatin
M/E, the strong inhibition by recombinant one-chain form CTSL was
unexpected. Comparison of human liver CTSL from different suppliers
revealed that we have previously underestimated the inhibition of cys-
tatin M/E for reasons we cannot explain. Based on the CTSL prepara-
tions used in this study both the one-chain and two-chain form of CTSL
are inhibited equally well by cystatin M/E (not shown). CTSV is a
recently discovered protease, also known as cathepsin L2 or stratum
corneum thiol protease. CTSV is closely related to CTSL sharing80%
protein sequence identity (33–36). Their encoding genes are located on
adjacent sites on chromosome 9q22.2, suggesting that CTSV and CTSL
have evolved by duplication from an ancestral gene (35). However,
although CTSL is ubiquitously expressed, CTSV expression is more
restricted and predominantly found in thymus, testis, cornea of the eye,
and epidermis (33, 34, 36). Besides the general function of lysosomal
cathepsins, i.e. bulk proteolysis, studies using a knock-out mousemodel
have suggested that CTSL has specific functions in keratinocyte prolif-
eration and hair follicle morphogenesis and cycling (37–39).
The role of CTSV and CTSL in terminal differentiation of keratino-
cytes and hair follicle morphogenesis is unknown, but these proteins
probably process and activate other enzymes in pathways that lead to
skin barrier formation. Our biochemical assays show that CTSL is the
first identified mammalian protease that is able to cleave and activate
TGase 3 in vitro (Figs. 4 and 5). TGase 3 is an epidermis-specific enzyme
responsible for cross-linking loricrin and small proline-rich proteins in
the stratum granulosum (27, 40). TGase 3 is also the most efficient
FIGURE 5. Activity of TGase 3 proteolyzed by cathepsin L. The enzymatic activity of
proteolyzed TGase 3 was measured after digestion with CTSL for 3 min. The enzymatic
reaction products are shown as the value of A450 nm. The open and closed circles indicate
the reactions using 100 ng of zymogen and the proteolyzed forms, respectively.
FIGURE 6. Processing of TGase 3. The 77-kDa zymogen form of TGase 3 is proteolyzed
into the activated form consisting of 30- and 47-kDa fragments, which then associate
non-covalently to form the active enzyme (21). The N-terminal sequence of the 30-kDa
fragment of human TGase 3 was determined by automated Edman degradation. For
comparison, we show the cleavage site of TGase 3 after digestion by dispase, a neutral
bacterial protease that is commonlyused to activate TGase 3 in vitro. Theopen and closed
triangles represent the cleavage sites of dispase and CTSL digestion, respectively.
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cross-linking enzyme of soluble trichohyalin, a major structural protein
in hair follicle differentiation (41). Remarkably, a reduced expression of
trichohyalinwas found inCTSL-deficientmice (38).Our results provide
evidence that CTSL initiates the cross-linking activity of TGase 3 in the
process that leads to cornification, by cleavage of the 77-kDa TGase 3
zymogen and thereby activation of the enzyme. This mechanism could
possibly be regulated by the inhibitory activity of cystatin M/E against
CTSL. Legumain inhibition by cystatinM/E could have a regulatory role
in CTSL activity since legumain is involved in CTSL processing (18, 19).
Cystatin M/E-deficient mice show epidermal and follicular hyperkera-
tosis resulting in a scaly skin, abnormal hair follicles, and an impaired
barrier function (14). This could be explained by elevated CTSL and/or
legumain activities due to cystatin M/E deficiency that subsequently
lead to an early or excessive activation of TGase 3, resulting in a prema-
ture or enhanced cross-linking of loricrin molecules and small proline-
rich proteins, incomplete desquamation, thickening of the stratum cor-
neum, and abnormal hair morphogenesis.
N-terminal sequencing of the 30-kDa fragment revealed that CTSL
cleavesTGase 3 between amino acidsAla466 andAla467 (Fig. 6). TGase 3,
as well as other TGases, consists of four domains: a -sandwich, a cat-
alytic core, -barrel-1, and -barrel-2. In TGase 3, the unique hinge
region (Pro461–Glu479) separates the catalytic core and -barrel-1
domain (21). In our previous studies, the cleavage site of human TGase
3 by dispase-digestion was Phe465, which is located in this hinge region
(42). Since treatment of TGase 3 with thrombin or trypsin produces 30-
and 47-kDa fragments, this hinge region appears to be a domain that is
sensitive to proteolysis (43). As CTSL preferentially cleaves peptide
bonds with aromatic residues in P2 and hydrophobic residues in the P3
position (44), we believe that we have identified the exact cleavage site of
humanTGase 3 byCTLS. This conclusion is based on the fact that in the
P2 and P3 position of the TGase 3 cleavage site, an aromatic residue
(Phe465) and a hydrophobic residue (Pro464) are found, respectively.
Future studies should clarify whether this is the physiological cleavage
site in vivo as well.
It is likely that CTSV has a role in skin that is distinct from CTSL
because its expression is specifically restricted to the upper epidermal
layers. The secretion of both cystatin M/E and CTSV by differentiating
keratinocytes (12, 36) makes them both plausible candidates to be
involved in desquamation. A detailed description of the cellular and
subcellular localization of cystatin M/E and its target proteases in epi-
dermis and hair follicleswas beyond the scope of this report.Our immu-
nohistochemical data comprise only a small part of the human hair
follicle, and the transverse sections at the level of the infundibulum
(Fig. 3) preclude a detailed analysis of the inner and outer root sheet at
the deeper levels.
Biochemical enzyme assays with cystatins other than cystatin M/E
show that cystatins A, B, and C are strong inhibitors of CTSV andCTSL
as well. Cystatin A is known to be expressed in skin and participates in
epidermal barrier formation and function (45, 46). CystatinA belongs to
the type 1 cystatins, which are primarily intracellular proteins. Cystatin
M/E on the other hand can be secreted, probably into the extracellular
space between corneocytes. Keeping this in mind, it is possible that
CTSV and/or CTSL activity in the upper epidermal layers of the skin is
intracellularly regulated by cystatin A and extracellularly regulated by
cystatin M/E. Compartmentalization studies at the ultrastructural level
could shed further light on the exact role of cystatin M/E and its prote-
ase targets.
Recently, the phenotype of CTSL knock-out mice was rescued by
transgenic epidermal re-expression of either murine CTSL or human
CTSV, indicating that human CTSV can compensate for murine CTSL
(47, 48). No orthologue of CTSV in mice has been discovered yet, but it
is plausible that murine CTSL is actually the orthologue of human
CTSV, in view of the fact that human CTSV is phylogenetically more
closely related to murine CTSL than to human CTSL (47). Our immu-
nohistochemical data provide a novel clue in support of this theory since
in epidermis, CTSV expression in the upper epidermal layers is similar
to that of murine CTSL. Another possibility is that murine CTSL con-
trols the specific functional enzymatic activities of both human CTSL
and CTSV. A closer inspection of hair follicle morphogenesis in CTSL-
deficient mice showed that defects in the differentiation, keratinization,
and desquamation of the inner root sheet form the basis of the abnormal
hair phenotype (38). Therefore, a more in-depth study of cellular and
subcellular localization of CTSL and TGase 3 in the entire human hair
follicle is required to elucidate the potential role of these molecules in
hair follicle morphogenesis.
We conclude that cystatinM/E has an important regulatory function
in human epidermal differentiation. CystatinM/E could regulate cross-
linking of structural proteins by TGase 3 in cornified envelope forma-
tion through inhibitory activities against CTSL and legumain. In addi-
tion, cystatinM/E could also have a role in the desquamation process as
CTSV activity is involved in the degradation of corneodesmosomes.
Further studies are necessary to elucidate the regulatory role of cystatin
M/E in pathways that are involved in desquamation. CTSV and CTSL
may activate other transglutaminases such as TGase 1 and TGase 5, or
other proteases, such as cathepsin D, that are involved in terminal dif-
ferentiation. Recently, it has been demonstrated that cathepsin D-defi-
cient mice show a reduced TGase 1 activity and impaired stratum cor-
neum morphology, similar to the skin of TGase 1 knock-out mice and
the human skin disease lamellar ichthyosis (49). Collectively, this find-
ing and the data from our studies strongly support a functional link
between protease activity and activation of TGases in the epidermis.
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Colocalization of Cystatin M/E and Cathepsin V
in Lamellar Granules and Corneodesmosomes
Suggests a Functional Role in Epidermal Differentiation
Patrick L.J.M. Zeeuwen1,3, Akemi Ishida-Yamamoto2,3, Ivonne M.J.J. van Vlijmen-Willems1, Tsing Cheng1,
Mieke Bergers1, Hajime Iizuka2 and Joost Schalkwijk1
Cystatin M/E is a cysteine protease inhibitor with two distinct binding sites for papain-like cysteine proteases
(family C1) and the asparaginyl endopeptidase (AEP) legumain of family C13. We have previously demonstrated
that deficiency of cystatin M/E in mice causes ichthyosiform skin changes and barrier disruption, which could
be caused by unrestrained AEP activity. Recently, we provided biochemical evidence that human cathepsin V
(CTSV) and cathepsin L (CTSL) are additional biological targets for human cystatin M/E. To address the possible
role of these three proteases and their inhibitor in epidermal differentiation, we investigated the localization of
these proteins in normal human skin. Whereas CTSL and AEP were broadly expressed in epithelial cells of the
skin, we found a specific colocalization of cystatin M/E and CTSV in the stratum granulosum and in the root
sheets of the hair follicle, using immunofluorescence microscopy. Immunoelectron microscopy revealed that
cystatin M/E and CTSV are separately transported within the lamellar granules. Cystatin M/E was also found in
the extracellular space in the stratum corneum associated with corneodesmosomes, where it was closely
associated with CTSV. Based on the striking stratum-specific colocalization of cystatin M/E and CTSV, we
propose that these molecules could have an important role in epidermal differentiation and desquamation.
Journal of Investigative Dermatology (2007) 127, 120–128. doi:10.1038/sj.jid.5700480; published online 27 July 2006
INTRODUCTION
Cystatin M/E is a cysteine protease inhibitor whose expression is
largely confined to cutaneous epithelia. In human skin, it is
expressed in the sweat glands, hair follicles, and stratum
granulosum (SG) of the epidermis. In addition to its function as a
cysteine protease inhibitor, cystatin M/E could also serve as a
target for crosslinking by transglutaminases (TGase) (Zeeuwen
et al., 2001). We have previously reported that a null mutation
in the mouse cystatin M/E gene (Cst6) causes the murine ichq
phenotype, which is characterized by neonatal lethality and
abnormalities in cornification and desquamation, demonstrating
an essential role for cystatin M/E in the final stages of epidermal
differentiation (Zeeuwen et al., 2002). We have shown that
absence of cystatin M/E and appearance of asparaginyl
endopeptidase (AEP) activity colocalizes with the observed
pathology in ichq mice, that is, excessive cornification in hair
follicles and epidermis. Furthermore, these investigations have
revealed that AEP could indirectly mediate the activation of
TGase 3 zymogen, via lysosomal cysteine proteases in vitro
(Zeeuwen et al., 2004). A biochemical study from another
group has indicated that cystatin M/E in vitro binds to AEP with
high affinity (Alvarez-Fernandez et al., 1999), which was an
unexpected finding, as the cystatins were primarily regarded as
inhibitors of the papain-like cysteine proteases in the unrelated
family C1 (Abrahamson et al., 2003). Although cystatin M/E
contains a predicted binding site for papain-like cysteine
proteases, no high-affinity binding for any member of this
family has been published so far. Recently, we have shown that
cystatin M/E is a high-affinity inhibitor of cathepsin V (CTSV)
and cathepsin L (CTSL) by a reactive site that is distinct from the
AEP-binding site (Cheng et al., 2006). On the basis of the
analogous sites in cystatin C (Alvarez-Fernandez et al., 1999),
we used site-directed mutagenesis to identify the binding sites of
these proteases in human cystatin M/E, and we found that AEP
and papain-like cysteine proteases are inhibited by two distinct
non-overlapping sites. In addition, we showed that human CTSL
is the elusive enzyme that is able to process and activate human
TGase 3 (Cheng et al., 2006). Altogether, these data strongly
imply an important role for cystatin M/E and its protease targets
in the differentiation process of human epidermis.
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Desquamation is the final event in terminal differentiation
of the epidermis, which occurs by the action of proteolytic
enzymes. During desquamation, breakdown of lipids in the
intercellular spaces and loss of residual intercellular desmo-
somal connections leads to cell shedding of the dead
corneocytes from the stratum corneum (SC) surface (Elias,
2005). A number of studies have shown the involvement of
different epidermal proteases in the progressive degradation
of the desmosomal proteins desmocollin-1, desmoglein-1,
plakoglobin, and corneodesmosin (Lundstrom and Egelrud,
1990; Suzuki et al., 1996; Simon et al., 2001; Caubet et al.,
2004). A convincing role in desquamation has been demons-
trated for at least two epidermis-specific serine proteases, the
SC chemotryptic and SC tryptic enzymes (currently known as
kallikreins KLK7 and KLK5), which are able to degrade
corneodesmosome proteins (Hansson et al., 1994; Brattsand
and Egelrud, 1999; Ekholm et al., 2000; Caubet et al., 2004).
KLK7 and KLK5 are highly expressed in the SG, and are
present in the intercellular spaces of the SC (Sondell et al.,
1995). Both these enzymes are most active at neutral to
alkaline pH, but also showed some activity at a more acidic
pH. In addition to these serine proteases, both cysteine and
aspartic protease activities with acidic pH optima have been
found in the SC (Horikoshi et al., 1999; Watkinson, 1999).
We have previously suggested that a new cysteine protease of
late epidermal differentiation, stratum corneum thiol pro-
tease, could be a possible target for cystatin M/E (Zeeuwen
et al., 2001). Stratum corneum thiol protease appears to be a
specific product of differentiated keratinocytes, and further-
more it is apparently not stored within these cells but is
actively secreted (Watkinson, 1999). Because stratum cor-
neum thiol protease is able to degrade desmocollin-1 in in
vitro degradation experiments, an extracellular proteolytic
function for this protease in mediating desquamation has
been proposed. It was shown by others that ‘‘stratum
corneum thiol protease’’ activity was also able to hydrolyze
corneodesmosin, and finally it appears that this so-called
stratum corneum thiol protease was identical to CTSL2
(Bernard et al., 2003), also known as CTSV (Adachi et al.,
1998). Our recent data on CTSV and CTSL as additional
biological targets for cystatin M/E suggest that these enzymes
could possibly play an important regulatory role in epidermal
barrier formation and desquamation.
In this study, we sought to address the possible role of
cystatin M/E and its physiological target proteases in
epidermal differentiation and desquamation. We have
examined the localization and compartmentalization of
cystatin M/E, CTSV, CTSL, and AEP in normal human skin
by immunofluorescence microscopy and immunoelectron
microscopy. We found that cystatin M/E and CTSV are
separately transported within lamellar granules (LGs). Both
proteins are secreted in the extracellular space where they
associate with corneodesmosomes, suggesting a regulatory
role for cystatin M/E in the desquamation process.
RESULTS
We have recently shown that cystatin M/E is an inhibitor of
CTSV and CTSL by a reactive site that is distinct from the AEP-
binding site. For a comprehensive biochemical and kinetic
analysis of the interaction between cystatin M/E and its target
proteases, see Cheng et al. (2006).
In order to examine the localization of cystatin M/E and its
physiological target proteases CTSV, CTSL, and AEP in
normal human skin, immunofluorescence microscopy was
performed (Figures 1–3). A strong and consistent staining of
cystatin M/E was found in the SG (Figure 1a) and in the inner
half of the root sheet of the hair follicle (Figure 1d). Staining of
the SC was present but often discontinuous (Figure 1a).
Furthermore, cystatin M/E was found in the secretory coil
epithelium of the eccrine sweat glands (Figure 1g), but not in
the ductal portion. In the sebaceous glands, only the inner
mature cells were positive (Figure 1j). Cystatin M/E specifi-
cally colocalizes with CTSV in the most superficial granular
layer, whereas colocalization in the SC shows a patchy
distribution (Figure 1c and m). Double immunostaining
revealed that cystatin M/E was expressed earlier during
epidermal differentiation than CTSV (Figure 1c and m). At
higher magnifications, immunofluorescent staining for cysta-
tin M/E and CTSV shows a typical granular pattern (Figure 1n
and o). Cystatin M/E and CTSV also colocalize in the most
inner layer of the root sheet of the hair follicle (Figure 1f), and
in a few cells of the sebaceous glands (Figure 1l). CTSL and
AEP are both broadly expressed throughout the epidermis and
its appendages (Figures 2 and 3). At higher magnifications,
immunofluorescent staining for CTSL and AEP shows a diffuse
staining pattern (not shown). Colocalization of cystatin M/E
with CTSL was found at the cellular level in the SG, in the
inner half of the hair follicles root sheet, in the secretory coil
epithelium of the eccrine sweat glands, and in the inner
mature cells of the sebaceous glands (Figure 2c, f, i, and l).
We could not detect CTSL expression in the SC (Figure 2c).
Furthermore, staining for cystatin M/E overlapped with that
for AEP in the SG and the SC, in the inner half of the root
sheet of the hair follicle, in the secretory coil epithelium of
the eccrine sweat glands, and in the inner mature cells of the
sebaceous glands (Figure 3c, f, i, and l).
As shown above, using immunofluorescence microscopy,
we could demonstrate co-expression of cystatin M/E and its
presumed targets at the cellular level, in the most superficial
granular cells of the epidermis. In order to define the
expression of cystatin M/E and its target proteases at the
subcellular level, immunoelectron microscopy was per-
formed. We used two different methods that we have
recently described: post-embedding and cryo-ultramicrotomy
electron microscopy (Ishida-Yamamoto et al., 2004). In the
first method, LG appeared as isolated granules as in
conventional transmission electron microscopy. In contrast,
the cryo-ultramicrotomy method showed different images of
LG, namely branched tubules with a partial internal lamellar
structure. Using post-embedding immunoelectron micro-
scopy, we could show that cystatin M/E and CTSV gold
labels are found in LG within the cells of the SG (Figures 4a
and 5b), and in the extracellular spaces of the SC where both
molecules are associated with desmosomes (Figures 4b–d and
5c and d). We used cryo-ultramicrotomy electron microscopy
to study the coexpression of cystatin M/E and CTSV. It was
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found that both proteins are aggregated but not mixed with
each other in the LG of the cells of the SG (Figure 6a and b).
In the extracellular spaces of the SC, cystatin M/E was
colocalized with CTSV, and both proteins are found to be
closely associated with desmosomes (Figure 6c and d).
Furthermore, post-embedding immunoelectron microscopy
revealed that AEP and CTSL are not LG proteins. Labeled
proteins were found in the cytoplasm of SG cells (Figures 7
and 8), where some of the labeling was associated with
keratin filaments. No expression of AEP and CTSL was found
in the extracellular spaces of the SC.
DISCUSSION
In this study, we analyzed the tissue localization and
subcellular compartmentalization of cystatin M/E and its
physiological target proteases in normal human skin. We
showed for the first time that cystatin M/E and CTSV are
separately transported within LG. Moreover, both proteins are
secreted in the extracellular space where they associate with
corneodesmosomes, suggesting a regulatory role for cystatin
M/E and CTSV in epidermal desquamation.
Here, we showed by immunofluorescence microscopy








b cCystatin M/E CTSV Merge
Figure 1. Colocalization of cystatin M/E and CTSV in human normal skin. Immunofluorescence staining of (green color; a, d, g, j) cystatin M/E and
(red color; b, e, h, k) CTSV, and (yellow-orange merge color; c, f, i, l) double staining for both proteins in (a–c) the epidermis, (d–f) the hair follicle,
(g–i) the sweat glands, and (j–l) the sebaceous glands. The rectangular area marked in (c) is shown enlarged in (m). Note that the SC is detached from the
SG. The rectangular areas marked in (d and e) are shown enlarged in (n and o). DNA staining by 40,6-diamidine-20-phenylindole dihydrochloride is
colored in blue. Bar= (a–I) 50 mm; (j–l) 100 mm; and (m–o) 12.5 mm.
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CTSL, and CTSV in some parts (mainly the most superficial
cells) of the epidermis (Figures 1–3). The granular staining
pattern in the cells that we found for cystatin M/E and CTSV
suggested that both proteins are associated with LG. To
evaluate this hypothesis, post-embedding immunoelectron
microscopy was performed, and we indeed could confirm the
localization of cystatin M/E and CTSV in LG, which appear as
isolated oval-shaped granules (Figures 4 and 5). LG, or
lamellar bodies, are secretory granules of keratinizing
squamous epithelia and are thought to be essential in barrier
formation and desquamation. It is widely accepted that LG
originate from the Golgi apparatus, and that the assembly of
these secretory granules begins at the trans most cisternae of
the Golgi complex (Madison, 2003). Recent work on the
trans-Golgi network, which is the highly tubulated sorting
and delivery part of the Golgi apparatus, has revealed that
transport to the plasma membrane is mediated by pleio-
morphic tubulovesicular structures, rather than by vesicles
(Mironov et al., 2001). It was shown by high magnification
electron microscopy that LG do not represent a uniform
vesicular population, but are consistent with sections through
a tubular network (Elias et al., 1998), which suggest that
keratinocyte LG are trans-Golgi network structures and not
vesicles. Norle´n has therefore proposed a new model for the
delivery of the contents of LG to the plasma membrane
(Norlen, 2001). This so-called ‘‘membrane folding model’’
implies that the trans-Golgi network and LG of the uppermost
SG cells as well as the multilamellar lipid matrix of the
intercellular space at the border zone between SG and SC
could be representations of one and the same continuous
membrane structure. Indeed, direct visualization of the skin
barrier formation process using cryotransmission electron
microscopy confirmed the presence of folded multilamellar
continuous structures adjacent to apparent active sites of skin
barrier formation (Norlen et al., 2003).
Recently, it was shown that epidermal LG transport
different cargoes (e.g., cathepsin D, glucosylceramides,
corneodesmosin, and KLK7) as distinct aggregates, which
were delivered to the apical region of granular keratinocytes






a Cystatin M/E CTSL Merge
Figure 2. Colocalization of cystatin M/E and CTSL in human normal skin. Immunofluorescence staining of (green color; a, d, g, j) cystatin M/E and
(red color; b, e, h, k) CTSL, and (yellow-orange merge color; c, f, i, l) double staining for both proteins in (a–c) the epidermis, (d–f) the hair follicle,
(g–i) the sweat glands, and (j–l) the sebaceous glands. DNA staining by 40,6-diamidine-20-phenylindole dihydrochloride is colored in blue. Bar= (a–I) 50 mm
and (j–l) 100 mm.
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that the serine protease inhibitor LEKT1 (lympho-epithelial
kazal type inhibitor) is localized in LG, separated from its
epidermis-specific target proteases KLK7 and KLK5, and is
secreted in the extracellular spaces of the superficial SG
(Ishida-Yamamoto et al., 2005). LEKT1 is encoded by the
SPINK5 gene, which is the causative gene of the severe
ichthyotic skin disorder called Netherton syndrome (Chava-
nas et al., 2000). Recent studies have reported that defective
inhibitory regulation of epidermal serine protease activity
owing to LEKT1 deficiency results in the early degradation of
desmosomal proteins, possibly causing the skin pathology in
Netherton syndrome (Caubet et al., 2004; Ishida-Yamamoto
et al., 2005). We have observed a similar distribution for
cystatin M/E and CTSV in LG using the cryo-ultramicrotomy
method. Cystatin M/E and CTSV are both localized in the LG,
however, double staining revealed that these proteins are
localized separately within the presumed trans-Golgi LG
network (Figure 6). Moreover, cystatin M/E and CTSV are
detected in the extracellular spaces of the upper SC layers
where both proteins are associated with desmosomes (Figures
4–6), suggesting that these molecules could have an
important role in desquamation. Because an acidic pH
dominates in the outer SC layers (Elias, 2004), it is
conceivable that CTSV activity in these layers fulfills a
significant function in the desquamation process (e.g.,
degradation of desmosomal constituents), as opposed to
serine proteases which act in the neutral pH environment of
the lower SC layers. One could speculate that separate
transport of cystatin M/E and CTSV by LG may prevent
interaction within the cells. Altogether, we propose a
regulatory role for cystatin M/E in desquamation by control-
ling the CTSV activity in the SC (Figure 9).
In contrast with cystatin M/E and CTSV, the staining
pattern for AEP and CTSL that we observed using fluoresence
microscopy was diffuse and was not associated with granular
structures. Immunoelectron microscopy showed that AEP and
CTSL are not located within LG, but are found in the
cytoplasm of the SG cell (Figures 7 and 8). As both AEP and
CTSL are considered to be endosomal/lysosomal proteins, the






a Cystatin M/E AEP Merge
Figure 3. Colocalization of cystatin M/E and AEP in human normal skin. Immunofluorescence staining of (green color; a, d, g, j) cystatin M/E and
(red color; b, e, h, k) AEP, and (yellow-orange merge color; c, f, i, l) double staining for both proteins in (a–c) the epidermis, (d–f) the hair follicle,
(g–i) the sweat glands, and (j–l) the sebaceous glands. DNA staining by 40,6-diamidine-20-phenylindole dihydrochloride is colored in blue. Bar= (a–I) 50 mm
and (j–l) 100 mm.
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is at least remarkable. However, other studies have also
shown that precursors of CTSL are found in the cytoplasm of
epidermal keratinocytes (Kawada et al., 1997), and in the
cytoplasm of cortical thymic epithelial cells (Arudchelvan
et al., 2002). It has been coined that AEP, like CTSL, could be
secreted from cells under some conditions, and may be active
in the pericellular and intracellular environment (Barrett
et al., 2004). Furthermore, recent studies have reported
increasing evidence that lysosomal proteases play important
roles in physiological processes not solely restricted to
lysosomes (Turk et al., 2002). Protease activity and regulation
outside lysosomes potentially contributes to the propagation
of apoptosis, a process that is distinct from terminal
differentiation of the epidermis, but nevertheless shares some
molecular and cellular features (Lippens et al., 2005). The
signals for the release and activation of lysosomal proteases
during cornification are unknown, and also the mechanism
by which they degrade the cellular organelles.
In the epidermis, there is a balanced regulation of protease
activity that, when disturbed, could lead to faulty cornifica-
tion processes in the epidermis and upper part of the hair
follicle (Zeeuwen, 2004). We have recently shown that
human CTSL is the elusive enzyme that is able to process and
activate human TGase 3 (Cheng et al., 2006), an epidermis-
specific enzyme responsible for the crosslinking of loricrin
and small proline-rich proteins during the cornification
process. The presence of TGase 3 in the cytoplasm of the
cell is in accordance with the cytosolic localization of CTSL.
At this point, we think that in normal healthy skin, post-
translational proteolytic processing of TGase 3 is completed
at the final stage of the granular cell layer when cell integrity
is lost and proteases are released leading to progressively
more TGase 3 enzyme activity. Despite the apparent loss of
cell integrity, organization, and compartmentalization in the
terminally differentiating keratinocyte, this must be a highly
ordered and well-orchestrated process. We suppose that
processing and activation of TGase 3 in terminally differen-
tiating keratinocytes could be regulated by the inhibitory
activity of cytoplasmic cystatin M/E against CTSL (Figure 9).
AEP inhibition by cystatin M/E could have a regulatory role in
CTSL activity as AEP is involved in CTSL processing (Maehr
et al., 2005). In addition, TGase 3 is also expressed in hair
follicles, where it crosslinks soluble trichohyalin, a major
structural protein in hair follicle differentiation (Tarcsa et al.,
1997). In this study, we show that cystatin M/E and its target
proteases are all present in the root sheet of the hair follicle,
which suggests that these molecules could play an important













Figure 4. Cystatin M/E is an LG protein and is associated with desmosomes
after secretion. Post-embedding immunoelectron microscopy using Lowicryl
HM20 resin. (a) Cystatin M/E labels (5 nm gold, black arrows) are within the
LGs. Note oval-shaped LGs with partial lamellar internal structures (white
arrowheads). (b) In the SC, cystatin M/E labels are associated with
desmosomes (d). (c, d) Double labeling of cystatin M/E (5 nm gold, smaller



















Figure 5. CTSV is an LG protein and is associated with desmosomes in the
SC. Post-embedding immunoelectron microscopy using Lowicryl K11M resin.
(a, b) SG of the epidermis where CTSV labels (5 nm gold, black arrows) are
associated with LGs within the cells (white arrowhead) and those released
into the extracellular spaces (upper right) between desmosomes (d). (c, d) SG
(G) and the 1st (C1) to the 5th (C5) layer of the SC. CTSV labels are associated
with desmosomes. The rectangular areas marked in (a) and (c) are shown at
higher magnification in (b) and (d), respectively.
www.jidonline.org
PLJM Zeeuwen et al.
Cystatin M/E in Lamellar Granules
65
M/E-deficient mice (as described in the Introduction) as well
CTSL-deficient mice show a skin/hair phenotype (Roth et al.,
2000; Benavides et al., 2002). Recently, the phenotype of
CTSL knockout mice was rescued by transgenic epidermal re-
expression of either murine CTSL or human CTSV, indicating
that human CTSV can compensate for murine CTSL
(Hagemann et al., 2004; Reinheckel et al., 2005).
We conclude that cystatin M/E has probably two important
regulatory functions in epidermal differentiation and hair
follicle morphogenesis. First, cystatin M/E could have a role
in desquamation by the regulation of CTSV protease activity,
which is involved in the degradation of corneodesmosomal
components. Second, cystatin M/E could regulate cross-
linking of structural proteins by TGase 3 in the cornification
process of the epidermis and the hair follicle by controlling
CTSL and AEP activities. We have recently developed a
human reconstructed skin model that recapitulates the
expression pattern of several of the proposed players in this
process (unpublished results), and as such will be a valuable
tool in further delineation of the role of cystatin M/E and its
















Figure 6. Cystatin M/E and CTSV are colocalized at the desmosomes after
secretion. Immunoelectron microscopy using the cryo-ultramicrotomy
method. (a) Granular layer (G) and the cornified layer (C1). The marked
rectangular area is shown at higher magnification in (b). Cystatin M/E labels
(10 nm gold, lager arrows) are aggregated and not mixed with CTSV labels
(5 nm gold, smaller arrows) in the LGs of the granular layer. (c) Granular layer
and the 1st to 5th cornified layer. (d) Higher magnification of the area marked
in (c), where cystatin M/E and CTSV labels are colocalized at desmosomes.
a b




Figure 7. AEP is not an LG protein. Post-embedding immunoelectron
microscopy using Lowicryl HM20 resin. (a) A lower magnification view of the
SC and SG. The rectangular area is shown at higher magnification in (b),
which shows AEP labels (10 nm gold, black arrows) are not associated with





Figure 8. CTSL is not an LG protein. Post-embedding immunoelectron
microscopy using Lowicryl HM20 resin. (a) A lower magnification view of the
SC and SG. The rectangular area is shown at higher magnification in (b),






















Figure 9. Regulation of epidermal protease activity by cystatin M/E.
A simplified scheme of the presumed regulatory role of cystatin M/E in
processes that control epidermal cornification and desquamation. Cystatin M/
E is an inhibitor of AEP and the cysteine proteases CTSL and CTSV. Inhibition
of CTSV activity could possibly regulate desquamation, as CTSV is able to
degrade (corneo)-desmosomal proteins. Inhibition of CTSL activity by cystatin
M/E is presumably important in the cornification process, as CTSL is the
elusive processing and activating enzyme for TGase 3. Inhibition of AEP might
regulate the processing of (pro)-cathepsins, a process that is also under control
of intra- and extracellular pH changes.
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Together with the use of knockout mouse models that we are
currently generating (cystatin M/E – AEP and cystatin M/E –
CTSL double-knockout mice), this work extends our know-
ledge on the components that are involved in epidermal
cornification and desquamation. We expect that these data
will lead to further understanding of human disorders with
disturbed skin barrier function.
MATERIALS AND METHODS
Antibodies
Primary antibodies used in this study were as follows: affinity-
purified polyclonal rabbit anti-human cystatin M/E antibodies
(Zeeuwen et al., 2001), affinity-purified polyclonal sheep anti-
human AEP antibodies (Li et al., 2003), monoclonal mouse anti-
human CTSV, monoclonal rat anti-human/mouse CTSL, monoclonal
mouse anti-human cystatin M/E (all from R&D Systems, Minneapo-
lis, MN), and mouse anti-DSG1-P23 (Progen, Heidelberg, Germany).
For immunofluorescence analysis, the following secondary
reagents were used: Alexa-Fluor 488 goat anti-rabbit IgG highly
cross-absorbed, and Alexa-Fluor 594 goat anti-rat, goat anti-mouse,
and donkey anti-sheep IgG highly cross-absorbed (Molecular
Probes, Eugene, OR). Secondary antibodies used for immunoelec-
tron microscopy were 5 or 10 nm gold-conjugated goat anti-mouse
IgG, gold-conjugated rabbit anti-goat IgG, and gold-conjugated goat
anti-rabbit IgG (all from Amersham Bioscience, Buckinghamshire,
UK), and 10 nm gold-conjugated donkey anti-sheep IgG (BBInterna-
tional, Cardiff, UK).
Immunofluorescence analysis
Biopsies of normal skin from healthy volunteers were rinsed in
phosphate-buffered saline, fixed for 4 hours in buffered 4% formalin,
and embedded in paraffin wax (skin biopsies were collected with
informed consent using protocols approved by the local medical
ethics committee that complies with the Declaration of Helsinki
Principles). All material was cut in 7-mm sections, mounted on
SuperFrost slides (Menzel, Braunschweig, Germany), deparaffinized,
and rehydrated. The sections were subsequently incubated with
primary antibodies diluted in 1% BSA/phosphate-buffered saline for
1 hour at room temperature. After washing in phosphate-buffered
saline, fluorescent secondary antibodies were applied for 30minutes
at room temperature. For double labeling with antibodies raised in
different animals, a mixture of primary antibodies was applied and
this was followed by incubation with a mixture of secondary
antibodies conjugated with different fluorescent dyes. Nuclei were
stained with 40,6-diamidine-20-phenylindole dihydrochloride (Dako-
Cytomation, Copenhagen, Denmark), and the slides were mounted
using Prolong Gold Antifade reagent (Molecular Probes). The slides
were subsequently examined using an immunofluorescence micro-
scope (Axioskop 2 MOT, Zeiss, Sliedrecht, The Netherlands), and
images were photographed using a digital camera (Sony DXC-390P
3 CCD, Scanalytics, Fairfax, VA) and edited using Axiovision
Software (Zeiss).
Immunoelectron microscopy
Post-embedding immunoelectron microscopy using Lowicryl K11M
resin and Lowicryl HM20 resin (Chemische Werke Lowi, Waldkrai-
burg, Germany) was performed as described previously (Ishida-
Yamamoto et al., 2004). Immunoelectron microscopy on ultrathin
cryosections was carried out according to the Tokuyasu method
(Tokuyasu, 1989), with slight modifications as described previously
(Ishida-Yamamoto et al., 2004).
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Desquamation  is  the physiological process of  shedding dead  corneocytes  from  the 




upper  stratum  corneum  layers  both  proteins  are  closely  associated  with 
corneodesmosomes,  indicating  a  potential  role  for  these  molecules  in  epidermal 
desquamation.  In  the  present  study  we  analyzed  the  ability  of  cathepsin  V  to  cleave 
recombinant and natural forms of corneodesmosomal components. Cathepsin V proteolyses 
desmoglein‐1,  desmoglein‐3,  and  corneodesmosin  at  pH  5.5, which  resembles  the  acidic 
environment of the upper stratum corneum  layers. At a neutral pH of 7.0, which  is the pH 
environment of  the  lower stratum corneum  layers,  little proteolysis was observed and  the 
corneodesmosomal  proteins  remained  largely  unaffected.  Furthermore,  we  found  that 
legumain,  another physiological  target protease of  cystatin M/E,  is  able  to process  active 
single‐chain  cathepsin  V  in  vitro  into  a  previously  unknown  active  two‐chain  form. 
Subsequently, we  determined  the  cleavage  site  by N‐terminal  sequencing  and MALDI‐MS 






During  terminal differentiation of  the epidermis, keratinocytes  from  the basal  layer 
gradually  differentiate  into  the  dead  corneocytes  of  the  stratum  corneum  (SC),  and  are 
eventually  shed  from  the  skin  surface  by  the  process  of  desquamation.  Desquamation 
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requires  degradation  of  corneodesmosomes,  which  are  modified  desmosomes  of  the 
epidermis  that  provide  strong  cell‐cell  adhesion.  These  functions  are  important  in 
maintaining the integrity of the tissue and in providing the cells resistance to physical stress 
and pressure1,2. Desmosomes are composed of proteins  from multiple  families  (cadherins, 
armadillo  proteins,  and  plakins),  but  the  adhesive  intercellular  junction  is  formed  by  the 
extracellular  domains  of  two  types  of  transmembrane  cadherins:  desmogleins  and 
desmocollins3.  Four  desmogleins  (DSG1‐4)  and  three  desmocollins  (DSC1‐3)  have  been 
identified,  all  clustered  on  chromosome  18,  but  each with  its  own  epidermal  expression 
pattern, e.g. DSG1 and DSC1 are more expressed in the upper granular layers, whereas DSG3 
and  DSC3  are  expressed  in  the  basal  and  spinous  layers.  These  differential  expression 
patterns could have a role in epidermal morphogenesis as DSG1 and DSC1 seem to promote 
strong  cell‐cell  adhesion  and  keratinocyte  terminal  differentiation, whereas  expression  of 
DSG3  and  DSC3  may  be  related  to  inhibition  of    differentiation  and  stimulation  of 
keratinocyte proliferation4,5. In corneodesmosomes the intercellular junction is enhanced by 
the  secreted  glycoprotein  corneodesmosin  (CDSN),  which  has  homophilic,  adhesive 
properties6,7.  Various  human  diseases  and mouse models  have  shown  the  importance  of 
these adhesive components in epidermal barrier formation and function2,4,8,9. 
Proteolysis  of  corneodesmosomal  proteins  is  essential  for  desquamation,  and  this 
process  is  mediated  by  secreted  skin  proteases,  primarily  serine,  but  also  aspartic  and 
cysteine proteases10‐12. Previous studies have mainly focused on the potential role of serine 
proteases  in  desquamation,  especially  the  kallikreins  (KLKs).  KLK5  and  KLK7  are  able  to 
degrade DSG1, DSC1, and CDSN6,13, while other KLKs such as KLK6 and KLK14 also have been 
suggested  as  desquamatory  enzymes14. Mutations  in  the  SPINK5  gene,  encoding  the  KLK 
inhibitor lympho‐epithelial Kazal type inhibitor (LEKTI), have been identified as the cause of 




pH  than  at an  acidic pH14.  The  gradual  change  in pH of  the  SC  from neutral  in  the  lower 
layers to acidic in the upper layers has implications for KLK activity and favors the activity of 
other proteases such as the acid cathepsins. 
Cystatin M/E  is a cysteine protease  inhibitor that  is highly expressed  in the stratum 
granulosum and SC of human epidermis, hair follicles, sebaceous glands, and sweat glands17. 
We have previously demonstrated the importance of cystatin M/E in epidermal homeostasis 
in  a  mouse  model.  The  cystatin  M/E  deficient  ichq  mouse,  which  is  characterized  by 
abnormal  SC  and  hair  follicle  formation,  displays  a  disturbed  skin  barrier  function  and 












M/E  (unpublished  data). We  found  that  cystatin M/E  regulates  crosslinking  of  structural 
proteins  by  transglutaminase  3  (TGM3)  in  the  cornification  process,  by  controlling  CTSL 
activity, as human CTSL  is the elusive enzyme that processes and activates human TGM321. 
Furthermore, another study provided morphological evidence that cystatin M/E may have a 
role  in desquamation by  regulating CTSV  activity. We have  shown  that CTSV  and  cystatin 
M/E co‐localize  in the stratum granulosum and the SC of the epidermis, that both proteins 




the  processing  of  lysosomal  proteases  such  as  cathepsins  B, H,  and  L  in mice23,24,  LGMN 
could have a regulatory role in processing of human cathepsins L and V. These cathepsins are 
produced as inactive prepro‐enzymes and are subsequently processed in multiple steps into 
mature  active  forms  via  autoactivation  and/or  cleavage  by  other,  hitherto  unknown, 
proteases.  

















4 mm biopsies were  taken  from  lesional psoriatic  skin and  from normal abdominal 
skin of patients undergoing plastic  surgery.  The  study was  approved by  the  local medical 
ethical  committee  (Commissie  Mensgebonden  Onderzoek  Arnhem‐Nijmegen)  and 
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conducted according to the Declaration of Helsinki principles. Written informed consent was 
obtained  from  each  volunteer.  Biopsies  were  taken  under  local  anesthesia  with  4  mm 
punches. Subsequently,  the epidermis was  separated  from  the dermis by  incubation  for 5 
min  in  PBS  at  56°C.  Epidermal  proteins  were  extracted  by  repeated  freeze/thawing  of 
epidermis  in extraction buffer  (40 mM Tris‐HCl, 10 mM EDTA, 0.5% Nonidet‐P40, pH 7.0), 
followed by centrifugation for 10 min at 15000 × g. The supernatants that harbor the soluble 
epidermal proteins were  stored at  ‐80°C.  For determination of CTSV  in human epidermis, 
biopsies from normal skin and psoriasis skin were subjected to dermo/epidermal separation 
by  incubation  for  4  h  in  PBS  (with  Ca2+/Mg2+)  containing  12  mg/ml  dispase  (Roche 
Diagnostics, Basel, Switzerland) at 4˚C. Epidermal proteins were extracted in PBS containing 
protease  inhibitor  cocktail  Complete  (Roche  Diagnostics)  by  repeated  freeze/thawing  as 




Human  recombinant DSG1/Fc  chimera, DSG3/Fc  chimera  (150  ng,  both  from  R&D 




contained  2  ng  CTSV  (with  DSG1/Fc,  DSG3/Fc)  or  4  ng  CTSV  (with  CDSN), while  12.5  ng 
cystatin M/E per ng CTSV was added to reaction samples with CTSV and its inhibitor. Human 
epidermal  protein  extracts  (2.5  μg)  were  incubated  with  100  ng  CTSV  at  37ºC.  For 





GST‐proCTSV  fusion protein, GST‐proCTSL  fusion protein (both  from Abnova, Taipei, 
Taiwan), CTSV and CTSL  (recombinant  scCTSL protein, R&D  systems;  tcCTSL: purified  from 








proteins were  visualized  by  Coomassie  blue  staining  (Fluka  Chemie,  Buchs,  Switzerland), 
silver  staining  or  immunoblotting.  Silver  staining  of  gels  was  performed  using  the 
SilverXpress  kit  (Invitrogen)  according  to manufacturer’s  protocol with  a minor  change  in 
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order to minimize background: amounts of pre‐diluted solutions were reduced by 50% in the 
total  volume.  For  immunoblotting  the  proteins  were  electroblotted  onto  polyvinylidene 
difluoride membrane  (Invitrogen).  The membrane was  incubated with monoclonal mouse 
anti‐human  DSG1  antibodies  (R&D  Systems),  monoclonal  mouse  anti‐human  CDSN 
antibodies26, monoclonal mouse anti‐human CTSV antibodies (R&D Systems), or monoclonal 
rat  anti‐human/mouse  CTSL  antibodies  (R&D  Systems).  Detection  of  the  proteins  was 
established using the Phototope‐HRP detection kit (Cell Signaling, Beverly, MA) according to 





Activity  of  scCTSV  and  tcCTSV was  determined with  fluorometric  assays  using  the 
CTSV‐specific  fluorogenic  substrate  Z‐Leu‐Arg‐AMC  (7‐amino‐4‐methyl‐coumarin,  R&D 
Systems)  in  CTSV  assay  buffer  with  5  ng/μl  bovine  serum  albumin21.  The  amount  of 






amino acid  sequence of  the  fragment was determined by automated Edman degradation. 







To  study  the  presumed  role  of  CTSV  in  the  desquamation  process  of  the  skin we 
incubated  recombinant  corneodesmosomal  proteins  as well  as  human  epidermal  protein 
extracts with  recombinant human CTSV. Reactions were performed using  two buffers  that 
only differed in pH from each other (pH 5.5 and pH 7.0) as CTSV has its optimal activity at an 
acidic  pH, while  at  a  neutral  pH  its  activity  is  greatly  reduced.  Recombinant  DSG1/Fc  is 
rapidly  degraded  by  CTSV  at  pH  5.5;  within  30  min  the  DSG1/Fc  protein  is  degraded 
completely (Fig. 1A). At a neutral pH proteolysis of DSG1/Fc by CTSV is limited and after 240 
min of incubation most of the protein is still intact. To verify that CTSV is responsible for the 
degradation  of  DSG1/Fc, we  incubated  DSG1/Fc with  CTSV  at  pH  5.5  in  the  presence  of 
recombinant  human  cystatin M/E,  a  natural  and  strong  inhibitor  of  CTSV.  This  reaction 
showed  that after 2 h of  incubation  the DSG1/Fc protein  is still  intact due  to  inhibition of 
CTSV activity by  cystatin M/E, whereas  in  the  sample without  cystatin M/E all DSG1/Fc  is 
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degraded  (Fig. 1B). As  the previous experiments were performed with  recombinant  fusion 
protein, we  subsequently  studied  the  ability  of  CTSV  to  degrade  native  epidermal DSG1. 
Human  epidermal  protein  extracts  were  incubated  with  and  without  an  excess  of 
recombinant CTSV  for 2 and 4 h at pH 5.5.  Immunoblotting against DSG1 showed that the 
epidermal  DSG1  band  of  ~110  kDa  disappears  in  the  reactions  with  recombinant  CTSV, 
indicating  that  CTSV  also  degrades  the  natural  form  of  DSG1  (Fig.  1C).  Experiments 
performed with human recombinant DSG3/Fc and recombinant CDSN showed similar results 








that  these  are  completely  degraded  thereafter. No  significant  degradation  is  visible  at  pH  7.0. B) 
recombinant DSG1/Fc (lane 1) was incubated with CTSV alone (lane 2) or with CTSV in the presence 





to endogenous DSG1  is detected.  In addition, three other  low‐molecular weight bands, presumably 
breakdown  products  extracted  from  the  differentiated  epidermis  and  SC,  are  visible. Arrowheads 
indicate the intact DGS1/Fc and DSG1 proteins. 
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bands  that  appear  in  lane  2  to  6  (Fig.  2,  right  panel).  These  intermediate  degradation 
products of DSG3/Fc are only observed within  the  first 30 min  incubation at an acidic pH, 
after  longer  incubation periods  these  intermediate bands are  fully degraded. Cystatin M/E 
prevents degradation of DSG3/Fc at pH 5.5 by inhibition of CTSV activity (lane 8). Note that 
the degradation of DSG3/Fc at neutral pH  is  fully  inhibited by  cystatin M/E. Furthermore, 
CTSV  is able to degrade recombinant CDSN  (52‐56 kDa)  (Fig. 3A) as well as native CDSN  in 






Cathepsins  are  produced  as  prepro‐enzymes  that  need  to  be  processed  into  their 
mature forms via autoactivation and/or cleavage by other proteases. CTSL has two mature 
active  forms,  single‐chain  (sc) CTSL  and  two‐chain  (tc) CTSL, while CTSV  is until now only 









Figure  2:  Degradation  of  recombinant  DSG3/Fc  by  CTSV.  Recombinant  DSG3/Fc    (lane  1)  was 













probably  tcCTSV, based on  its  size and  the homology between CTSV and CTSL. Within 1 h 
small amounts of  scCTSV are processed  into  tcCTSV and after 8 h only  tcCTSV  is detected 
(Fig. 4A). When scCTSV was incubated only in LGMN assay buffer for similar periods of time, 
the single‐chain form remained intact and no two‐chain form could be detected, suggesting 
that  LGMN  activity  is  responsible  for  processing  of  scCTSV  into  tcCTSV  and  that  no 
autoprocessing  occurred  (data  not  shown).  Subsequently,  we  examined  the  potential 
protease activity of  the  tcCTSV  form  for  its  identification as a  truly mature  form of CTSV. 
Samples  that were partly  and  fully processed  into  tcCTSV were  subjected  to  fluorometric 
enzyme assays using a CTSV‐specific substrate showing that after processing into tcCTSV the 
protease remains active with a similar level of activity as scCTSV (Fig. 4B). Experiments with 
human  CTSL  and  LGMN  did  not  show  processing  of  scCTSL  into  tcCTSL  by  LGMN  as  the 
single‐chain  form was  still  visible, while  no  two‐chain  form  appeared  after  incubation  of 
scCTSL with LGMN for 8 h (Fig. 4C). Since cathepsins are capable of processing and activating 
proteins we  investigated whether CTSL and CTSV are  involved  in the activation of LGMN as 
proLGMN also has  to be processed  into  its active  form. Various experiments  in which we 
incubate proLGMN  and mature  LGMN with  scCTSL,  tcCTSL,  and  scCTSV did not  show  any 
processing of LGMN by the cathepsins (data not shown).  
Figure  3:  Degradation  of  recombinant  and 
epidermal CDSN by CTSV. A) recombinant CDSN 
(lane  1)  was  incubated  with  CTSV  for  30,  60, 
120,  240,  and  360 min  (lanes  2‐6);  CDSN was 
incubated alone for 360 min (lane 7); CDSN was 
incubated with CTSV  and  cystatin M/E  for 360 
min (lane 8). Reactions were performed in CTSV 
assay  buffer  pH  5.5  at  37°C,  and  visualized  by 




M/E  (lane 8)  the CDSN band  is  still present. B) 
human  epidermal  protein  extract  (lane  1) was 
incubated with CTSV  for 2, 4, and 8 h  (lanes 2‐
4);  human  epidermal  extract  was  incubated 
alone  for  8  h  (lane  5).  Reactions  were 
performed  in CSTV assay buffer pH 5.5 at 37°C, 
and visualized by immunoblotting using an anti‐
CDSN  antibody.  After  8  h  a  significant 
proportion of the endogenous CDSN was found 
to  be  degraded  by  added  recombinant  CTSV 
(lane  4),  whereas  8  h  of  incubation  in  buffer 





1,  2,  4,  6,  and  8  h  (lanes  2‐6)  in  LGMN  assay  buffer  at  37°C.  Reactions  were  visualized  by 
immunoblotting using an anti‐CTSV antibody. A time‐dependent processing of scCTSV was found. B, 










Since  human  CTSV  is  very  homologous  to  human  CTSL  and mouse  CTSL,  protein 
sequence alignment of these proteins could  indicate the expected cleavage site  in CTSV.  In 
human  CTSL  and mouse  CTSL  the  cleavage  site  between  the  heavy  and  light  chains  is  at 






Subsequently,  the  tcCTSV  fragment was subjected  to  trypsin digestion  followed by MALDI‐
MS  analysis  in  order  to  elucidate  the  sequence  of  the  resulting  tryptic  and  semi‐tryptic 





Our experiments have  revealed an active  two‐chain  form of CTSV  in vitro,  that has 
not been reported in tissues before. To address if the two‐chain form exists in vivo we used 
immunoblotting  to  detect  CTSV  in  human  epidermal  protein  extracts  from  normal  and 
psoriatic skin. Before extraction protease inhibitor cocktail was added to prevent processing 
of  CTSV  by  endogenous  proteases  in  the  extracts.  In  the  epidermal  protein  extracts  of 
normal skin all forms of CTSV are detected: the inactive prepro‐ and proCTSV (~35‐37 kDa), 







might  indeed  be  the  case.  In  this  study we  analyzed  the  ability  of  CTSV  to  degrade  the 
corneodesmosomal  proteins  DSG1,  DSG3,  and  CDSN  at  an  acidic  and  neutral  pH. 











are  underlined.  For  comparison,  the  cleavage  sites  of  human  CTSL  and mouse  CTSL  are  given  as 
reported previously by others44,45. 
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prevented  in the presence of  its natural  inhibitor cystatin M/E  (Fig. 1‐3). Although DSG1  is 
the main desmoglein component in corneodesmosomes, we have also included DSG3 in this 
study. DSG3  is mainly expressed  in the basal and spinous  layers of  the epidermis, while  in 
the  granular  layers  its  expression  is  gradually  reduced.  CTSV  could  be  responsible  for 
degradation of DSG3 remnants in the stratum granulosum or the SC.  
Our  initial  studies  in cystatin M/E deficient mice did not  suggest a  role  for cystatin 
M/E target proteases in desquamation. Retention of thick scales and plugging of hair follicles 
was found from day 5 to neonatal death between day 10‐12. Apparently, the excessive CTSL 
activity  (CTSV  is absent  in mice) caused massive crosslinking and  retention of corneocytes 
rather  than  promoting  desquamation  and  loss  of  scales.  Obviously,  the  phenotype  of  a 
mouse completely deficient for cystatin M/E does not necessarily reveal the subtleties of the 




our  findings with  immunoelectron microscopy on human skin22 and biochemical data  from 








human  epidermis of normal  skin  (NS,  n=3) 
and psoriasis skin  (PS, n=3) were subjected 
to  immunoblotting  using  an  anti‐CTSV 
antibody.  Arrowheads  show  the  multiple 
forms  of  CTSV,  including  the  newly 
discovered  two‐chain  form  of    CTSV. 




Interestingly,  it has been  suggested  that desquamation  results  from pH‐dependent 
activation of the several protease families as the pH of the SC changes from neutral  in the 




7.0, which can be explained by  the acidic pH optima  (4.5‐6.5) of CTSV. This  is opposite  to 
what was found for the proteolytic abilities of KLKs that have neutral to alkaline pH optima, 
and  showed  decreased  proteolytic  activity  at  pH  5.4  compared  to  pH  7.614. Our  findings 
suggest that desquamation is regulated by protease inhibitors that control protease activity 
in the SC and that gradual change in pH of the SC indicates which proteases are mainly active 
in  each  of  the  different  layers.  Recently,  it was  shown  that  the  interaction  between  the 
serine protease inhibitor LEKTI and KLK5 is pH‐regulated. LEKTI had a strong affinity for KLK5 
at  pH  7.5,  but  acidification  of  the  environment  decreased  the  strength  of  the  binding 
resulting  in  an  increased  dissociation  of  the  LEKTI‐KLK5  complex  and  thereby  releasing 
KLK528. Despite  reduced  KLK5  activity  at  lower  pH,  the  pH‐regulated  interaction  between 
LEKTI  and  KLK5 might  be  necessary  to  prevent  premature  desquamation  at  the  stratum 
granulosum‐SC  interface.  Although  CTSV  activity  is  limited  at  neutral  pH,  the  interaction 
between cystatin M/E and CTSV could be influenced by pH gradient in a similar way. 








active  forms  by  autoactivation  and/or  processing  by  other  proteases.  However,  the 







the mature cathepsin  forms37,38. LGMN  is  involved  in the processing of scCTSL  into tcCTSL, 
since complete absence of tcCTSL was detected in LGMN deficient mice, although the single‐





form  (Fig. 4). The existence of a  two‐chain  form of CTSV  is not  surprising  since  two‐chain 
forms of both human and mouse CTSL are known23,39. No functions specifically for the single‐
chain  or  two‐chain  forms  of  CTSL  have  been  found,  and  it  is  not  known  whether  this 
conversion  regulates CTSL activity or substrate specificity, but  the distribution and ratio of 
both mature  forms may differ  among  tissues40.  Similar matters  regarding  the  single‐chain 
and  two‐chain  forms  of  CTSV  remain  to  be  solved.  Autocatalytic  processing  of  proLGMN 
produces an active intermediate form of LGMN that requires further processing by another 
protease to yield the final mature LGMN25. We found that human CTSV and CTSL were not 
able  to process proLGMN or  the active  intermediate  form of LGMN, and  these  results are 
consistent with a previous report in which the processing of the intermediate form of LGMN 
to  the  final mature  form  in  vivo  is not blocked by  the  cysteine protease  inhibitors E64 or 
leupeptin25. 




human  CTSL  has  a  Asp‐residue  (D291)  in  the  cleavage  site.  Since  LGMN  is  specific  for 
hydrolysis of asparaginyl bonds, the Asp‐residue  in human CTSL could explain why LGMN  is 
not able to process human CTSL  into the two‐chain  form. Based on the homology of CTSV 
with  human  and mouse  CTSL  the  cleavage  site  in  CTSV was  expected  to  be  at  Asn292. 






to mouse CTSL  than  to human CTSL42. Another possibility  is  that mouse CTSL controls  the 
specific functional activities of both human CTSL and CTSV. 
In epidermal protein extracts of normal skin all forms of CTSV were clearly visible, but 
very  little  CTSV  could  be  detected  in  the  extracts  of  psoriatic  skin  (Fig.  6).  Previous 
experiments have  shown  that CTSV expression  is decreased  in psoriatic  skin, both on  the 
mRNA and the protein level27. Decreased CTSV activity could lead to delayed desquamation 
and  retention  of  the  corneocytes  and  thereby  induce  thickening  and  visible  scaling  of 
psoriatic  skin.  This  report  shows  for  the  first  time  detection  of  tcCTSV  protein  in  human 
tissue. CTSV protein expression  in tissues has only been studied  in two previous studies so 
far, that performed Western blot analysis in extracts of SC and thymus. In SC multiple forms 
of  CTSV  of  33‐39  kDa  were  detected,  that  were  assumed  to  be  proCTSV,  scCTSV  and 
degradation products, but the two‐chain  form of CTSV was not seen12. However, the CTSV 
antibody used in that study was raised against the end‐part of the propeptide of CTSV, and 
the  detected  bands  probably  represent  proCTSV  and  intermediate  forms  of  scCTSV with 
extended N‐termini, whereas  the  fully matured  single‐chain  form and  the  two‐chain  form 
82
are  not  recognized  by  the  antibody.  In  thymus  only  one  form  of  ~30  kDa was  detected, 
probably indicating scCTSV43. The antibody used for detection in thymus extracts is reported 
to  interact specifically with CTSV, but production and characterization of  this antibody has 
not  been  published.  Another  possibility  is  that  tcCTSV  is  not  produced  in  thymus  since 
distribution of the mature forms may vary among tissues, which has been shown for CTSL40. 
Altogether, we have shown that CTSV degrades corneodesmosomal proteins and that 
CTSV  is processed by LGMN  into a previously unknown active two‐chain form that exists  in 
human epidermis. Since the activities of both CTSV and LGMN can be  inhibited by cystatin 
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Colocalization of Cystatin M/E and its Target
Proteases Suggests a Role in Terminal Differentiation
of Human Hair Follicle and Nail
Tsing Cheng1, Ivonne M.J.J. van Vlijmen-Willems1, Kiyotaka Hitomi2, Marcel C. Pasch1, Piet E.J. van Erp1,
Joost Schalkwijk1 and Patrick L.J.M. Zeeuwen1
The cysteine protease inhibitor cystatin M/E is a key regulator of a biochemical pathway that leads to epidermal
terminal differentiation by inhibition of its target proteases cathepsin L, cathepsin V, and legumain. Inhibition of
cathepsin L is important in the cornification process of the skin, as we have recently demonstrated that
cathepsin L is the elusive processing and activating protease for transglutaminase 3, an enzyme that is
responsible for crosslinking of structural proteins in cornified envelope formation. Here, we study the
localization of all players of this pathway in the human hair follicle and nail unit in order to elucidate their
possible role in the biology of these epidermal appendages. We found that cathepsin L and transglutaminase 3
specifically colocalize in the hair bulb and the nail matrix, the regions that provide cells that terminally
differentiate to the hair fiber and the nail plate, respectively. Furthermore, transglutaminase 3 also colocalizes
with the structural proteins loricrin and involucrin, which are established transglutaminase substrates. These
findings suggest that cathepsin L and transglutaminase 3 could be involved in the pathway that leads to terminal
differentiation, not only in the epidermis but also in the human hair follicle and nail unit.
Journal of Investigative Dermatology advance online publication, 13 November 2008; doi:10.1038/jid.2008.353
INTRODUCTION
Recent work of our group has revealed a previously
unreported biochemical pathway that controls skin barrier
formation by regulation of both crosslinking and desquama-
tion of the stratum corneum. The cysteine protease inhibitor
cystatin M/E, which is a key molecule in this pathway, has
two important regulatory functions in epidermal differentia-
tion and hair follicle morphogenesis. First, cystatin M/E
regulates crosslinking of structural proteins by transglutami-
nase 3 (TGase 3) in the cornification process of the epidermis
and the hair follicle by controlling cathepsin L (CTSL) and
legumain activities (Zeeuwen et al., 2004; Cheng et al.,
2006). We provide evidence for this assumption when we
demonstrated that human CTSL is the elusive enzyme that is
able to process and activate human TGase 3, an epidermis-
specific enzyme responsible for the crosslinking of loricrin
and small proline-rich proteins (SPRs) in the cornification
process of the skin (Cheng et al., 2006). During keratinocyte
differentiation, TGase 3 is activated by limited proteolysis
(Hitomi et al., 1999; Ahvazi et al., 2002), a process that is
apparently under control of cystatin M/E, at least during skin
morphogenesis in the neonatal phase (Zeeuwen et al., 2004).
We suppose that processing and activation of TGase 3 in
terminally differentiating keratinocytes is regulated by the
inhibitory activity of cytoplasmic cystatin M/E against CTSL.
Legumain inhibition by cystatin M/E could have a regulatory
role in CTSL activity as legumain is involved in CTSL
processing (Maehr et al., 2005). As a second regulatory
function, cystatin M/E could have a function in desquamation
by the regulation of cathepsin V (CTSV) protease activity,
which is involved in the degradation of corneodesmosomal
components. We recently showed that cystatin M/E and
CTSV are separately transported within lamellar granules and
that both proteins are secreted in the extracellular space of
the stratum corneum where they associate with corneodes-
mosomes as determined at the ultrastructural level (Zeeuwen
et al., 2007).
Misregulation of this pathway by unrestrained protease
activity, as seen in cystatin M/E-deficient mice, leads to
abnormal stratum corneum and hair follicle formation,
disturbance of skin barrier function, and neonatal death
(Sundberg et al., 1997; Zeeuwen et al., 2002, 2004). The
importance of regulated proteolysis in epithelia is well
demonstrated by the recent identification of the SPINK5
& 2008 The Society for Investigative Dermatology www.jidonline.org
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serine protease inhibitor as the defective gene in the
Netherton syndrome, cathepsin C mutations in the Papillon-
Lefevre syndrome, ichthyosis because of matriptase defi-
ciency, and targeted ablation of CTSL and cathepsin D in
mice (for a comprehensive review see Zeeuwen, 2004).
The hair follicle and nail unit are epidermal appendages
that also show processes of terminal differentiation. Hair
follicles undergo cycles of growth, regression, and rest, which
are, respectively, named anagen, catagen, and telogen phase
(Paus and Foitzik, 2004; Alonso and Fuchs, 2006). During the
anagen phase the entire hair from tip to root is produced
when matrix cells in the hair bulb proliferate and differentiate
into the several layers of the hair follicle (Figure 1): the
medulla, cortex, and cuticle layer of the hair shaft (the actual
hair fiber); the Huxley’s and Henle’s layers, and the cuticle of
the inner root sheath (IRS), and the outer root sheath (ORS)
(Niemann and Watt, 2002; Fuchs, 2007). Keratinization of
hair follicles occurs in specific compartments, that is the hair
shaft, cuticle, and IRS, through crosslinking of structural
precursor proteins by TGases (Commo and Bernard, 1997;
Thibaut et al., 2005). The degeneration of the IRS in the
infundibulum of the hair follicle near the opening of the
sebaceous duct requires desquamation, a process in which pro-
teolytic enzymes are involved (Ekholm and Egelrud, 1998).
Contrary to hairs, nails show continuous growth of the
hard nail plate out of the nail matrix, sliding over the
underlying nail bed (Dawber et al., 2001; Baran et al., 2005).
Keratinization of the nail starts in the nail matrix, but the
relative contribution of TGases to the formation of nail
corneocytes which end up in the nail plate is not exactly
known. Nevertheless, it is known that lack of TGase 1 in
lamellar ichthyosis patients could be reflected in structural
nail alterations (Rice et al., 2003).
In the present study we sought to address the possible role
of cystatin M/E and its physiological target proteases in the
biology of the human nail unit and hair follicle. We have
examined the localization of cystatin M/E, CTSV, CTSL,
TGase 3, and legumain in (longitudinal and/or transversal)
sections of the human hair follicle and nail unit by
immunofluoresence microscopy. We also examined the
localization of known TGase substrates like the structural
proteins involucrin, loricrin, and trichohyalin (THH). We
found colocalization of CTSL, TGase 3, involucrin, and
loricrin in the hair bulb and the nail matrix, suggesting that
these proteins are key players in the pathway that initiate




Immunofluorescence microscopy was performed on both
longitudinal and transversal sections of human hair follicle in
order to examine the localization of cystatin M/E and its
physiological target proteases in the different layers of the
hair follicle. For a comprehensive biochemical and kinetic
analysis of the interaction between cystatin M/E and its target
proteases (see Cheng et al., 2006). Double staining was
performed for cystatin M/E with its target proteases, for TGase
3 with its activating protease CTSL, and for TGase 3 with its




Outer root sheath (ORS)
















Figure 1. Schematic overview of longitudinal and transversal sections demonstrating the various components of the hair follicle.
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Cystatin M/E is expressed in the IRS, the inner half of the
ORS, and in the sebaceous glands of the hair follicle.
However, cystatin M/E is only expressed in the distal part and
infundibulum of the hair follicle, but is absent in the proximal
part, the hair bulb (Figures 2a, g, m, and 3g). Furthermore,






















Figure 2. Colocalization of cystatin M/E and its target proteases CTSV, CTSL, and legumain in human hair follicle. Immunofluorescence staining of (a, d,
g, j, m, and p) cystatin M/E (green color), and (b, e, h, k, n, and q) CTSV, CTSL, or legumain (red color), and (c, f, i, l, o, and r) double staining (yellow–orange
merge color) for both proteins on (c, i, and o) longitudinal and (f, l, and r) transversal sections of the hair follicle. Nuclei are blue (DNA staining by 40,
6-diamine-20-phenylindole dihydrochloride (DAPI)). Bar¼ 100mm.
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expression of cystatin M/E is weak or absent in the cuticle and
Huxley’s layer (Figure 2d, j, and p). Colocalization of cystatin
M/E and CTSV can be found specifically in the Henle’s layer
of the IRS, as CTSV expression is restricted to this layer of
cells of the hair follicle (Figure 2e–f). Interestingly, colocali-
zation of cystatin M/E and CTSV is only seen in the
infundibulum of the hair follicle near the opening of the
sebaceous ducts into the hair canal (Figure 2c). CTSL shows a
less restricted expression pattern and is expressed in IRS (but
not in the Huxley’s layer), ORS, and sebaceous glands (Figure
2h and k). Coexpression of cystatin M/E and CTSL can be
seen in the distal part and infundibulum of the hair follicle
and is located in the Henle’s layer of the IRS, the inner half of
the ORS, and the sebaceous glands (Figure 2i and l). CTSL is
also expressed in the medulla and cortex of the hair shaft, but
only in the lower hair bulb (inset Figure 3e). Legumain
expression can be found throughout the entire hair follicle
resulting in a colocalization with cystatin M/E in the IRS, the
inner layers of the ORS, and the sebaceous glands (Figure 2o
and r), but again only in the distal part and infundibulum of
the hair follicle.
TGases are enzymes involved in protein crosslinking of
structural proteins in cornified envelope formation. In human
epidermis TGase 3 is expressed in the upper layers of the
stratum granulosum and the stratum corneum, where the
keratinocytes undergo cornification (Figure 3a). Previously,
we have demonstrated that CTSL is the elusive enzyme that
processes and activates TGase 3. Here, we show that in
human epidermis TGase 3 and CTSL colocalize in the stratum
granulosum (Figure 3c). Note that the yellow merge staining
forms a transition zone between the red CTSL staining in the
spinous and granular layers and the green TGase 3 staining in
the upper granular layers and the stratum corneum, which
suggests that first the activating protease is expressed
followed by its substrate. Double staining of TGase 3 and
CTSL in the hair follicle shows a similar overlapping
colocalization in the hair bulb (Figure 3f). First, CTSL is
expressed at the bottom of the hair bulb followed by the
expression of TGase 3 in the upper part of the hair bulb.
TGase 3 expression is restricted to the medulla and cortex of
the hair shaft, whereas CTSL is also expressed in the root
sheaths (see insets Figure 3d–f). Subsequently, CTSL expres-
sion disappears from the hair shaft and only TGase 3
expression remains (Figure 3f). However, staining of TGase
3 in the hair shaft was only seen in the proximal part of the
hair follicle; no expression could be detected in the distal part
and infundibulum of the hair follicle (data not shown).
Remarkably, cystatin M/E is not present in the hair bulb, as is
CTSV, whereas legumain staining was positive for this section
(Figure 3g–i). During epidermal cornification TGase 3 is
responsible for crosslinking of loricrin and small proline-rich
proteins into the cornified envelope. Loricrin is abundantly
expressed in the hair shaft; a weak signal can be detected in
the Henle’s layer of the IRS, but not in Huxley’s layer (Figure
4b). This expression pattern results in a colocalization with
TGase 3 in the medulla, cortex, and cuticle of the hair shaft
(Figure 4c). We also found colocalization of TGase 3 with







TGase 3a b c
d e f
g h i
Figure 3. Colocalization of TGase 3 and CTSL in human epidermis and hair follicle. Immunofluorescence staining of (a and d) TGase 3 (green color), and
(b and e) CTSL (red color), and (c and f) double staining (yellow–orange merge color) for both proteins on epidermis (a–c), and both longitudinal (d–f) and
transversal (insets d–f) sections of the hair follicle. The arrows (f) show the position of the transversal section (inset). Immunofluorescence staining of
legumain was found in the (h) hair bulb, whereas no positive staining could be detected for (g) cystatin M/E or (i) CTSV in this part of the follicle. Nuclei are
blue by DAPI staining for DNA. Bar¼100 mm.
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as involucrin is expressed in the hair shaft and the IRS (Figure
4e). However, colocalization of these proteins is only
detected in the medulla and cortex, but not the cuticle,
as involucrin seems to be absent in this layer as indicated
by green staining surrounding the medulla and cortex (Figure
4f). Immunofluorescence detection of THH, the major
structural component of hair follicles and a presumed
substrate for TGase 3, shows positive staining of granules in
the IRS (Figure 4h and k). However, TGase 3 and THH
show no colocalization in this part of the hair follicle
(Figure 4i and l). Finally, we studied the distribution of TGase
1 in the hair follicle as TGase 3 expression is restricted to
the hair shaft. Interestingly, TGase 1 is specifically expressed
in the IRS at the same location where THH is expressed
(Figure 4k and n). Double staining of TGase 1 and TGase 3
shows no overlap between both enzymes in the hair follicle
(Figure 4o).
Nail unit
Five specific regions of the nail unit were studied in close-up,
namely the epidermis (at the proximal side of the nail), the
proximal nail fold, the nail matrix, the nail bed, and the
hyponychium (Figure 5). We performed immunofluorescence
microscopy for double staining of cystatin M/E and its target
protease CTSL, and for TGase 3 with its activating protease
CTSL (Figures 6 and 7).
Cystatin M/E is expressed in the upper granular layers of
epidermis and proximal nail fold (Figure 6a and d), but
expression diminishes towards the nail matrix where staining
of cystatin M/E is faint and located in the cell layers bordering
the nail plate (Figure 6g). Cystatin M/E is not present in the
nail bed, but reappears at the hyponychium (Figure 6j
and m). Positive staining of CTSL can be seen throughout
the entire nail unit and is suprabasal with the exception


















Figure 4. TGase 3 and its presumed substrates in human hair follicle. Immunofluorescence staining of (a, d, g, j, and m) TGase 3 (green color), and
(b, e, h, k, and n) loricrin, involucrin, THH, or TGase 1 (red color), and (c, f, i, l, and o) double staining (yellow–orange merge color) for these proteins on
transversal (a–i) and longitudinal (j–o) sections of the hair follicle. Nuclei are blue by DAPI staining for DNA. Bar¼ 100 mm.
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(Figure 6b, e, h, k, and n), resulting in a colocalization with
cystatin M/E in all regions of the nail unit that express cystatin
M/E (Figure 6c, f, i, l, and o). The double staining of cystatin
M/E and legumain shows a similar picture as legumain is also
expressed in the entire nail unit (data not shown). No
colocalization of cystatin M/E with CTSV can be found as
CTSV seems to be absent in the nail unit, except for the
epidermis and the hyponychium (data not shown). TGase 3 is
expressed in all regions of the nail unit except the nail bed,
which is completely negative for TGase 3 (Figure 7a, d, g, j,
and m). The expression of TGase 3 in the epidermis, proximal
nail fold, and hyponychium is suprabasal, but most intense in
the upper granular layers, although the distal part of the
proximal nail fold shows a weaker expression of TGase 3.
However, TGase 3 staining is very strong in the nail matrix,
but restricted to only the upper cell layers bordering the nail
plate (Figure 7g). Colocalization of TGase 3 and CTSL is seen








Figure 5. Cross-section through the finger demonstrating the various
components of the nail unit. Different parts of the nail unit (epidermis,
proximal nail fold, nail matrix, nail bed, and hyponychium) that were













Figure 6. Colocalization of cystatin M/E and CTSL in the human nail unit. Immunofluorescence staining of (a, d, g, j, and m) cystatin M/E (green color),
and (b, e, h, k, and n) CTSL (red color), and (c, f, i, l, and o) double staining (yellow–orange merge color) for both proteins in epidermis (a–c), proximal
nail fold (d–f), nail matrix (g–i), nail bed (j–l), and hyponychium (m–o). Nuclei are blue by DAPI staining for DNA. Bar¼ 100mm.
Journal of Investigative Dermatology
T Cheng et al.
Cystatin M/E in Human Nail and Hair Follicle
93
proximal nail fold, and hyponychium (Figure 7c, f, and o), but
is most prominent in the nail matrix (Figure 7i).
DISCUSSION
Cystatin M/E is a key regulator of a previously unreported
biochemical pathway that leads to epidermal terminal
differentiation through its inhibitory activities against its
target proteases CSTL, CTSV, and legumain. Inhibition of
CTSL is important in the cornification process as CTSL
processes and activates TGase 3. In this study we analyzed
the localization of the key molecules of this pathway in the
human hair follicle and nail unit. CTSL and TGase 3
specifically colocalize in the hair bulb and the nail matrix,
the regions that provide cells that terminally differentiate into
the hair fiber and the nail plate, respectively. Moreover, the
structural proteins loricrin and involucrin are also expressed
at these sites suggesting an involvement in the pathway that
leads to terminal differentiation, not only in the epidermis but
also in the human hair follicle and nail unit.
Our results show that CTSL and TGase 3 are coordinately
expressed in the epidermis and the developing human hair
follicle. CTSL expression appears in the lower (suprabasal)
layers of the epidermis where terminal differentiation of the
cells starts, followed by the expression of TGase 3 in the
upper granular layer where processing and activation of the
crosslinking enzyme takes place (Figure 3). Likewise, CTSL is
expressed in the bottom of the hair bulb, which contains
matrix cells that produce progeny cells that terminally
differentiate to form the growing hair shaft. Just above this
area, TGase 3 appears in the hair bulb at a location where
hair shaft precursors are normally expressed (Rogers, 2004).
The colocalization of CTSL and TGase 3 in the hair bulb fits
well with our previous discovery that CTSL is the elusive
protease that processes and activates TGase 3 (Cheng et al.,
2006). The nail matrix does also show a gradual transition
from CTSL to TGase 3 expression (Figure 7i). Terminally
differentiated cells comprising the nail bed originate from the
nail matrix, which suggests that activation of TGase 3 takes
place at a location that is analogous to the human hair bulb,
the location where the matrix cells of the hair reside.
Remarkably, cystatin M/E is absent in the hair bulb and












Figure 7. Colocalization of TGase 3 and CTSL in the human nail unit. Immunofluorescence staining of (a, d, g, j, and m) TGase 3 (green color), and
(b, e, h, k, and n) CTSL (red color), and (c, f, i, l, o) double staining (yellow–orange merge color) for both proteins in epidermis (a–c), proximal nail fold (d–f), nail
matrix (g–i), nail bed (j–l), and hyponychium (m–o). Nuclei are blue by DAPI staining for DNA. Bar¼ 100 mm.
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that full, uninhibited activity of CTSL is necessary for
activating sufficient amounts of TGase 3. It is also possible
that another cysteine protease inhibitor regulates CTSL
activity in these regions. Cystatin A is able to inhibit CTSL
and has been detected in hair shaft and nail extracts
(Tsushima et al., 1992; Tsushima, 1993). Expression of
cystatin M/E starts above the hair bulb and is further
continuously present in the distal part and the infundibulum,
up to the epidermis where the hair exits the skin. One might
speculate that in these parts of the hair follicle CTSL has other
functions than processing TGase 3 (which is not expressed at
these sites), and that at these locations CTSL activity has to be
regulated by cystatin M/E. Nonetheless, the colocalization of
CTSL and TGase 3 supports the proposed role of CTSL in the
processing and activation of TGase 3 and the ensuing
keratinization of the hair shaft and nail matrix.
In the epidermis TGases are responsible for crosslinking of
loricrin, involucrin, and other structural barrier proteins into
the cornified envelope of keratinocytes (Candi et al., 2005).
To our knowledge we showed for the first time colocalization
of TGase 3 and loricrin in the hair follicle suggesting that
TGase 3 is involved in cornified envelope formation of this
epidermal appendage. We also found expression of loricrin
and involucrin in the nail matrix at the same location were
TGase 3 is expressed (not shown). The colocalization of
TGase 3 and involucrin in the hair follicle was surprising as a
previous study, also based on immunofluorescence micro-
scopy, reported that these proteins did not colocalize in the
hair follicle. It was found that involucrin was abundantly
expressed only in the IRS and the internal layer of the ORS of
the hair follicle, whereas TGase 3 expression was restricted to
the hair shaft and the hair cuticle (Thibaut et al., 2005). We
could confirm the involucrin expression in the IRS, but in
contrast to the study of Thibaut et al., we also found high
expression of involucrin in the medulla and the cortex of the
hair shaft at the level of the hair bulb. We suppose that the
transversal sections of the hair follicle in our study (Figure 4)
originate from a more proximal part of the hair follicle,
whereas the transversal sections in the study of Thibaut et al.
were taken at a higher level of the follicle. Nevertheless, as
TGase 3 is not expressed in the IRS other TGases such as
TGase 1 and TGase 5, which are both expressed in the IRS
and the internal layer of the ORS, could be responsible for
involucrin crosslinking in the more distal parts of the hair
follicle.
Surprisingly, our results showed no colocalization of
TGase 3 and THH in the hair follicle. THH could be a
substrate of TGase 3 in the hair shaft as a biochemical in vitro
study has revealed that TGase 3 is the most efficient
crosslinking enzyme of THH and also showed colocalization
of TGase 3 and THH in mouse skin (Tarcsa et al., 1997). THH
is a major structural hair follicle protein that is crosslinked to
cornified envelope proteins and keratin intermediate fila-
ments in cells of the hair shaft and the IRS providing
mechanical strength to the cells (Lee et al., 1993; Steinert
et al., 2003). In our study THH is specifically expressed in the
Huxley’s layer of the IRS, whereas previous studies generally
reported localization of THH in the IRS and also in the
medulla (Rothnagel and Rogers, 1986; Hamilton et al., 1991;
Tarcsa et al., 1997; Steinert et al., 2003). However, none of
these studies did use human material, and it is clear that THH
expression and also the expression of TGase 3 is different
between mice and men. Furthermore, in these studies a
polyclonal antibody was used to detect TGase 3, which could
possibly crossreact with other TGases resulting in the positive
staining of the IRS. As TGase 3 does not show staining in the
IRS in our study, other TGases could be responsible for THH
crosslinking at this location. We found that TGase 1 is
specifically expressed in the IRS (Figure 4n) suggesting that
not TGase 3 but TGase 1 is the crosslinking enzyme of THH
in human hair follicle. This colocalization of THH and TGase
1 in the IRS of the human hair follicle was previously also
found by another group (Commo and Bernard, 1997). In our
study THH could not be detected in the nail unit, whereas a
previous study showed staining of the nail matrix for THH.
Interestingly, the matrix cells showed an apparent absence of
THH granules and only cytoplasmic THH was detected
(O’Keefe et al., 1993). This could explain our results as the
used THH antibody of our choice, AE15, only stains THH in
granules and not when THH is associated with keratin
intermediate filament (O’Guin et al., 1992; Takahashi et al.,
2007).
We showed colocalization of cystatin M/E and CTSV in the
IRS of the hair follicle, especially in Henle’s layer (Figure 2a–f).
This colocalization is restricted to the infundibulum of the hair
follicle around the opening of the sebaceous duct into the hair
canal. At this point the IRS is degenerated allowing the
secretion of sebum into the hair canal and movement of the
hair fiber (Stenn and Paus, 2001; Alonso and Fuchs, 2003). The
expression pattern of cystatin M/E and CTSV suggests that both
proteins are involved in the degeneration of the IRS, possibly
through desquamation of the IRS cells. Epidermal desquama-
tion requires the proteolysis of corneodesmosomes,
specialized junctions that keep epidermal cells together. In
normal human skin the kallikreins KLK5 and KLK7 (two
epidermis-specific serine proteases) are able to degrade
corneodesmosomal proteins desmoglein-1, desmocollin-1,
and corneodesmosin (Caubet et al., 2004) and it is presumed
that cysteine proteases such as CTSV could have a similar
function (Elias, 2005; Zeeuwen et al., 2007). Desquamation in
the hair follicle could result from proteolytic activity of both
serine and cysteine proteases. Desmoglein-1 and corneodes-
mosin are expressed in the IRS as well as KLK7 (Ekholm and
Egelrud, 1998; Nachat et al., 2005), which both show an
identical expression pattern as observed for CTSV in this study.
Altogether these findings provide a plausible explanation for
the degeneration of the IRS at the opening of the sebaceous
duct. Furthermore, we found no expression of CTSV in the
ventral part of the proximal nail fold (bordering the nail plate),
the nail matrix, and the nail bed. As desquamation does not
occur in the regions bordering the nail plate, CTSV is not
expected to be expressed at this location.
It is likely that regulation of protease activity by cystatin
M/E is important in terminal differentiation of the hair
follicle and nail unit, and that disturbance could lead to
abnormal development of these skin appendages. Cystatin
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M/E-deficient mice show a severe skin and hair phenotype
characterized by defects in cornification processes, although
the nails on digits of both front and rear paws were normal
(Sundberg et al., 1997). It must be noted however, that these
mice die shortly after birth, and nail abnormalities cannot be
studied beyond day 10. CTSL-deficient mice show abnormal
hair follicle cycling and morphogenesis including faulty
cornification and incomplete desquamation of the IRS (Roth
et al., 2000; Benavides et al., 2002; Tobin et al., 2002). The
latter observation is interesting as murine CTSL is likely to
harbour the specific enzymatic activities of both human CTSL
and CTSV as no murine ortholog of CTSV appears to exist
(Bro¨mme et al., 1999; Hagemann et al., 2004). Moreover,
other proteases and inhibitors, as well as TGases, may also be
involved in terminal differentiation of the hair follicle and
nail unit. Mutations in the human cathepsin C gene have
been identified as the cause of Haim-Munk syndrome
(MIM245010), a rare disorder resembling Papillon-Lefevre
syndrome but with the addition of nail abnormalities (Hart
et al., 2000). Recently, a human autosomal recessive
ichthyosis with hypotrichosis syndrome (MIM610765) was
linked to a specific mutation in the ST14 gene, which
encodes the serine protease matriptase (Basel-Vanagaite
et al., 2007; List et al., 2007). Furthermore, the Netherton
syndrome (MIM256500) features ichthyosis and hair shaft
defects caused by mutations in the SPINK5 gene resulting in a
reduced activity of the serine protease inhibitor lympho-
epithelial Kazal type inhibitor (LEKTI) (Chavanas et al., 2000).
Concerning TGases, it is known that lack of TGase 1 in
lamellar ichthyosis (MIM242300) patients could cause nail
and hair shaft abnormalities (Rice et al., 2003, 2005),
whereas patients with acral peeling skin syndrome
(MIM609796), due to a missense mutation in the TGase 5
gene, do not show nail nor hair defects (Cassidy et al., 2005).
So far no patients are known that are deficient for TGase 3.
We conclude that the previously unreported biochemical
pathway regulated by cystatin M/E, could also be involved in
terminal differentiation of the hair follicle and nail unit. The
localization of all key molecules, from protease and protease
inhibitor to structural components, suggests a role for these
proteins in both cornification and desquamation. Terminal
differentiation could start in the hair bulb and the nail matrix
where CTSL is able to process and activate TGase 3, followed
by crosslinking of loricrin, involucrin, and other structural
proteins. One should keep in mind that other TGases such as
TGase 1 and TGase 5 contribute to this process as well. In the
hair follicle, CTSV could be involved in the proteolysis of
corneodesmosomal proteins, which is required for desqua-
mation of the IRS cells. Altogether, this study provides more
insight in the molecular processes that underlie terminal
differentiation of the hair follicle and nail unit, and could lead
to further understanding of human skin disorders with
impaired barrier function and hair and nail abnormalities.
MATERIALS AND METHODS
Tissue samples
Human hair follicles (n¼ 3) were obtained from surgically removed
scalp tissue from patients with basal-cell carcinoma on the head.
Nail specimens (n¼ 2) were obtained from toes of patients
after distal limb amputations. All samples were collected with
written, informed consent using protocols approved by the local
ethics committee, Commissie Mensgebonden Onderzoek Arnhem-
Nijmegen, that complies with the Declaration of Helsinki principles.
Antibodies
Primary antibodies that were used in this study: affinity-purified
polyclonal rabbit anti-human cystatin M/E antibody (Zeeuwen et al.,
2001), affinity-purified polyclonal sheep anti-human legumain
antibody (Li et al., 2003), monoclonal mouse anti-human CTSV
antibody, monoclonal rat anti-human/mouse CTSL antibody (both
from R&D Systems, Minneapolis, MN), monoclonal mouse anti-
human TGase 3 antibodies C2D and C9D (Hitomi et al., 2003),
monoclonal mouse anti-human involucrin antibody MON150
(Sanbio, Uden, The Netherlands), polyclonal rabbit anti-human/
mouse loricrin antibody (BAbCO, Richmond, CA), and mouse anti-
human THH antibody AE15 (Santa Cruz Biotechnology, Santa Cruz,
CA). For immunofluorescence analysis, the following secondary
reagents were used: Alexa-Fluor 488 goat anti-rabbit IgG highly
cross-absorbed, Alexa-Fluor 594 goat anti-rat, goat anti-mouse, and
donkey anti-sheep IgG highly cross-absorbed (Molecular Probes,
Eugene, OR).
Immunofluorescence analysis
Tissues were rinsed in phosphate-buffered saline, fixed for 4 hours in
buffered 4% formalin, and embedded in paraffin wax. All material
was cut in 7-mm sections, mounted on SuperFrost slides (Menzel,
Braunschweig, Germany), deparaffinized and rehydrated. The
sections were subsequently incubated with primary antibodies
diluted in 1% BSA/phosphate-buffered saline for 1 hour at room
temperature. After washing in phosphate-buffered saline, fluorescent
secondary antibodies were applied for 30minutes at room tempera-
ture. For double labeling with antibodies raised in different animals,
a mixture of primary antibodies was applied and this was followed
by incubation with a mixture of secondary antibodies conjugated
with different fluorescent dyes. Nuclei were stained with 40,6-
diamine-20-phenylindole dihydrochloride (DakoCytomation, Copen-
hagen, Denmark), and the slides were mounted using Prolong Gold
Antifade reagent (Molecular Probes). The slides were subsequently
examined using an immunofluorescence microscope (Axioskop 2
MOT; Zeiss, Sliedrecht, The Netherlands) and images were
photographed using a digital camera (Sony DXC-390P 3 CCD;
Scanalytics, Fairfax, VA) and edited using Axiovision Software
(Zeiss).
Immunohistochemistry
Immunohistochemical staining was performed using the Vectastain
ABC kit (Vector Laboratories, Burlingame, CA) as previously
described (Latijnhouwers et al., 1996). Sections stained for
involucrin received a pretreatment with citrate buffer and needed
antigen retrieval in the microwave oven.
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volunteers,  and  lesional  skin  from  atopic  dermatitis  and  psoriatic  patients were  used  to 
study  the  expression  of  the  above  mentioned  molecules  at  the  mRNA  level  by  qPCR. 









Conclusions  Disturbance  of  the  cystatin  M/E  –  cathepsin  pathway  could  contribute  to 






Cystatin  M/E  is  a  cysteine  protease  inhibitor  encoded  by  the  CST6  gene  that  is  highly 
expressed  in the upper  layers of the human epidermis, hair follicles, sebaceous glands, and 
in the sweat glands1. Recently we unraveled a novel biochemical pathway that controls skin 
barrier  formation  by  regulation  of  both  cornification  and  desquamation  of  the  stratum 
corneum  (SC)  (Fig. 1). Cystatin M/E, which  targets  two different  classes of proteases,  is a 
central molecule in this pathway as it controls the activity of cathepsin V (CTSV), cathepsin L 
(CTSL) and  legumain  (LGMN). Cystatin M/E  regulates  crosslinking of  structural proteins by 
transglutaminase‐3  (TGM3)  in  the  cornification  process  by  controlling  CTSL  and  LGMN 
activities, as human CTSL is the elusive enzyme that processes and activates human TGM32,3. 
During  keratinocyte  differentiation,  TGM3  is  activated  by  limited  proteolysis4,5,  a  process 
that  is apparently under control of cystatin M/E, at  least during skin morphogenesis  in the 
neonatal  phase2.  We  suppose  that  processing  and  activation  of  TGM3  in  terminally 
differentiating  keratinocytes  is  regulated by  the  inhibitory  activity of  cystatin M/E  against 
CTSL.  LGMN  inhibition by  cystatin M/E  could have  a  regulatory  role  in CTSL  activity  since 
LGMN  is  involved  in  CTSL  processing6.  Furthermore,  cystatin  M/E  could  have  a  role  in 
 
 
Figure  1: Regulation  of  epidermal  protease  activity  by  cystatin M/E. A  simplified  scheme  of  the 
presumed  regulatory  role  of  cystatin M/E  in  processes  that  control  epidermal  cornification  and 
desquamation. Cystatin M/E is an inhibitor of the asparaginyl endopeptidase LGMN and the cysteine 
proteases CTSL  and CTSV.  Inhibition of  LGMN might  regulate  the processing of  (pro)cathepsins,  a 
process that is also under control of intra‐ and extracellular pH changes. Inhibition of CTSV putatively 




desquamation  by  regulation  of  CTSV  activity,  which  is  involved  in  degradation  of 
corneodesmosomal  components. We  showed  that  cystatin M/E  and  CTSV  are  separately 
transported within lamellar granules and that both proteins are secreted in the extracellular 
space of the SC where they associate with corneodesmosomes7. Recently, we have reported 






hair  follicle  cycling  and  morphogenesis  including  faulty  cornification  and  incomplete 
desquamation  of  the  inner  root  sheath11‐13.  Murine  CTSL  possibly  controls  the  specific 
enzymatic activities of both human CTSL and CTSV since no murine orthologue of CTSV has 
been discovered14,15. Disturbed biosynthetic processing of  cathepsins and accumulation of 
macromolecules  in  the  lysosomes  in  the  proximal  tubule  cells  of  the  kidney was  seen  in 
LGMN deficient mice, however, no apparent skin or hair phenotype was observed16. These 
mouse models  show  that  the  balance  between  proteases  and  their  cognate  inhibitors  is 
important  for  correct  skin  barrier  formation  and  that  imbalance may  lead  to  disease17. 
Although  no  human  skin  disease  has  been  linked  to  cystatin  M/E  deficiency  yet,  the 
importance of this balance is emphasized in view of other proteases and inhibitors that are 









diseases  in which  the  expression  of  genes  and  the  formation  of  the  epidermal  barrier  is 
altered.  Although  both  diseases  are  generally  regarded  as  immune‐mediated  conditions, 
recent  genetic  studies  have  indicated  the  importance  of  abnormalities  in  epithelium‐
expressed  genes  as  a  primary  cause.  Loss  of  function  alleles  of  the  skin  barrier  protein 
filaggrin  were  found  to  be  a major  predisposing  factor  for  AD22,  and  we  have  recently 
demonstrated  that  a  copy  number  polymorphism  of  a  beta‐defensin  gene  cluster  is 
associated with increased risk for PS23. 
In view of the fact that the cystatin M/E – cathepsin pathway is important for correct 
epidermal differentiation, we  investigated  the expression of all players of  this biochemical 
pathway  in major  inflammatory skin diseases with a disturbed skin barrier  function.  In  the 
present study we show the expression and  localization of cystatin M/E, CTSV, CTSL, LGMN 
and  TGM3  in  AD  and  PS  skin  compared  to  normal  skin  (NS)  from  healthy  volunteers. 
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Expression  of  some  of  these molecules was  significantly  different  between  diseased  and 
normal skin, both on  the mRNA and  the protein  level. Furthermore, we show  that human 






Patients and healthy volunteers were  recruited by  the Dermatology  clinic of  the Radboud 
University Nijmegen Medical Centre. All patients were diagnosed by  a dermatologist. The 
study  was  approved  by  the  local medical  ethical  committee  (Commissie Mensgebonden 
Onderzoek  Arnhem‐Nijmegen)  and    conducted  according  to  the  Declaration  of  Helsinki 
principles.  Written  informed  consent  was  obtained  from  each  volunteer.  Patients  who 
suffered  from  chronic  AD,  diagnosed  according  to  the Hanifin  criteria, were  in  an  active 
phase of disease  for which  they were hospitalized and biopsies were  taken  from subacute 
lesions.  Care  was  taken  to  exclude  vesicles  or  scratched  skin.  All  psoriasis  patients  had 
moderate  to  severe  plaque  type  psoriasis.  Biopsies  of  normal  skin,  psoriatic  lesions  and 





Primary  antibodies  that  were  used  in  this  study:  affinity‐purified  polyclonal  rabbit  anti‐
human  cystatin  M/E  antibody1,  affinity‐purified  polyclonal  sheep  anti‐human  LGMN 
antibody24,  monoclonal  mouse  anti‐human  CTSV  antibody,  monoclonal  rat  anti‐
human/mouse  CTSL  antibody  (both  from  R&D  Systems,  Minneapolis,  MN),  monoclonal 
mouse  anti‐human  TGM3  antibodies  C2D  and  C9D25,  monoclonal  mouse  anti‐human 
involucrin  antibody  MON150  (Sanbio,  Uden,  The  Netherlands),  polyclonal  rabbit  anti‐
human/mouse  loricrin  antibody  (BAbCO,  Richmond,  CA),  and  rabbit‐anti‐human  filaggrin 
antibody  BT576  (Biomedical  Technologies,  Stoughton,  MA).  For  immunofluorescence 





Immunohistochemical  stainings  were  performed  using  the  Vectastain  ABC  kit  (Vector 
Laboratories,  Burlingame,  CA)  as  previously  described26.  Sections  stained  for  involucrin 






In  order  to  examine  gene  expression  patterns  exclusively  in  the  epidermis  we  have 
previously  developed  a  protocol  that  allows  rapid  separation  of  the  epidermis  from  the 
underlying dermis under conditions that would minimize de novo expression or degradation 








Sybr Green  and melting  curve  analysis  (Bio‐Rad)  as  previously  described29.  Primers were 
designed using Primer Express 1.0 Software (Applied Biosystems) and produced by Biolegio 
(Nijmegen,  The  Netherlands).  Primer  validation,  qPCR  reactions,  and  determination  of 
relative mRNA expression were performed  as previously described28.  Expression of  target 





















CST6  ENST00000312134  cystatin M/E  tccgagacacgcacatcatc  ccatctccatcgtcaggaagtac  1.96 
CTSL2  ENST00000259470  cathepsin L2/V, CTSV  gctatggatgcaggccattc  acaccatgatccaggtttttgc  1.97 
CTSL  ENST00000257498  cathepsin L  gttgctattgatgcaggtcatga  actgctacagtctggctcaaaataaa  1.86 
LGMN  ENST00000334869  legumain, AEP, PRSC1  tgcagtatggaaacaaaacaatctc  gggtgaggtcaaggtgtgtga  1.85 
RPLP0  ENST00000228306  ribosomal protein P0, hARP  caccattgaaatcctgagtgatgt  tgaccagcccaaaggagaag  2.00 







Human  skin  equivalents were  prepared  as  described  previously31.  Briefly,  de‐epidermized 
dermis (DED) was punched with a 8‐mm biopter. DED was generated using abdominal skin 
from donors who underwent surgery for abdominal wall correction. Punches were placed in 
a  24  well  transwell  plate  (Costar,  NY,  USA),  and  seeded  with  105  keratinoyctes.  After 








of  the  protein  staining  in  the  whole  epidermis.  Regarding  the  expression  of  all 
genes/proteins  in  the  epidermis  of  healthy  controls  and  in  AD  and  PS  skin,  the  one‐way 





We  have  previously  shown  by  immunohistochemistry  and  RT‐PCR  that  cystatin  M/E 
expression  is  largely confined to human skin and  its appendages1,3,7.  Immunohistochemical 
data have also shown a moderate but specific expression of cystatin M/E  in the bronchi of 
the lung, the proximal tubuli of the kidney, and in the cornea of the eye (unpublished data). 
Some other  studies have  reported expression of  cystatin M/E at  the mRNA  level  in  some 
other human  tissues32,33  that  are  contradictory with our data.  Therefore we  analyzed  the 
expression of cystatin M/E, CTSV, CTSL, LGMN, and TGM3 in a large panel of human tissues 
at  the  mRNA  level  by  qPCR,  which  is  currently  the  most  accurate  method  to  detect 
quantitative gene expression  levels  (Fig. 2). These experiments revealed that cystatin M/E, 
CTSV, and TGM3 show a more restricted tissue expression pattern, whereas CTSL and LGMN 







  To  investigate  the  cystatin M/E –  cathepsin pathway  in AD and PS we  studied  the 
expression of the above mentioned molecules in skin biopsies from these patients compared 
to skin from healthy controls. Figure 3 shows the relative mRNA expression  levels of these 
molecules  in purified epidermal cells. We  found significant changes  in expression  for each 
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mRNA  in  PS  compared  to  AD.  To  study  the  expression  at  the  protein  level 
immunofluorescence  microscopy  was  performed  followed  by  quantitative  analysis  using 
ImageJ  software.  The  localization of  the proteins  in  inflamed  skin did not differ  from NS. 




qPCR  analysis  (Fig.  5). Western  blotting  on  epidermal  protein  extracts  from  AD,  PS,  and 
normal  skin  showed  similar  results  for  CTSV  (data  not  shown).  However,  the  protein 





skin,  in which  skin constructs differentiate  from 1‐2 basal  layers of keratinocytes at day 0 
into a completely stratified epidermis on day 12  (Fig. 6).  Immunohistochemical staining of 





of  human  tissues.  Equal  amounts  from  each  tissue were  analyzed  by  qPCR.  CTSV  expression  in 
tongue was set to the value 1. Note that the relative quantity  is presented  in a  log10 scale. All ΔCt 
values were  corrected  for  the  efficiency of  each primer  set  in  relation  to  the housekeeping  gene 
primers (see table 1). CysM = cystatin M/E. 
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construct  on  day  0  and  that  during  differentiation  of  the  epidermis  the  other  structural  
proteins are being expressed: loricrin from day 3 and filaggrin from day 6. Subsequently, we 
















Figure  3:  Relative mRNA  expression  levels  of  cystatin 
M/E,  CTSV,  CTSL,  LGMN  and  TGM3  in  inflamed  skin. 
qPCR was  performed  on  RNA  from  purified  epidermal 
cells  of  NS  (n=7  individuals),  lesional  AD  skin  (n=9 
patients)  and  lesional  PS  skin  (n=9  patients).  LGMN 
expression  in NS was  set  to  the value 1. All ΔCt values 
were  corrected  for  the efficiency of each primer  set  in 
relation to the housekeeping gene primers (see table 1). 
qPCR  data  are  presented  in  mean  ±  SEM.  Statistical 
significance was P < 0.001  (***), P < 0.01  (**), and P < 





Figure  4:  Protein  expression  of  cystatin  M/E  and  its  target  proteases  in  inflamed  skin. 
Representative immunofluorescence stainings (each group n=6) of Cystatin M/E, CTSV, CTSL, LGMN, 















method  for detection of quantitative  gene  expression  levels. Here we  show  cystatin M/E 




genes, but  is also more accurate  in detecting  low mRNA  levels  that could not be detected 
using Northern blot and RT‐PCR analysis. A similar observation is made when comparing our 
Figure  5:  Quantitative  measurement  of  protein 




Data  represent  intensity  of  proteins  in  epidermis 
(Fluoresence  Units)  and  are  given  as  mean  ±  SEM. 










we  also present  the  tissue distribution of human  LGMN  and TGM3 on  the  transcriptional 
level. Like CTSL, LGMN is also ubiquitously expressed at the mRNA level, while LGMN protein 
expression has been detected by immunohistochemistry only in human skin, kidney and liver 
so  far3,36. Extensive expression  analysis of TGM3 mRNA has only been performed  in mice 
showing  distribution  in  skin,  stomach,  and  testis37.  Our  study  suggests  that  the  tissue 
distribution  of  human  TGM3  is  restricted  to  skin,  esophagus,  and  oropharyngeal  tissues. 
Remarkably, mRNA  expression  of  all  five  proteins was  only  seen  in  skin,  esophagus,  and 
oropharyngeal tissues, all of which generate stratified epithelia that are directly exposed to 
micro‐organisms and physical stress, which is another clue that the cystatin M/E – cathepsin 





Figure  6:  Expression  of  epidermal  differentiation  markers  in  human  reconstructed  skin. 
Development of normal human skin equivalents. Adult human keratinocytes were seeded on DED, 
and  cultured  for 3 days  submerged,  followed by 0, 3, 6, 9  and 12 days  culturing  at  the  air‐liquid 
interface. Morphology of the skin constructs was studied by H&E staining. Differentiation of the skin 
constructs was studied by  immunohistochemical stainings for  involucrin,  loricrin and filaggrin. Bar = 
100 µm. 
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Recent  studies have  shown  that  the expression of genes and  the  formation of  the 
epidermal  barrier  is  altered  in  inflammatory  skin  diseases,  which  has  encouraged  us  to 
analyze the expression pattern of all players of the novel biochemical pathway in AD and PS. 
qPCR analysis showed that mRNA expression  levels of some genes are changed  in diseased 
skin  compared  to  NS.  Generally, mRNA  expression  levels  of  cystatin M/E  and  CTSV  are 
decreased in inflamed skin, while the levels of CTSL and TGM3 are increased. These findings 
are in accordance with micro‐array analyses in patients with AD or PS (GEO profiles GDS2381 
and  GDS2518,  accessible  at  http://www.ncbi.nlm.nih.gov).  GDS2381  contains  mRNA 









Figure  7: Relative mRNA  expression  levels  of  Cystatin 
M/E,  CTSV,  CTSL,  LGMN  and  TGM3  in  reconstructed 
skin. Adult  human  keratinocytes were  seeded on DED, 
and cultured for 3 days submerged, followed by 0, 3, 6, 9 
and  12  days  culturing  at  the  air‐liquid  interface.  qPCR 
was  performed  on  RNA  from  epidermal  cells  derived 
from  the  cultured  human  skin  equivalents.  CTSV 
expression at day 0 was set to the value 1. All ΔCt values 
were  corrected  for  the efficiency of each primer  set  in 
relation to the housekeeping gene primers (see table 1). 




Previously, we  have  reported  that  cystatin M/E  expression  in AD  and  PS  skin was 
extended  to  some  spinous  layers and  therefore,  seemed  to be  increased38. However, only 
the number of positive cell layers was increased, but not necessarily the relative expression 
as  staining  intensity was  less  in  AD  and  PS  compared  to  normal  skin.  The  present  study 
confirms  that  relative  cystatin  M/E  expression  is  actually  decreased.  Although  our 
immunofluorescence  stainings  show  that  cystatin M/E  is mainly expressed  in  the  stratum 
granulosum and stratum corneum of AD and PS skin, we did detect cystatin M/E in the upper 
spinous layers, but this is difficult to see in figure 4. Differences in protocol, strength of signal 






Figure 8: Expression of cystatin M/E and  its  target proteases  in  reconstructed human skin. Adult 
human keratinocytes were seeded on DED, and cultured for 3 days submerged, followed by 0, 3, 6, 9 






In  both  AD  and  PS  decreased  protein  expression  of  cystatin  M/E  and  CTSV  was 
confirmed by quantification of immunofluorescent stainings, but the elevated transcriptional 
levels of CTSL and TGM3 were not matched by  increased protein expression. Surprisingly, 
CTSL protein expression  is decreased  in  inflamed skin, which not only contradicts our qPCR 
data, but also a previous study that reported increased expression of CTSL in PS39. However, 
Bylaite  et al. were not  able  to detect CTSL expression  in NS which questions  their  report 
since CTSL is expressed quite abundantly in NS3,7,40. The decrease of CTSL protein expression 
in  inflamed  skin  could  be  explained  by  altered  processing  of  CTSL. Multiple  forms  of  the 
active CTSL enzyme exist and in NS only inactive proCTSL and the mature active single‐chain 
CTSL form are detected40. Expression of CTSL in NS appears as a diffuse staining of the entire 
epidermis except  the SC.  In PS enhanced processing of CTSL  results  in a mixture of active 
single‐chain  and  two‐chain  CTSL  forms,  which  shows  a  different,  more  granular  and 
condensed  staining pattern of CTSL  in psoriatic  skin40.  It  could be  that our CTSL  antibody 
cannot detect  the  two‐chain  form as well as  it does  the single‐chain  form, or perhaps  the 
antibody is not suited for staining CTSL in condensed granules resulting in decreased protein 
detection. Our data suggest that the cystatin M/E ‐ cathepsin pathway is disturbed in AD and 
PS,  which  might  contribute  to  an  abnormal  skin  barrier  formation  and  function,  as  an 
unbalanced  protease/protease  inhibitor  interaction  would  have  consequences  for 
downstream  processes  in  the  pathway.  Since  the  cystatin  M/E  –  cathepsin  pathway  is 




that  in  diseased  skin most  of  the  TGM3  protein  could  be  inactive,  resulting  in  impaired 
barrier  formation  by  insufficient  cross‐linking  of  structural  proteins  into  the  cornified 
envelope.  Since  CTSV  could  have  an  important  role  in  desquamation,  decreased  CTSV 
activity could  lead to delayed desquamation of corneocytes and thereby  induce thickening 
and scaling of the skin in AD and PS. 
Other  cystatins and  cathepsins have been  implicated  in  skin barrier  formation  and 
function and as such could have a role in the development of AD and/or PS lesions. Cystatin 
A  is expressed  in skin and participates  in epidermal barrier formation and function41.  It has 
been suggested  that cystatin A  inhibits exogenous cysteine proteases preventing microbial 
infection  and  inflammatory  stimulation  of  the  keratinocytes  by mite  allergens  in  AD42,43.  
Cystatin  A  expression  is  decreased  in  AD,  whereas  in  psoriatic  skin  cystatin  A  is 
overexpressed44,45.  Interestingly,  the  CTSA  gene  is  located  in  the  PS  and  AD  loci  on 
chromosome  3q2146,47.  Cathepsin D  (CTSD)  is  an  aspartic  protease  that  is  involved  in  the 
processing and activation of TGM1. CTSD deficient mice  show  reduced TGM1 activity and 
impaired  SC morphology,  similar  to  the  skin of TGM1  knockout mice and  the human  skin 
disease  lamellar  ichthyosis48.  In  addition,  CTSD  is  able  to  degrade  corneodesmosomal 
proteins and could have a role in the desquamation process49,50. CTSD expression is shown to 
be  altered  in  PS;  expression  shifts  from  the  upper  granular  layers  and  the  SC  in  normal 
113
human  skin  to  all  suprabasal  layers  except  the  SC  in  psoriatic  skin51.  Similar  to  CTSL, 
enhanced processing of CTSD was found in PS40. 
The  use  of  knockout  or  transgenic  mouse  models  is  a  cornerstone  of  modern 
biomedical research and has provided mechanistic insights in biology and pathology. We are 
currently  using  such  mouse  models  to  investigate  the  role  cystatin  M/E  and  its  target 





cystatin  M/E  –  cathepsin  pathway  compared  to  normal  human  skin.  Therefore,  this 
reconstructed skin model will be used as a tool for future research  in which we aim to use 
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cystatins  are  ubiquitously  expressed,  high  levels  of  cystatin  M/E  expression  are  mainly 
restricted  to  epithelia  of  the  skin  and  a  few  other  organs,  such  as  lung  and  eye. 
Homozygosity  for  cystatin  M/E  null  alleles  in  ichq  mice  leads  to  disturbed  epidermal 
cornification,  impaired barrier  function, and dehydration. Unfortunately, the consequences 
of cystatin M/E deficiency  in other  tissues and organs cannot be  studied  in  these mice as 
they die 6 to 12 days after birth. In order to overcome this, we devised a strategy to rescue 
the lethal skin phenotype of cystatin M/E deficient mice by transgenic expression of cystatin 
M/E  in  epidermis.  A  vector was  generated  in which mouse  cystatin M/E  (the  Cst6  gene 
product) was placed under the control of the involucrin (INV) promoter. In addition, the Cts6 
coding sequence was fused to an IRES – eGFP (enhanced green fluorescent protein) cassette, 
resulting  in  the  production  of  both  cystatin M/E  and  eGFP  from  a  bicistronic mRNA  in 
epidermis. Expression of  the cystatin M/E – eGFP  transgene  (Tg(INV‐Cst6‐IRES‐eGFP)), was 
validated  in  vitro  by  transient  transfection  of  cultured  primary  human  keratinocytes. 
Transfected  keratinocytes  that  were  stimulated  to  differentiate  indeed  displayed  eGFP 
protein  expression  as  measured  by  flow  cytometry  and  fluorescence  microscopy.  Also, 
mouse  cystatin M/E  encoding  transcripts  as well  as  production  and  secretion  of mouse 
cystatin  M/E  protein  were  successfully  detected  in  these  cultures.  As  a  next  step  the 
transgene  was  used  for  conventional  micro‐injection  into  mouse  zygotes  and  several 
transgenic  founder mice have been obtained. These  transgenic, epidermis‐specific cystatin 





Cystatin  M/E  is  a  cysteine  protease  inhibitor  that  is  mainly  expressed  in  the 
epidermis, more  specifically  in  the upper  layers of  the  stratum granulosum,  sweat glands, 
sebaceous glands, and the hair  follicles1,2, suggesting an  important role  for cystatin M/E  in 




proteases  cathepsins  L  and  V  (CTSL,  CTSV)  and  the  asparaginyl  endopeptidase  legumain 
(LGMN)  via  two  distinct  binding  sites3.  The  importance  of  cystatin  M/E  and  its  target 






desquamation  by  regulating CTSV  activity,  since  in  the  extracellular  space  of  the  SC  both 
proteins  are  closely  associated  with  corneodesmosomes,  and  CTSV  is  able  to  degrade 
corneodesmosomal  proteins7,8.  However,  no  orthologue  of  CTSV  in  mouse  has  been 
discovered yet and it has been suggested that mouse CTSL could actually be the orthologue 
of  human  CTSV9.  Another  possibility  is  that mouse  CTSL  controls  the  specific  functional 
activities of both human CTSL and CTSV.  Inhibition of LGMN by cystatin M/E probably also 
regulates  cathepsin  activity  as  LGMN  was  shown  to  be  involved  in  the  processing  of 
lysosomal proteases such as cathepsins B, H, and L in mice10,11.  
The  neonatal  lethal  skin  phenotype  of  cystatin  M/E  deficient  mice  makes  it 
impossible to study the consequences of cystatin M/E deficiency in other tissues and organs 
in adult animals. The generation of double knockout and/or transgenic “rescued” mice will 
therefore  be  a  good  approach  to  circumvent  this  problem.  Recently, we  have  generated 
CTSL‐cystatin M/E  double  knockout mice  to  study  the  role  of  cystatin M/E  and  its  target 
protease  in skin physiology. Preliminary  results showed  that  the CTSL‐cystatin M/E double 
knockout mouse  is viable, which suggests that the balance between the protease CTSL and 
its  inhibitor  cystatin M/E  is highly  important  in epidermal barrier  formation and  function. 
Remarkably, the combination of cystatin M/E deficiency and heterozygosity for CTSL (Cst6‐/‐
/Ctsl+/‐)  resulted  in  an  “intermediate”  skin  phenotype  with  severe  non‐lethal  epidermal 




in  skin  by  classical  transgenesis  involving  a  keratinocyte‐specific  mouse  cystatin  M/E 
expression  construct. For  specific epidermal expression  the  involucrin  (INV) promoter was 
chosen  since  this  is  active  in  the  suprabasal,  differentiating  layers  of  epidermis  and  hair 
follicles12.  Furthermore,  an  IRES  (internal  ribosomal  entry  site)  –  eGFP  (enhanced  green 
fluorescent  protein)  sequence  was  included  to  enable  easy  monitoring  of  transgene 
expression  by  virtue  of  the  intrinsic  fluorescence  of  the  eGFP  reporter  protein13,14.  The 











Gaithersburg,  MD)  as  previously  described4.  Oligo‐dT  primed  single  strand  cDNA  was 
synthesized  from  total  RNA  using  Moloney  murine  leukemia  virus  RNase‐H‐  reverse 
transcriptase  (Boehringer, Mannheim,  Germany).  To  amplify  the  full mouse  Cst6  coding 
sequence  we  used  the  following  oligonucleotide  primers:  forward  primer  5’‐
CTGAATCCGCGGCTATGGAG‐3’  and  reverse  primer  5’‐CCTGACTCTGTCACCCTGG‐3’ 
(corresponding to nucleotide positions 13‐32 and 483‐501, respectively,  in the mouse Cst6 
cDNA sequence; accession ID: MGI:1920970). PCR conditions (1 mM MgCl2) were: 94°C for 6 
min  followed by 35 cycles of 94°C  for 1 min, 57°C  for 1 min, and 72°C  for 2 min. Resulting 





plasmid pBS‐3700  (a kind gift  from Dr. Joseph M. Carroll), and the pIRES2‐EGFP vector  (BD 
Biosciences Clontech, Mountain View, CA), were used  for construction of the  final cystatin 
M/E  expression  vector  (pBS‐INV‐Cst6‐IRES‐eGFP).  First,  pIRES2‐EGFP  was  modified  by 
inserting a BamH I adaptor (5’‐TTAACGGGATCCCG‐3’) at the unique Afl II site. Subsequently, 
the  internal  ribosomal  entry  site  (IRES),  enhanced  green  fluorescent  protein  (eGFP),  and 
simian virus 40 (SV40) Poly(A) signal sequences were excised with BamH I and inserted into 





Human  epidermal  keratinocytes,  obtained  from  abdominal  skin  after  surgical 
correction, were cultured  in keratinocyte growth medium  (KGM) as described previously15. 
Transfection of keratinocytes with pBS‐INV‐Cst6‐IRES‐eGFP or pIRES2‐eGFP was performed 
at  90‐100%  confluency  followed  by  switching  to  KGM/5%  FCS  medium  to  stimulate 
keratinocyte  differentiation.  Transfections  were  performed  in  OptiMEM  I  medium 







Cultered  keratinocytes  that were  harvested  and  resuspended  in  PBS  were  sorted 










melting  temperature  of  61°C  using  the  following  primers:  forward  primer  5’‐
ATGGAGCGTCCTCACTTCC‐3’  and  reverse  primer  5’‐CCTGACTCTGTCACCCTGG‐3’ 
(corresponding to nucleotide positions 27‐45 and 483‐501, respectively,  in the mouse Cst6 










goat  serum  (Vector  Laboratories  Inc.,  Burlingame,  CA)  in  PBS  for  30 min.  Subsequently, 
standards, controls, and samples  (undiluted up  to 32x diluted) were  incubated  for 1 hour, 
followed  by  incubation  with  monoclonal  rat  anti‐mouse  cystatin  M/E  (R&D  Systems)  in 
PBS/1%  normal  rabbit  serum/0.1%  BSA/0.05%  Tween‐20  for  30  min.  Next,  wells  were 
incubated with goat anti‐rat biotinylated antibody (Vector Laboratories) for 30 min, followed 










was  isolated  from  bacteria  using  an  endotoxin‐free midi‐prep  kit  (Sigma,  St.  Louis, MO), 
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 followed by excision of the INV‐Cst6‐IRES‐eGFP transgene (Tg(INV‐Cst6‐IRES‐eGFP)) using Sal 
I  and  Spe  I  restriction  enzymes  and  subsequent  purification  of  the  linear DNA  fragment. 
Superovulation was induced in female C57BL/6J mice and at 0.5 dpc (days post‐coitum) the 
mice were  sacrificed and  the  fertilized eggs  (zygotes) collected. The  transgene was micro‐
injected into the male pronucleus and surviving zygotes were subsequently cultured in vitro 
overnight onto the two‐cell stage. Viable micro‐injected zygotes were then transferred  into 





were  collected  and  samples  were  incubated  overnight  at  55°C  for  cell  lysis  in  200  µl 
DirectPCR  solution  (Viagen,  Los Angeles, CA)  and  100 µl proteinase K  (0.5 mg/ml; Roche, 
Mannheim,  Germany).  Genomic  DNA  was  isolated  by  phenol‐chloroform  extraction  and 
alcohol  precipitation.  The  genotyping  PCR  (42  cycles)  contained  2.5 mM MgCl2  and was 
performed  at  a melting  temperature of 53°C using  the  following primers:  forward primer 
(exon  2)  5’‐TACTACCTGACTTTGGACATA‐3’  and  reverse  primer  (exon  3)  5’‐






quantitative PCR. As  an  internal  control  a part of  the  genomic  sequence of  Tgm3  (intron 
5/exon  6) was  amplified.  The  PCR  (35  cycles)  contained  5 mM MgCl2,  involved  a melting 
temperature of 60°C and was performed using the following primers sets: for amplification 
of  Cst6,  forward  primer  5’‐ATGGAGCGTCCTCACTTCC‐3’  with  a  3’‐end  tagged  fluorescent 
FAM‐label, and reverse primer 5’‐TTTGCATCGATGACTTTGGTGT‐3’, for amplification of Tgm3, 
forward  primer  5’‐CCCTCCCTCTAAGTGATTTGTT‐3’ with  a  3’‐end  tagged  fluorescent  FAM‐
label,  and  reverse  primer  5’‐GGATCTCCACACTACCATTCCA‐3’.  These  correspond  to 
nucleotide positions 27‐45  and  238‐259  in  the mouse Cst6  cDNA  sequence  (accession  ID: 
MGI:1920970) and positions 17716‐17737 and 17955‐17976 in mouse Tgm3 gene sequence 
(accession  ID: MGI:98732), respectively. 2 µl PCR product (amplicon size  is 233 and 261 bp 
for Cst6 and Tgm3,  respectively) was added  to 10 µl HiDi  formamide  (Applied Biosystems, 
Foster  City,  CA),  and  analyzed  by  electrophoresis  on  an  ABI3730  analyzer  using  POP7 











the  plasmid  pBS‐INV‐Cst6‐IRES‐eGFP  that  harbors  five main  elements  relevant  for  correct 
expression and function (Figure 1). The first is a 3.7 kb fragment covering the promoter and 
the  first  exon  and  intron  of  the  human  involucrin  (INV)  gene.  Involucrin  is  a  structural  
protein  of  keratinocytes  that  is  expressed  in  the  suprabasal,  differentiating  layers  of 
epidermis. The  involucrin promoter  is followed by the complete mouse cystatin M/E (Cst6) 
coding  sequence  that was  amplified  from mouse  total RNA by  reverse  transcriptase PCR. 
Then an IRES sequence and the eGFP coding sequence are included, making up a fluorescent 
reporter  for  transgene  expression,  and  finally  the  SV40  Poly(A)  signal  sequence  ensures 
proper  transcription  termination  and  mRNA  processing.  The  IRES  sequence  provides  an 
additional entry  site  for  ribosomes on  the mRNA, enabling  that not only  the cystatin M/E 
open reading frame but also the one encoding the enhanced green fluorescent protein will 






containing  plasmid  pBS‐INV‐Cst6‐IRES‐eGFP  or  with  a  control  vector  (pIRES2‐eGFP),  and 
stimulated  to  differentiate  for  72h  by  adding  5%  FCS  to  the  culture medium.  The  IRES 
sequence in the transgene construct will give rise to the parallel production of cystatin M/E 









Figure  1:  Map  of  the  cystatin  M/E  – 
eGFP  bicistronic  expression  construct. 
The  transgene  construct  for  specific 




an  IRES  sequence,  the  eGFP  coding 
sequence,  and  a  poly(A)  addition  signal 
from  the  SV40  genome.  The  transgene 








keratinocytes  that  have  been  selected.  Non‐transfected  keratinocytes  display  almost  no 
fluorescence (0.4%), whereas 2.8% of the keratinocytes transfected with pBS‐INV‐Cst6‐IRES‐
eGFP  are  eGFP‐positive.  Moreover,  the  observed  fluorescence  intensity  of  transfected 
keratinocytes  is  10  to  100‐fold  higher  than  that  of  the  non‐transfected,  negative  control 
(Figure 2A). Keratinocytes  transfected with pIRES2‐eGFP displayed similar results  (data not 











cystatin M/E  can  be  secreted  by  keratinocytes,  culture medium was  used  to  determine 
production of mouse cystatin M/E by transfected keratinocytes. We developed an ELISA for 
Figure  2:  Expression  of  eGFP  in  transfected 
keratinocytes. A) eGFP protein expression analysis 
by flowcytometry in non‐transfected and pBS‐INV‐
Cst6‐IRES‐eGFP  transfected  keratinoctyes.  The 
transfected sample shows an increased number of 
fluorescent  keratinocytes  as  compared  to  non‐





polyclonal  rabbit  anti‐human  cystatin M/E  antibody,  coated  on  the  bottom  of  the  plate, 
recognizes both human and mouse cystatin M/E, whereas the second antibody, monoclonal 
rat  anti‐mouse  cystatin  M/E,  is  specific  for  mouse  cystatin  M/E  only.  Medium  from 
keratinocytes  transfected with pBS‐INV‐Cst6‐IRES‐eGFP  contained  approximately  15 ng/ml 





After  excision  from  the  expression  vector  the  linear  INV‐Cst6‐IRES‐eGFP  transgene 
(Tg(INV‐Cst6‐IRES‐eGFP)),  was  micro‐injected  into  wild  type  C57BL/6J  mouse  zygotes. 
Resulting  transgenic  founder mice may  contain  one  or multiple  copies  of  the  construct 
incorporated by  random  insertion  into  the host genomic DNA. Since  the Cst6  transgene  is 
intron‐less, specific genotyping of the litters for endogenous and transgenic Cst6 sequences 
can be performed using a PCR with primers that span exon borders. A mouse exon 2 forward 
and exon 3  reverse primer pair  resulted  in a 473 bp  fragment  from  the endogenous Cst6 
gene and a smaller fragment of 126 bp that represents the transgene (Figure 4) on DNA from 







PCR on  cDNA  from non‐transfected  (lane  1), pIRES2‐eGFP  transfected  (lane  2),  and pBS‐INV‐Cst6‐
IRES‐eGFP  transfected  keratinocytes  (lane  3)  using  primers  specific  for  mouse  Cst6.  Only 
keratinocytes  transfected with  the  cystatin M/E  expression  vector  are  positive  for  Cst6 mRNA  as 
indicated by the 475 bp fragment (arrowhead). Water (lane 4) served as negative control for the PCR 








from  the endogenous Tgm3 gene using  fluorescently  tagged primers  for quantification.  In 
this  assay  the  resulting  signal  coming  from Cst6  loci  corresponds  to  the  two  endogenous 
alleles as well as any incorporated transgene copy, while the signal from Tgm3 corresponds 
to  the  only  two  endogenous  alleles  (Figure  5).  The  data  revealed  that  the  transgenic 
founders  have  incorporated  2  and  4  copies  of  Tg(INV‐Cst6‐IRES‐eGFP),  respectively,  into 








INV‐Cst6‐IRES‐eGFP,  for  specific  epidermal  expression  of  mouse  cystatin  M/E.  Human 
cultured  keratinocytes  that  were  transfected  with  the  plasmid  and  were  subsequently 
stimulated to differentiate did contain the bicistronic mRNA transcript and did successfully 
express the encoded proteins  (i.e. mouse cystatin M/E protein and the  fluorescent marker 
eGFP).  The  INV‐Cst6‐IRES‐eGFP  transgene  was  subsequently  micro‐injected  into  mouse 
zygotes and thus far the genotyping of resulting litters has revealed two transgenic founder 
mice that stably transmit the transgene insertion to their offspring. 
Figure  5:  Determination  of  Tg(INV‐Cst6‐IRES‐eGFP)  copy 
numbers.  Amplification  of  all  Cst6  alleles  (A1,  A2)  is 
compared  to  amplification  of  Tgm3  alleles  (B1,  B2)  that 




Figure  4:  Genotyping  of  potentially  Tg(INV‐
Cst6‐IRES‐eGFP)  carrying  mice.  Amplification 
of  Cst6  alleles  on  genomic  DNA  from  a  litter 
obtained after micro‐injection of the transgene 
(mice  Nos.  1‐9),  wild  type  control  (wt),  Cst6 
cDNA  control  (cDNA),  mixture  of  wild  type 
genomic  DNA  and  Cst6  cDNA  (mix),  and  a 
control  for  the PCR  reaction  (water).  The 473 
bp  fragment  represents wild  type  Cst6  alleles 
in  the  genomic  DNA,  whereas  the  126  bp 
fragment  represents  Tg(INV‐Cst6‐IRES‐eGFP) 
(arrowheads). Mouse  No.  3  has  incorporated 
the transgene into its genomic DNA (arrow). 
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   Since cystatin M/E  in skin  is expressed  largely  in  the differentiated keratinocytes of 
the  epidermis,  we  aimed  to  generate  a  construct  with  a  similar  epidermal  specific 
expression. We chose to use the human involucrin promoter that is active in the suprabasal, 
differentiating  layers of epidermis12. The 3.7 kb  involucrin promoter  fragment used  in our 
study has been optimized  for maximal expression  in  keratinocyte  cultures and  covers  the 
promoter  and  the  first  exon  and  intron17.  Importantly,  this  promoter  segment  has  been 
successfully  used  in  vivo  for  the  generation  of  transgenic  mice  that  express  the  β‐
galactosidase  reporter  exclusively  in  the  suprabasal  layers  of  the  epidermis  and  the  hair 
follicles. Using the sensitive reverse transcriptase PCR assay  it was shown that the reporter 
gene  was  also  active  in  some  other  tissues  with  stratified  squamous  epithelia  such  as 
bladder  and  cervix,  but  X‐Gal  histochemistry  showed  that  expression was  less  uniform  in 
those tissues as compared to epidermis. No transgene expression was detectable  in organs 
with  simple,  non‐stratified  epithelia  including  brain,  heart,  liver,  lung,  and  kidney18. 
Transgenic mice with  human  involucrin  promoter‐driven  (over)expression  of  integrins  or 
interferon‐γ have  also been  generated  and  show  skin and hair phenotypes  that  resemble 
psoriasis  and  eczema,  respectively,  underscoring  the  differentiation  and  tissue  specific 
regulatory potential of this involucrin promoter fragment19,20. 
Initiation  of  translation  usually  occurs  by  cap‐scanning  of  the  RNA  as  ribosomal 
proteins  bind  at  the  cap‐structure  at  the  5’‐end  of  the  RNA  strand  followed  by  linear 
scanning  in  the  5’‐3’  direction  until  the  initiation  site  is  reached.  Originally  identified  in 
picornaviruses,  that  have  uncapped  RNA,  the  IRES  enables  the  binding  of  ribosomes  and 
initiation of translation at sites that are downstream of the 5’‐end of the RNA strand21,22. In 
this  study  we  have  used  the  encephalomyocarditis  virus  (ECMV)  IRES,  that  has  been 







findings25,26.  However,  for  our  specific  purpose  a  low  transfection  efficiency  is  not 
problematic. 
The  human  keratinocyte  transfection  experiments  indicated  the  suitability  of  the 
expression construct for animal studies. Transgenic founder mice were generated by micro‐
injection of the excised  linear  INV‐Cst6‐IRES‐eGFP transgene  into wild type mouse zygotes. 
These transgenic mice are currently used for further breeding. Importantly, to verify proper 
transgene expression we do not rely on mRNA or protein  isolation  from epidermis, but by 
virtue  of  the  IRES‐eGFP  sequence we may  confine  ourselves  to  the monitoring  of  eGFP 
expression  in  skin  using  straightforward  fluorescence.  After  confirmation  of  proper 
transgene  expression,  mice  will  be  crossed  with  Cst6+/‐  mice  in  order  to  introduce  the 
transgene  into  the cystatin M/E null background. The  resulting compound  transgenic mice 
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 will then be intercrossed to generate the desired “rescued” mouse (Cst6‐/‐‐Tg(INV‐Cst6‐IRES‐
eGFP); Figure 6). Assuming  that our conjecture regarding  the cause of neonatal  lethality  is 
correct,  “rescued”  cystatin M/E deficient mice will not develop  the  lethal  skin phenotype 
due to epidermal expression of the cystatin M/E transgene. Such a rescue would offer long‐
awaited opportunities  to  study  the effects of  cystatin M/E deficiency  in other  tissues and 
organs that normally express cystatin M/E (although at lower levels), such as lung, stomach, 
and brain4. Cystatin M/E has also been detected in cornea of the eye, and since keratitis was 
observed  in Cst6‐/‐/Ctsl+/‐ mice we hypothesize  that  regulation of CTSL  activity by  cystatin 
M/E  is  important  in  the  development  of  corneal  epithelium  as  well  (Zeeuwen  et  al., 
manuscript  in  preparation).  Unfortunately,  we  may  not  be  in  the  position  to  test  this 
hypothesis in our “rescued” mouse model since a recent study demonstrated expression of 
involucrin  in  human  cornea27.  Extrapolating  this  finding  to mouse  tissue,  the  cornea  of 
“rescued” mice would probably no  longer be  cystatin M/E deficient as  transgenic  cystatin 
M/E  expression  is  controlled  by  the  INV  promoter.  A  previous  study  that  used  the  INV 
promoter  for  transgenic expression of  integrins  in mice has  reported abnormalities of  the 
eyelid and cornea including inflammatory exudate and corneal scarring19, suggesting that the 
INV promoter  is  indeed active  in the cornea.  Irrespective, a successful “rescue” of the skin 
phenotype  in  cystatin M/E deficient mice will provide  a unique opportunity  to  gain more 
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agents and  loss of essential body  fluids. Correct development of  the epidermis  is essential 
for  skin  barrier  function  as  abnormalities  in  cornification  and  desquamation  can  lead  to 





of  cystatin M/E deficient mice. However,  the physiologic processes  that are  influenced by 





The  human  skin  barrier  is  a  result  of  terminal  differentiation  of  the  epidermis,  an 
intricate process of cornification and desquamation that is described in chapter 1. Epidermal 
differentiation  involves  a  variety  of  proteins  including  proteases  and  their  inhibitors.  An 
overview  on  the  classification,  characteristics,  and  functions  of  proteases  in  general  is 











two novel  target proteases. By using biochemical  assays we  showed  that  in  vitro  cystatin 
M/E  is a high affinity  inhibitor of the cathepsins L and V with dissociation constants  (Ki) of 
the protease inhibitor‐protease complexes in the nM range. Using recombinant cystatin M/E 
variants with mutations  in predicted binding sites we showed that  inhibition of cathepsin L 
and  cathepsin  V  by  cystatin M/E  is mediated  by  a  reactive  site  that  is  distinct  from  the 
legumain binding site.  
Following  identification  of  the  target  proteases  of  cystatin  M/E,  localization  and 
compartmentalization  studies,  as  described  in  chapters  2  and  3,  were  performed  to 
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 investigate  the  biological  relevance  and  function  of  these  proteases  in  vivo.  Chapter  2 
includes immunohistochemical stainings,  which showed that all molecules are expressed in 
normal human epidermis. Localization of cystatin M/E and cathepsin V  is  restricted  to  the 
stratum  granulosum  and  the  stratum  corneum,  whereas  cathepsin  L  and  legumain  are 
expressed in all layers except the stratum corneum. Using immunofluorescence microscopy, 
specific co‐localization of cystatin M/E with cathepsin L and  legumain was detected  in  the 
stratum granulosum, whereas cystatin M/E and cathepsin V co‐localize in the upper granular 
layers  and  the  stratum  corneum  (Chapter  3).  In  addition,  immunoelectron  microscopy 
revealed  that  cystatin  M/E  and  cathepsin  V  are  separately  transported  within  lamellar 
granules  and  secreted  into  the  extracellular  space  of  the  stratum  corneum, where  both 
proteins  are  associated  with  corneodesmosomes.  In  contrast,  cathepsin  L  and  legumain 
were  not  found  in  lamellar  granules,  but  in  the  cytoplasm  of  granular  cells,  which  is 
remarkable as cathepsin L and  legumain are considered to be  lysosomal proteins  (Chapter 
3).  However,  lysosomal  proteases  may  participate  in  physiologic  processes  outside 
lysosomes such as apoptosis, a process  that  is distinct  from  terminal differentiation of  the 
epidermis but nevertheless shares some molecular and cellular features.  
During epidermal cornification cytosolic transglutaminase 3 (TGM3) is responsible for 
crosslinking of  loricrin molecules and  small proline‐rich proteins. TGM3  is produced as an 
inactive 77 kDa zymogen, that  is activated via proteolytic cleavage  into 47 kDa and 30 kDa 
fragments   by  an unknown protease. Our previous  finding of premature TGM3  activity  in 
cystatin M/E deficient mice has  led  to  the  suggestion  that one of  the  target proteases of 
cystatin M/E might be responsible for TGM3 activation. In chapter 2 we demonstrated that 
cathepsin  L  is    the elusive protease  that  can process and activate human TGM3, whereas 
other cathepsins (B, D, S, and V) were not able to cleave the TGM3 zymogen into the 47 kDa 
and 30 kDa fragments. Cleavage of the TGM3 zymogen by cathepsin L resulted in biologically 





stratum  corneum  near  the  corneodesmosomes  suggested  a  role  for  both  proteins  in 
desquamation.  Desquamation  requires  degradation  of  the  corneodesmosomes,  which  is 




at  pH  7.0  little  proteolysis  was  observed.  Interestingly,  it  has  been  suggested  that 
desquamation is a pH‐dependent process in which the gradual change in pH of the stratum 
corneum,  from neutral  in  the  lower  layers  to acidic  in  the upper  layers, determines which 
proteases are mainly active in each of the different layers. 
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 Lysosomal proteases  are  involved  in  the processing  and maturation of each other, 
and  it  is known that  in mice  legumain  is  involved  in the processing of  lysosomal cathepsins 






and MALDI‐MS analysis. Although  cathepsin  L and  cathepsin V are  closely  related  to each 
other,  human  legumain  did  not  process  human  cathepsin  L  since  cleavage  of  human 















sebaceous duct  into  the hair canal. At  this  location degeneration of  the  inner  root  sheath 
occurs and  the co‐expression of cystatin M/E and cathepsin V  suggests  that both proteins 
are  involved  in this process, possibly through desquamation of the  inner root sheath cells. 
These  findings  suggest  that  cystatin M/E and  its  target proteases are not only  involved  in 
terminal differentiation of the epidermis, but also of the hair follicle and the nail unit.  
Since  our  previous  studies  have  suggested  an  important  role  for  cystatin M/E  in 
correct epidermal differentiation,  the expression of cystatin M/E,  its  target proteases, and 
TGM3 was  investigated  in  inflammatory skin diseases with disturbed skin barrier formation 
(Chapter  6). mRNA  expression  levels  of  cystatin M/E  and  cathepsin  V were  found  to  be 
decreased  in  lesional  skin  of  psoriatic  and  atopic  dermatitis  patients, whereas  increased 








human  epidermis.  Therefore,  the  expression  patterns  of  several  differentiation  markers 
(involucrin,  loricrin,  filaggrin)  as well  as  the  proteins  of  the  cystatin M/E  pathway were 
studied  at  different  time  points  during  the  development  of  reconstructed  skin.  The 




and  immunohistochemistry.  However,  real‐time  quantitative  PCR  (qPCR)  is  currently  the 
most accurate method for detection of quantitative gene expression levels. In chapter 6 we 
performed qPCR  analysis on  a  large panel of human  tissues, which  revealed  that  cystatin 
M/E  tissue  distribution  is  less  restricted  than  previously  assumed.  In  addition  to  above 
mentioned  tissues,  human  cystatin M/E  expression  was  also  observed  in  oropharyngeal 
tissues,  esophagus,  and  aorta.  The  same  panel  of  tissues was  used  for  qPCR  analysis  of 
cathepsin L, cathepsin V, legumain, and TGM3 gene expression.  
Similar  to  human  cystatin  M/E,  mouse  cystatin  M/E  is  not  only  expressed  in 
epidermis,  but  also  in  various  other  tissues.  Unfortunately,  the  neonatal  lethal  skin 
phenotype of cystatin M/E deficient mice makes it impossible to study the consequences of 
cystatin M/E deficiency  in other tissues and organs  in adult animals.  In order to overcome 
this, we devised a strategy to rescue the lethal skin phenotype of cystatin M/E deficient mice 
by transgenic expression of cystatin M/E in epidermis (Chapter 7). A vector was generated in 
which  the coding  sequences of both mouse cystatin M/E and enhanced green  fluorescent 
protein (eGFP) were placed under the control of the involucrin promoter. Expression of the 
transgene was validated in vitro by transient transfection of the vector into cultured human 
keratinocytes.  Transfected  keratinocytes  showed  eGFP  and  mouse  cystatin  M/E  protein 
expression  after  stimulation  to  differentiate.  As  a  next  step  the  transgene was  used  for 
micro‐injection  into mouse zygotes, which has resulted  in several transgenic founder mice. 
The transgenic founder mice will be used for cross‐breeding with cystatin M/E deficient mice 







by  regulation of both  cornification  and desquamation of  the  stratum  corneum  (Figure 1). 
First, cystatin M/E could have a role in desquamation by regulation of cathepsin V protease 
activity,  which  is  involved  in  degradation  of  corneodesmosomal  components.  Second, 
cystatin M/E could regulate crosslinking of structural proteins by TGM3  in the cornification 
process  of  the  epidermis  and  the  hair  follicle  by  controlling  cathepsin  L  and  legumain 
activities.  Furthermore,  cystatin M/E might  also  be  involved  in  the  regulation  of  TGM1 
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 activity as  it  is known that cathepsin L can process and activate cathepsin D1,2.  It has been 
reported that cathepsin D, an aspartic protease,  is  involved  in the regulation of TGM13,4. In 
vitro experiments have shown that TGM1 activity is stimulated by exogenous cathepsin D in 
cultured keratinocytes, and in cathepsin D deficient mice a reduced TGM1 enzymatic activity 
and defective  TGM1 processing was observed.  The  regulatory  role of  cystatin M/E  in  the 
cornification process of the epidermis was further supported by the observation that in skin 
extracts of 6 to 12 day old cystatin M/E deficient mice relatively high  levels of proteolyzed 
cathepsin  D  and  TGM1  are  found,  whereas  no  appreciable  levels  of  these  proteolyzed 










role  of  cystatin  M/E  in  regulation  of  processes  that  control  epidermal  cornification  and 
desquamation. Cystatin M/E  is  an  inhibitor of  legumain  and  the  cathepsins  L  and V  (CTSL, CTSV). 
Inhibition of legumain activity could regulate processing and activation of (pro)cathepsins, a process 
that  is  also under  control of  intra‐  and  extracellular pH  changes.  Inhibition of CTSV  activity  could 
regulate  desquamation  as  CTSV  is  able  to  degrade  (corneo‐)desmosomal  proteins  such  as 
desmoglein‐1 (DSG1), desmocollin‐1 (DSC1), and corneodesmosin (CDSN).  Inhibition of CTSL activity 
could regulate cornification as CTSL processes and activates the crosslinking enzyme TGM3. CTSL  is 






The past  few years have  taught us a great deal on  the  role of cystatin M/E and  its 
cognate proteases in epidermal biology. Currently no human disease is known that is caused 
by  genetic  alterations of  the proteins  in  this newly discovered pathway. Nevertheless,  all 
unresolved  heritable  human  skin  disorders  that  show  faulty  cornification,  desquamation, 
and/or  hair  follicle  morphogenesis  are  candidates  for  cystatin  M/E  deficiency,  and  the 
identification of such a disorder remains a major challenge. As cathepsin V and cathepsin D 
are  involved  in  breakdown  of  corneodesmosomal  proteins,  they  could  also  be  candidate 
genes  for  ichthyosiform  skin  diseases  that  show  disturbed  desquamation  by  retention  of 
scales. In addition to excessive TGM activity due to cystatin M/E deficiency, as seen  in  ichq 
mice,  lack  of  TGM  activity  can  also  lead  to  disturbed  cornification  as  witnessed  by  the 
autosomal recessive lamellar ichthyosis in which mutations in TGM1 are responsible for the 
disease6.  Although  TGM3  accounts  for more  than  75%  of  the  total  TGM  activity  in  the 
epidermis7, it cannot compensate for cornified envelope formation in patients with lamellar 
ichthyosis  in  which  TGM1  activity  is  absent8,  probably  because  crosslinking  by  TGM1 
precedes  crosslinking  by  TGM3  according  to  the  model  for  assembly  of  the  cornified 
envelope (described in Chapter 1). Although this might seem paradoxical at first glance, both 
loss and  inappropriate gain of TGM activity could explain  ichthyotic changes, although  the 
mechanisms could be different. Excessive TGM1 and TGM3 activity could lead to retention of 
scales by hyper‐crosslinked corneocytes, whereas deficiency for TGM1 could lead to irregular 
scaling  due  to  lack  of  attachment  of  involucrin  to  the  ω‐hydroxyceramides.  There  are, 
however, other  forms  that are clinically similar  to  lamellar  ichthyosis but are not  linked  to 
the  locus of  the TGM1 gene. The  redundancy of TGM3  is  indicated by knockout mice  that 
show no particular skin phenotype9. This leaves open the possibility that mutations in genes 
that are involved in the processing of TGMs into the active form might be causative for other 




Recent  epigenetic  studies  have  provided  evidence  that  regulation  of  cystatin M/E 
gene expression  is regulated by methylation of the CpG  islands present  in the cystatin M/E 
proximal promoter  region  and exon 110‐13. Methylation of CpG  islands  is  a postreplicative 
modification  thought  to  play  a  role  in  gene  transcription  in  eukaryotes,  either  through 
interference with transcription factor binding or through the recruitment of repressors that 
specifically bind sites containing methylated CpG dinucleotides. A growing number of human 
diseases was  found  to  be  associated with  aberrant DNA methylation14,15.  It was  reported 
that  cystatin  M/E  expression  is  frequently  silenced  in  breast  carcinomas  by  epigenetic 
inactivation  related  to  DNA‐methylation  (see  Chapter  1  for  details).  Cystatin  M/E  is 
expressed  in  the  differentiating  layers  of  the  epidermis,  but  absent  in  the  basal  layer, 
suggesting  that during epidermal differentiation cystatin M/E  is  transcriptionally activated. 
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 Alternatively,  cystatin M/E might be epigenetically  silenced  in basal keratinocytes by DNA 
methylation  of  the  promoter  region.  Initiation  of  epidermal  differentiation  could  trigger 
demethylation  of  the  cystatin M/E  promoter  and  result  in  transcriptional  activity  of  the 
cystatin M/E gene. Investigating the degree of methylation of the CpG island in the cystatin 
M/E promoter  in non‐differentiated vs. differentiated keratinocytes might provide clues for 
epigenetic  regulation  of  epidermal  cystatin  M/E  expression.  For  these  experiments 
keratinocytes  could be used  from  in  vitro  cell  cultures  in which primary keratinocytes are 
stimulated to differentiate, or ex vivo from biopsies of normal human skin. Keratinocytes can 
be sorted by  flowcytometry based on  their expression of a specific differentiation marker, 
e.g.  keratin  10.  It  would  be  interesting  to  investigate  if  the  cystatin  M/E  promoter  is 
methylated  in  non‐differentiated  keratinocytes  and  demethylated  in  differentiated 
keratinocytes. This  could  indicate  if epidermal expression of  cystatin M/E  is epigenetically 
regulated.  Epigenetic  changes  in  DNA  and  chromatin  have  been  implied  in  ageing  and 
longevity16. Studies have revealed  that genome‐wide  levels of DNA methylation, usually of 
repetitive sequences, decrease with age, while on the other hand hypermethylation of CpG 
islands  in gene promoters  is  increased17,18.  Interestingly, ageing skin shows  thinning of  the 
epidermis,  dehydration  (dry  skin),  and  susceptibility  to  pruritus  (itching)  and  infection19, 
which  implies  impaired skin barrier  formation and  function. Since the cystatin M/E gene  is 







The  cystatin  M/E  deficient  mouse  model  has  provided  more  insight  in  the 
physiological  processes  that  are  involved  in  epidermal  differentiation,  and  has  led  to  the 
discovery of  a novel biochemical pathway  in  stratum  corneum homeostasis  that we have 
presented in this thesis. Fortunately, we were able to obtain mice deficient for cathepsin L, 
legumain or TGM3, which have been previously generated by other groups9,20,21. Generation 
of  double  knock‐out  mice  that  are  deficient  for  cystatin  M/E  and  either  cathepsin  L, 
legumain or TGM3 might provide  in vivo evidence for the role of cystatin M/E  in epidermal 




One  disadvantage  of  using mouse models  is  that  results  cannot  automatically  be 
extrapolated  to  humans.  Recently,  our  group  has  adapted  an  in  vitro model  of  normal 





human  epidermis.  Our  study,  as  presented  in  Chapter  6,  on  the  expression  patterns  of 
several differentiation markers and the key molecules of the novel biochemical pathway has 
shown that the expression of all these molecules in reconstructed skin was qualitatively and 
quantitatively  similar  to  the  in  vivo  situation,  suggesting  that  human  reconstructed  skin 
could  be  used  to  study  the  cystatin  M/E  pathway  in  vitro.  Gene  knockdown  or 
overexpression of certain genes in human reconstructed skin could be achieved by lentiviral 
delivery  of  constructs  that  drive  expression  of  siRNA  or  genes  under  stratum  specific 
promoters  in  keratinocytes.  Lentiviral  transduction  results  in  the  incorporation  of  the 
transgene  into  the  genomic  DNA  of  keratinocytes.  Knockdown  of  cystatin  M/E  in 
reconstructed skin could lead to impaired epidermal differentiation resulting in a phenotype 
characterized  by  hyperkeratosis,  stratum  corneum  abnormalities,  and  excess  protease 
activity,  as  observed  in  ichq  mice.  Subsequently,  co‐transduction  of  lentiviral  constructs 
targeted to gene knockdown of cystatin M/E and either cathepsin L, cathepsin V,  legumain 
or TGMs, could be performed to reverse the abnormal phenotype. Alternatively, the use of 




In  view  of  the  fact  that  expression  of  cystatin M/E  is  not  restricted  to  epidermis, 
cystatin M/E could be involved in physiologic and pathophysiologic processes in other tissues 
and  organs.  Disturbed  cystatin  M/E  expression  or  function  could  speculatively  result  in 
various  pathologies:  abnormal  keratinization  in  hair  follicles  and  nails,  impaired  barrier 
formation  and  function  of  oropharyngeal  epithelia,  altered  lung  function,  cardiovascular 
disease,  renal  dysfunction,  and  corneal  abnormalities.  The  generation  of  cystatin  M/E 
deficient mice with  transgenic  cystatin M/E  expression  in  epidermis  could  be  a  first  step 
towards  the  elucidation  of  cystatin  M/E  function  in  other  tissues  and  organs  besides 
epidermis. This transgenic mouse will be “rescued” from the neonatal lethal skin phenotype 
and offers opportunities to study the effects of cystatin M/E deficiency in later stages of life. 
Since  cystatin  M/E  could  also  act  as  tumor  suppressor,  it  would  also  be  interesting  to 





Epidermal differentiation  is an  intricate process  that  involves  structural, enzymatic, 
and signaling functions of a variety of proteins. Elucidation of the molecular processes that 
underlie  epidermal  differentiation  is  of  great  importance  for  understanding  skin  barrier 
formation  and  function.  The  studies  in  this  thesis  have  revealed  the  role  of  the  cysteine 
protease  inhibitor  cystatin M/E as a  key molecule  in a biochemical pathway  that  controls 
stratum corneum homeostasis by regulation of processes in cornification and desquamation. 
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huid  een  esthetische  functie  die  van  belang  is  in  sociale  en  psychologische  context. Huid 
bestaat hoofdzakelijk uit twee componenten: de epidermis, die zichzelf constant vernieuwt 
en het stratum corneum (hoornlaag) vormt; daaronder bevindt zich de dermis, bestaande uit 
bindweefsel,  bloedvaten  en  zenuwen.  Een  juiste  ontwikkeling  van  de  epidermis  is  van 
essentieel  belang  voor  een  goed  functionerende  huidbarrière  en  een  verstoorde  vorming 
van het stratum corneum kan tot ernstige huidziekten leiden. Terminale differentiatie van de 
epidermis  is  een  complex  proces  van  verhoorning  en  afschilfering  van  de  keratinocyten 
(huidcellen) dat beschreven wordt in hoofdstuk 1. Bestudering van de moleculaire processen 
die  betrokken  zijn  bij  epidermale  differentiatie  vergroot  onze  kennis  over  de  vorming  en 
functie van de huidbarrière en  is van belang voor de ontwikkeling van nieuwe  therapieën 
voor huidziekten. Vele eiwitten met diverse functies blijken betrokken te zijn bij epidermale 




hoofdstuk  1  besproken, waarna  de  aandacht  vervolgens wordt  gevestigd  op  lysosomale 
cysteine proteases. De maturatie en het  intracellulaire transport van de cathepsines wordt 
behandeld en tevens worden specifiek  cathepsine L, cathepsine V en legumaine besproken. 
Het onderzoek beschreven  in dit proefschrift  richt zich op cystatine M/E, een  remmer van 










Eerder  onderzoek  heeft  aangetoond  dat  cystatine  M/E  een  remmer  is  van  de 
lysosomale  asparaginyl  endopeptidase  legumaine,  wiens  activiteit  in  de  epidermis  en 
haarfollikel  door  cystatine  M/E  gereguleerd  zou  kunnen  worden.  Cystatines  zijn  echter 
hoofdzakelijk  remmers van  lysosomale cathepsines die  tot een andere klasse behoren dan 







dat  de  activiteit  van  deze  proteases  geremd wordt. De  dissociatie  constanten  (Ki)  van  de 





cathepsine  V  en  legumaine  in  normale  humane  epidermis  bestudeerd  met  behulp  van 
immunohistochemie. Cystatine M/E en  cathepsine V werden  aangetroffen  in de bovenste 
lagen van het stratum granulosum en het stratum corneum, terwijl expressie van cathepsine 
L  en  legumaine  in  de  gehele  epidermis met  uitzondering  van  het  stratum  corneum werd 
gevonden. Eén van de bevindingen  in de cystatine M/E deficiënte muis was voortijdige en 
verhoogde activatie van transglutaminase 3 (TGM3) in de epidermis. Transglutaminases zijn 
enzymen  die  structurele  eiwitten  aan  elkaar  koppelen  tijdens  de  verhoorning  van  de 
keratinocyten.  Inactief  TGM3 met  een  grootte  van  77  kDa wordt  door  een  tot  dan  toe 
onbekende protease  geknipt  in de actieve  vorm bestaande uit 30 en 47  kDa  fragmenten. 
Hoofdstuk  2  beschrijft de  betrokkenheid  van  cathepsine  L  bij  de  activatie  van  TGM3. Uit 
experimenten met verschillende cathepsines (B, D, L, S en V) bleek dat alleen cathepsine L in 
staat was  om  inactief  TGM3  te  knippen  in  de  30  en  47  kDa  fragmenten,  die  daarna  ook 
daadwerkelijk  biologische  activiteit  vertoonde.  Met  behulp  van  N‐terminale  sequencing 
werd de knipplaats van cathepsine L in TGM3 bepaald op Ala466.  
In  hoofdstuk  3  wordt  de  co‐lokalisatie  van  cystatine  M/E  met  cathepsine  L, 
cathepsine  V  en  legumaine  alsmede  de  cellulaire  compartmentalisatie  van  deze  eiwitten 
bestudeerd.  Met  behulp  van  immunofluorescentie  microscopie  werd  co‐lokalisatie  van 
cystatine M/E met cathepsine L en legumaine aangetoond in het stratum granulosum, terwijl 
co‐lokalisatie van cystatine M/E met cathepsine V gevonden werd in de bovenste lagen van 
het  stratum  granulosum  en  het  stratum  corneum. De  compartmentalisatie  van  deze  vier 
eiwitten  is  vervolgens  bestudeerd  met  behulp  van  immuno‐elektronen  microscopie. 
Cystatine M/E  en  cathepsine  V  bleken  apart  van  elkaar  door  de  cel  getransporteerd  te 
worden  in  lamellaire granules. Vervolgens kunnen beide eiwitten worden uitgescheiden  in 
de  extracellulaire  ruimte  van  het  stratum  corneum,  waar  zij  lokaliseren  rondom 
corneodesmosomen, de verbindingen tussen de verhoornde keratinocyten die de cellen bij 
elkaar  houden.  Cathepsine  L  en  legumaine werden  niet  gevonden  in  lamellaire  granules, 
maar in het cytoplasma, wat opmerkelijk was aangezien beide eiwitten beschouwd worden 
als  lysosomale  proteases.  Echter,  lysosomale  proteases  blijken  ook  betrokken  te  zijn  in 







van  verschillende uitgescheiden proteases. Daarom werd het  vermogen  van  cathepsine V 
om  in  vitro  de  (corneo‐)desmosomale  eiwitten  desmogleine‐1,  desmogleine‐3  en 
corneodesmosine af te breken bestudeerd in hoofdstuk 4. Cathepsine V bleek deze eiwitten 
snel te kunnen afbreken bij een pH van 5,5, welke ook heerst in de bovenste lagen van het 
stratum  corneum.  Bij  een  neutrale  pH  van  7,0  was  er  nauwelijks  afbraak  van  de 
corneodesmosomale eiwitten door cathepsine V. Deze  resultaten passen  in de  theorie dat 
de  afschilfering  van  de  huid  een  pH‐afhankelijk  proces  is,  waarin  de  geleidelijke  pH‐
verandering  in  het  stratum  corneum,  van  neutraal  in  de  onderste  lagen  naar  zuur  in  de 
bovenste  lagen, bepaalt welke proteases hoofdzakelijk actief zijn  in de verschillende  lagen 
van het stratum corneum. Het is bekend dat lysosomale proteases elkaar kunnen knippen en 
activeren en uit studies met legumaine deficiënte muizen is gebleken dat legumaine dit kan 
doen met  cathepsines.  In  hoofdstuk  4  is  onderzocht  of  dit  ook  voor  humaan  legumaine, 
cathepsine  L  en  cathepsine  V  geldt.  Legumaine  bleek  in  staat  te  zijn  om  “single‐chain” 
cathepsine  V  te  knippen  in  een  tot  nu  toe  onbekende  actieve  “two‐chain”  vorm  van 
cathepsine V. Deze nog niet bekende vorm van cathepsine V  is vervolgens door middel van 
immunoblotting aangetoond in humane epidermale eiwitextracten, wat aangeeft dat dit een 
natuurlijk  voorkomende  vorm  is. Met  behulp  van  N‐terminale  sequencing  en MALDI‐MS 
analyse werd de knipplaats van legumaine in cathepsine V bepaald op Asn290. Ondanks dat 
cathepsine V en cathepsine L zeer verwant aan elkaar zijn, bleek  legumaine “single‐chain” 
cathepsine  L  niet  naar  de  “two‐chain”  vorm  te  kunnen  knippen,  waarschijnlijk  omdat 
cathepsine L de knipplaats op Asp291 heeft en legumaine specifiek knipt na een Asn residu. 
Verder  onderzoek  leerde  dat  zowel  cathepsine  L  als  cathepsine  V  niet  in  staat  zijn  om 
legumaine te knippen of te activeren. 
  Eerder  onderzoek  heeft  aangetoond  dat  cystatine M/E  ook  tot  expressie  komt  in 
haarfollikels  en  waarschijnlijk  betrokken  is  bij  haarfollikel  morfogenese.  In  hoofdstuk  5 
wordt de (co‐)lokalisatie van cystatine M/E, cathepsine L, cathepsine V, legumaine en TGM3 
in  zowel  de  haarfollikel  als  de  nagel  bestudeerd  met  behulp  van  immunofluorescentie 
microscopie. De  haarfollikel  en  de  nagel  zijn  een  soort mini‐organen  in  de  huid met  hun 
eigen  stamcellen  en  zij  vertonen  tevens  terminale  differentiatie.  Co‐lokalisatie  van 
cathepsine L en TGM3 werd aangetoond in de haar bulbus en de nagel matrix, de locaties die 
de  terminaal  differentiërende  cellen  leveren  die  uiteindelijk  de  haar  en  de  nagelplaat 
vormen.  Tevens wordt  in  deze  studie  de  co‐lokalisatie  van CTSL  en  TGM3  in  het  stratum 
granulosum van de epidermis aangetoond. De dubbelkleuring  laat een geleidelijke transitie 
van  cathepsine  L  expressie  naar  TGM3  expressie  zien, wat  duidt  op  een  gecoördineerde 
expressie van de activerende protease (cathepsine L) en het substraat (TGM3). Verder werd 
co‐lokalisatie  van  cystatine  M/E  en  cathepsine  V  aangetoond  in  de  binnenste 
haarwortelschede  van  de  haarfollikel,  specifiek  ter  hoogte  van  het  infundibulum  nabij  de 
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 monding van de talgklier in het haarkanaal. Op deze plek vindt degeneratie van de binnenste 
haarwortelschede  plaats  en  de  co‐lokalisatie  van  cystatine M/E  en  cathepsine V wekt  de 
suggestie dat beide eiwitten een rol spelen in dit proces, mogelijk in de afschilfering van de 
cellen van de binnenste haarwortelschede. Deze studie suggereert dat cystatine M/E en de 
cathepsines L en V niet alleen betrokken  zijn  in  terminale differentiatie van de epidermis, 
maar ook in die van de haarfollikel en de nagel. 








al eerder  aangetoond;  in de qPCR  analyse werd naast de eerder  genoemde weefsels ook 
expressie  van  cystatine M/E  aangetroffen  in oropharyngeale weefsels,  slokdarm en  aorta. 
Verder  is  in  hoofdstuk  6  de  expressie  van  cystatine  M/E,  cathepsine  L,  cathepsine  V, 
legumaine  en  TGM3  in  psoriasis  en  atopisch  eczeem  onderzocht.  Psoriasis  en  atopisch 
eczeem  zijn  twee  veel  voorkomende  ontstekingsziekten  van  de  huid met  een  verstoorde 
huidbarrière. De kwantitatieve expressie werd bepaald op zowel mRNA als eiwitniveau met 
behulp  van  respectievelijk  qPCR  en  kwantitatieve  analyse  van  immunofluorescente 
kleuringen.  In  lesionale  huid  van  patiënten  met  psoriasis  en  atopisch  eczeem  bleek, 
vergeleken met gezonde vrijwilligers, de mRNA expressie van cystatine M/E en cathepsine V 
te zijn verminderd, terwijl de mRNA expressie van cathepsine L en TGM3 verhoogd was. De 
verminderde  genexpressie  van  cystatine  M/E  en  cathepsine  V  komt  overeen  met 





bleek  dat  het  expressiepatroon  van  alle  onderzochte  eiwitten  in  de  humane 
gereconstrueerde  huid  zowel  kwalitatief  als  kwantitatief  overeen  kwam  met  humane 
normale huid. Hieruit kan worden verondersteld dat dit  in vitro huidmodel  in de toekomst 
kan  worden  gebruikt  om  de  rol  van  cystatine  M/E  in  epidermale  differentiatie  te 
onderzoeken. 
  Net als humaan cystatine M/E komt muis cystatine M/E niet alleen tot expressie in de 
huid, maar  ook  in  diverse  andere weefsels.  Helaas  zorgt  het  letale  huidfenotype  van  de 
cystatine M/E deficiënte muis ervoor dat deze muis kort na de geboorte overlijdt, waardoor 
het  niet  mogelijk  is  om  het  effect  van  cystatine  M/E  deficiëntie  in  andere  (volwassen) 




transgene  expressie  van  cystatine M/E  in  de  epidermis. Hiervoor  is  een  vector  gecreëerd 
waarin  de  coderende  DNA  sequenties  voor  muis  cystatine  M/E  en  enhanced  green 
fluorescent  protein  (eGFP)  onder  de  controle  van  de  involucrine  promoter  zijn  geplaatst. 
Expressie van het  transgen werd  in vitro getest door gekweekte humane keratinocyten  te 
transfecteren met de vector. In getransfecteerde keratinocyten die gestimuleerd werden om 
te  differentiëren  werd  zowel  eGFP  als muis  cystatine M/E  eiwit  tot  expressie  gebracht. 
Vervolgens  zijn  enkele  transgene  “founder”  muizen  verkregen  door  middel  van  micro‐
injectie van het  transgen  in muis  zygoten. Deze  transgene  founder muizen  zullen gekruist 
worden met  cystatine M/E  deficiënte muizen waaruit  uiteindelijk  levensvatbare  cystatine 
M/E deficiënte muizen worden geboren met  transgene expressie  van  cystatine M/E  in de 
epidermis en met cystatine M/E deficiëntie in de overige weefsels. 
  De resultaten van het onderzoek beschreven in dit proefschrift hebben geleid tot een 
model  dat  de  rol  van  cystatine  M/E  in  epidermale  differentiatie  beschrijft,  zoals  dat 
gepresenteerd wordt  in hoofdstuk 8. Tijdens epidermale differentiatie heeft cystatine M/E 





activiteit,  de  activatie  van  TGM3  en  daarmee  het  aan  elkaar  koppelen  van  structurele 
eiwitten  door  TGM3  reguleert.  Eventueel  zou  cystatine M/E  ook  de  activiteit  van  TGM1 
kunnen reguleren, aangezien cathepsine L tevens cathepsine D kan activeren, een protease 
dat weer betrokken is bij het knippen en activeren van TGM1. Tot slot wordt in hoofdstuk 8 
vooruit  gekeken  hoe  de  rol  van  cystatine M/E  in  de  nieuwe  biochemische  route  verder 
bestudeerd kan worden. Tot nu toe zijn er geen huidziekten bekend waarvan de oorzaak ligt 
in genetische mutaties van de eiwitten die onderdeel zijn van deze biochemische route. Het 
cystatine  M/E  gen  lijkt  een  goede  kandidaat  voor  mutatie‐analyse  in  erfelijke 
huidaandoeningen met verstoorde verhoorning en afschilfering. Verder zou bestudering van 
DNA‐methylatie  in  de  cystatine  M/E  gen  promoter  in  ongedifferentieerde  en 
gedifferentieerde  keratinocyten  kunnen  aantonen  of  epidermale  expressie  van  cystatine 
M/E  epigenetisch  gereguleerd  wordt.  Dubbele  “knock‐out”  muismodellen  worden 





biedt mogelijkheden om de  functie  van  cystatine M/E  in  andere weefsels dan de huid  te 




































Waarschijnlijk ben  je gelijk doorgebladerd naar dit dankwoord, maar als  je het  straks een 
keertje hebt door genomen, dan heb  je enig  idee van wat  ik op het  lab heb uitgevoerd. Of 













experimenten,  artikelen,  figuren  en  het  proefschrift.  Ik  waardeer  het  zeer  en  ben  je 
dankbaar voor al het werk dat je hebt gedaan. Daarnaast ben je sociaal ook een prima kerel 






dat ene mailtje dat  je mij stuurde, waarin  je mij wees op een vacature die  jullie hadden en 
mij vroeg  te  solliciteren als  ik  interesse had.  Ik had die vacature  zelf nooit opgemerkt,  zo 
goed verstopt was hij, maar hij  sprak me wel ontzettend aan.  Ik ben blij dat Patrick en  jij 
uiteindelijk  mij  boven  de  andere  kandidaat  (met  de  twee  enorme  pluspunten)  hebben 










Het  lab  zou het  lab niet  zijn  zonder al die  leuke mensen die er werken en voor de 
gezellige sfeer zorgen, zowel binnen als buiten het  lab. Een  leuke werksfeer draagt  immers 
bij  aan  een  goed  resultaat.  En  natuurlijk  stonden  ze  ook  klaar  voor  advies  en  hulp  bij 
experimenten. Piet wil ik bedanken voor de flowcytometrie, zijn input en alle hulp bij vragen 







een  verschillende  achtergrond, maar  uiteindelijk met  hetzelfde  doel  (en  dezelfde  stress): 




Mijn  studenten  Christiaan  en Mohammed wil  ik  bedanken  voor  het werk  dat  zij  verricht 
hebben onder deze strenge begeleider, succes met jullie verdere opleiding en carrière. 
  I would like to thank all the co‐authors abroad: Kiyotaka Hitomi, Thomas Reinheckel, 
Colin Watts, Akemi  Ishida‐Yamamoto, Cécile Caubet,  and Michel  Simon,  for  their  support 
and contribution  to  this  research project. Graag wil  ik Wiljan Hendriks bedanken voor  zijn 
advies  en  hulp.  Connie  Verbaas, Maikel  School,  Iris  Lamers‐Elemans,  Claudia  Lagarde  en 
Debby  Smits  van  het CDL:  helaas  is  er  nog  geen  “rescued” muis, maar  bedankt  voor  alle 
moeite. A big  ‘thank you’ goes out to Angela Christiano for offering me the opportunity to 
work at her lab and continue my academic career in skin biology.  




En  dan  missen  we  nog  één  persoon  bij  Dermatologie  die  ik  nog  niet  bij  naam 
genoemd heb, maar die vermelding  zeker waard  is:  Jeanette, mijn maatje op de afdeling. 











  Nu  de  link met Utrecht  is  gelegd, wil  ik  graag mijn  oud‐studiegenoten  uit Utrecht 
bedanken  voor  alle  feestjes  en  de  bezoekjes  aan  Nijmegen:  Martin,  Roel,  Bert,  Judith, 
Monique,  Jurgen, Marnix en Yen. We  verspreiden ons  steeds meer over de wereld, maar 







leven  valt.  In  Nijmegen  wonen  namelijk  ook  leuke  mensen  en  heb  ik  goede  vrienden 
gemaakt. In het bijzonder wil ik Silvo, Pascal, Jos, Mart, Peter, Joost, Loek, Robert, Joris, Ivo 











afgelopen  jaren. Het  is niet altijd makkelijk geweest om uit  te  leggen waarmee  ik  zo druk 
bezig was, maar dit proefschrift bewijst dat ik toch wel iets heb uitgevoerd naast het werk in 
het restaurant. Mijn broers Djindji en Siao, grote neef Feng, schoonzusjes Hsu‐Sia, Shie Yee 
en  Jinting, en natuurlijk  kleine  Jamie, met  jullie heb  ik de afgelopen  jaren de  vele mooie, 
gelukkige en bijzondere momenten van het leven mogen meemaken, welke vaak een goede 
afleiding  van het onderzoek en  reden  voor  zelfreflectie waren. De  laatste  regels  zijn  voor 
mijn  ouders,  die mij  altijd  hebben  gestimuleerd  om  te  studeren  en  hard  te werken.  Zelf 
hebben  jullie  het  goede  voorbeeld  gegeven  van  hoe  je  door  hard werken  je  doelen  kunt 
bereiken. De verplichte weekendjes Limburg kwamen niet altijd goed uit, maar ik heb er ook 










en  neef  door  in  Born,  waar  zijn  ouders  een  Chinees 
restaurant  hebben.  In  1997  werd  het  Gymnasium 
diploma aan het College Sittard behaald, waarna hij  in 
hetzelfde  jaar begon  aan de  studie Medische Biologie 
aan de Universiteit Utrecht. De opleiding omvatte twee 
stages waarin  onderzoekservaring werd  opgedaan.  Bij 
de  afdeling Medische Genetica  van  het  UMC  Utrecht 
heeft hij meegewerkt aan een genome‐wide scan in type 2 Diabetes Mellitus in de groep van 





hij een  jaar  lang een bestuursfunctie vervulde. De studie werd  in 2003 succesvol afgerond 
met het behalen van het doctoraal diploma Medische Biologie. 
In  2004  is  hij  als  junior  onderzoeker  aan  zijn  promotieonderzoek  begonnen  bij  de 
afdeling  Dermatologie  van  het  UMC  St.  Radboud  Nijmegen  onder  leiding  van  dr.  Patrick 
L.J.M. Zeeuwen en prof. dr. Joost Schalkwijk. De resultaten van het verrichte onderzoek zijn 
beschreven  in  dit  proefschrift.  Tevens  heeft  hij  zijn  resultaten  op  diverse  nationale  en 
internationale congressen gepresenteerd en heeft hij een NCMLS Award en een ESDR Travel 
Grant ontvangen. Vanaf  juli 2009 zal hij werkzaam zijn als postdoctorale onderzoeker  in de 
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Figure 3: Cornified envelope assembly.  Initiation of  cornified envelope assembly  starts  in 
the  spinous  layers  with  the  attachment  of  envoplakin,  periplakin,  and  involucrin  to  the 
plasma membrane by transglutaminases. This  is followed by  incorporation of  lipids to form 






















Figure  3:  Immunostaining  for  cystatin  M/E,  cathepsin  V,  cathepsin  L,  and  legumain  in 
normal human  skin  and  its  appendages. Note  the  stratum‐specific expression of  cystatin 
M/E and CTSV in the stratum granulosum of the epidermis. CTSV is only present in the inner 
layer of the outer root sheet of the hair  follicle, whereas cystatin M/E  is also expressed  in 
many more layers of the outer root sheet of the hair follicle. The secretory coil epithelium of 
the sweat glands  is positively stained  for cystatin M/E  (arrowheads), but  the ductal part  is 
almost negative  (the asterisk  is surrounded by ducts). No expression of CTSV was  found  in 
the  sweat  glands.  CTSL  and  legumain  are  also  expressed  in  the  stratum  granulosum. 




































Figure  3:  Colocalization  of  cystatin  M/E  and  AEP  in  human  normal  skin. 
Immunofluorescence staining of (green color; a, d, g, j) cystatin M/E and (red color; b, e, h, 











in human hair  follicle.  Immunofluorescence  staining of  (a, d, g,  j, m, and p)  cystatin M/E 
(green color), and (b, e, h, k, n, and q) CTSV, CTSL, or  legumain (red color), and (c, f, i, l, o, 
and  r)  double  staining  (yellow–orange  merge  color)  for  both  proteins  on  (c,  i,  and  o) 








Figure  3:  Colocalization  of  TGase  3  and  CTSL  in  human  epidermis  and  hair  follicle. 
Immunofluorescence  staining of  (a and d) TGase 3  (green  color), and  (b and e) CTSL  (red 
color),  and  (c  and  f)  double  staining  (yellow–orange merge  color)  for  both  proteins  on 
epidermis (a–c), and both  longitudinal (d–f) and transversal (insets d–f) sections of the hair 
follicle.  The  arrows  (f)  show  the  position  of  the  transversal  section  (inset). 












































Figure  4:  Protein  expression  of  cystatin  M/E  and  its  target  proteases  in  inflamed  skin. 
Representative immunofluorescence stainings (each group n=6) of cystatin M/E, CTSV, CTSL, 
LGMN,  and  TGM3  protein  expression  in  normal  human  skin  (left  column),  and  in  skin  of 








Figure  6:  Expression  of  epidermal  differentiation markers  in  human  reconstructed  skin. 
Development of normal human skin equivalents. Adult human keratinocytes were seeded on 
DED, and cultured for 3 days submerged, followed by 0, 3, 6, 9 and 12 days culturing at the 
air‐liquid  interface.  Morphology  of  the  skin  constructs  was  studied  by  H&E  staining. 










Adult  human  keratinocytes  were  seeded  on  DED,  and  cultured  for  3  days  submerged, 
followed  by  0,  3,  6,  9  and  12  days  culturing  at  the  air‐liquid  interface.  Representative 











Figure  2:  Expression  of  eGFP  in  transfected  keratinocytes.  A)  eGFP  protein  expression 
analysis  by  flowcytometry  in  non‐transfected  and  pBS‐INV‐Cst6‐IRES‐eGFP  transfected 













and  desquamation.  Cystatin M/E  is  an  inhibitor  of  legumain  and  the  cathepsins  L  and  V 
(CTSL,  CTSV).  Inhibition  of  legumain  activity  could  regulate  processing  and  activation  of 
(pro)cathepsins, a process that  is also under control of  intra‐ and extracellular pH changes. 
Inhibition of CTSV activity could regulate desquamation as CTSV is able to degrade (corneo‐) 
desmosomal  proteins  such  as  desmoglein‐1  (DSG1),  desmocollin‐1  (DSC1),  and 
corneodesmosin  (CDSN).  Inhibition  of  CTSL  activity  could  regulate  cornification  as  CTSL 
processes  and  activates  the  crosslinking  enzyme  TGM3.  CTSL  is  also  able  to  process 
cathepsin D  (CTSD),  an  aspartic protease  that  can  regulate  TGM1  activity. Reprinted with 
permission  from: Zeeuwen, P.L., Cheng, T., Schalkwijk,  J.  (2009).  J  Invest Dermatol © 2009 
The Society for Investigative Dermatology 
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